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The cover illustration, created by Professor Antony
O’Hara of the Digital Multimedia Design Program, is a
composite of all of the previous Science Journal covers.

Letter from Dr. Robert S. Bressler

Dear Readers,
I have always avoided inserting a message from the editors or myself in this journal. However, I
just felt that this occasion called for some sort of statement. One of the several tasks suggested to me
when I first accepted my position at Touro was to get a Science Journal re-established. It was probably
more than coincidence that Rivka Borger and Michelle Gordon (now Grunin) approached me with
the same request. In my previous 44 years of teaching I had never been in involved in a similar activity.
The three of us plowed ahead with the overriding goal of keeping this a student publication from start
to finish. Given the multiple facets of my new job, it was difficult to maintain the priority for this one.
I am not sure that starting this journal could have been accomplished without the strong motivation
and commitment of Rivka and Michelle, and of course all of the student editors and contributors. We
have enjoyed support and expertise from two individuals in particular, Dean Robert Goldschmidt and
Mrs. Esther Greenfield. Dean Goldschmidt has championed our efforts and provided the funding. Mrs.
Greenfield has always been there to find even the most miniscule errors in my “printer ready” versions.
She has unknowingly challenged me to continuously move even closer to perfection. Thank you both!
The Science Journal is available on line at http://las.touro.edu/departments/biology/. At that site, you
can open each paper and see the full content.You will also be able to see the mastheads.That will document the student nature of this publication. Submitted articles are sent to the Editorial Board members
for peer-review (I review them as well). The reviewer’s comments are then forwarded to the authors
for their rebuttal or acceptance. After all of that they are formatted, assembled, and sent to the printer.
A few years ago, Professor Antony O’Hara of the Digital Multimedia Imaging Department learned about
the formatting and layout difficulties I was having. He graciously volunteered to involve his students in
the effort and has performed those tasks for us when students were not available. Additional thanks are
extended to Professor Atara Grenadir, Chair of the Art Department, who has arranged for Art students
to assist in designing and producing the more recent covers. Please enjoy the variety of articles we put
forth for you.
Sincerely yours,
Robert S. Bressler, Ph.D.
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Letter from The Charter Chief Editors

Dear Readers,
The Science Journal of the Lander College of Arts and Sciences has been in existence for ten years.
Ten years is a major accomplishment, not only in how far we have come, but in how much wonderful
and amazing scientific research has been written and published throughout ten years of excellence.
When we were students in the Biology track of LCAS, we were interested in working on our own
research, and looking for opportunities to advance, write, and publish work. Dr. Bressler, head of the
Biology department, encouraged our idea, and decided to revive the Touro Science Journal. The Touro
Science Journal had been in existence previously, but with Dr. Bressler’s guidance, we revived the idea,
revamped the Journal, its peer editorial committee drawn from interested students, and managed to
produce something unique: a science journal filled with excellent research, done and edited by the
Touro students themselves.
It gave students who had a desire to read and learn, to publish and to review, a place to submit their
work, where they could undergo for the first time in their college years, peer review and processing,
and to see their final work in print. It showcased original topics and ideas, and both the students and
professors gained in the creation. Editors changed as the student body graduated and shifted, but the
idea and concept remained the same, allowing it to become the gold standard for a Touro student to
show their research.
We feel privileged to have started it on that path, and we hope that it will continue in the future to
allow students a taste of what taking a research concept from start to the finished publication, can be.
We owe a tremendous gratitude towards Dr. Bressler, for encouraging us in our notion, helping us give
it its start, and continuing to produce and maintain it every year since, and for being the amazing science
teacher and professor that he is. He gives of his time, his devotion, and thinks big- and that’s exactly
what this Journal has become: from a thought to an amazing 10 year anniversary.We also owe gratitude
towards the Dean of Touro, and all the excellent scientific faculty, for funding, support, producing the
research, their time, effort and help every step of the way.
We both graduated from Touro College and pursued careers in the medical and biological sciences:
Michelle, defending her PhD thesis this year as a research geneticist, and Rivka, who has been working
as a Physician Assistant for over 6 years. We are sure that Touro College and the Lander School of Arts
and Sciences gave us the background and start we needed to pursue our goals.
We are honored to present to you the tenth edition of the Science Journal, and we hope that it will
continue for many, many more years.
Sincerely,
Rivka and Michelle
Charter Chief Editors
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Most Efficient Methods to Treat Breast Cancer
Esther Ehrman

Esther Ehrman graduated in June of 2016 with a B.S. in Biology

Abstract
Breast cancer is rampant in today’s world. Because there are many different cases and so many different ways to classify
breast cancer, a multidisciplinary approach must be taken. Many patients undergo breast conserving surgery which
creates a need for the eradication of any remaining tumor residue through radiation. Fifty Gy of radiation should be
applied to the breast with an additional 16 Gy as a boost. If a mastectomy is performed to remove a large tumor and 4
or more positive lymph nodes were present, radiation should be applied as well. If the tumor expresses HER2 protein,
Trastuzumab should be given to “turn off” the protein. If a patient’s cancer is hormone receptor positive, Tamoxifen
should be given. If, however, the patient is premenopausal, the Tamoxifen must be given together with ovarian suppressors.
Introduction
Breast cancer can almost be considered an epidemic in today’s
world. It is the most frequently occurring cancer in women
worldwide. (Li, 2016) It has become evident that breast cancer diagnoses have increased because screening methods have
become more efficient and because overall life expectancy has
been lengthened in recent years. In most cases, breast cancer is treated by removal of the tumor and surrounding areas.
Sometimes neo-adjuvant (prior to surgery) therapy is given.
Alternatively, treatment only begins after surgery. Afterwards
radiation is applied to the tumor site and surrounding areas. In
addition, if the tumor is hormone receptor (estrogen or progesterone or both) positive, patients will undergo hormone therapy as well as chemotherapy. This paper will discuss radiation
therapy and hormone therapy as a systemic treatment but will
not cover chemotherapy.

Methods
This article was written through the analysis of various original
research and peer reviewed journal articles. Access was obtained through PubMed and the Touro College Library.

Results and Discussion
Breast Conserving Treatment and Mastectomy
Breast cancer treatment has shifted from total mastectomy toward breast conserving therapy. From the 1970’s, studies have
shown that breast conserving surgery with radiation have the
same effects as the Halsted (radical) Mastectomy for tumors
up to 5 cm. (Veronesi, et.al 2013) When a patient with breast
cancer undergoes breast conserving therapy, radiation of the
breast and some surrounding areas is usually applied (Aebi, et.al
2011). Even after mastectomy, radiation is required if there are
four or more lymph nodes found that ae positive for cancer..
There was no observed benefit from radiation in women with
node negative disease. (EBCTCG, McGale, et.al. 2014) Postmastectomy radiation is recommended if the tumor is 5 cm or
larger, there are at least 4 positive nodes, a positive margin of
resection, or skin involvement. However, because of the psychological effects of mastectomy, breast conserving surgery is
now considered an acceptable form of treatment even when
the tumor is large, as long as the breast can be reshaped. Now,
about 25% of women diagnosed with breast cancer undergo

mastectomy, usually because of large tumor size, location of the
tumor, or local recurrence following a previous breast conserving surgery. (Orecchia, 2015)
In order to reduce the psychological effects and cosmetic drawbacks of mastectomy, the skin sparing method has been introduced. One recent development in the skin sparing method is
nipple-sparing mastectomy which allows for the preservation of
the nipple areola complex. However, there has been increased
recurrence behind the areola following nipple sparing mastectomy. Therefore, radiation is performed on patients that are
at greater risk of recurrence. There is no standard practice in
patients who have an intermediate or low risk and radiation’s
role in this case is unclear. (Orecchia, 2015) Although further
research is needed, this new method can open up new opportunities for better methods of breast reconstruction.

Comparison of Mastectomy, Lumpectomy, and
Lumpectomy plus Irradiation
A study was performed to see whether mastectomy, lumpectomy, and lumpectomy plus irradiation had different effects on
survival. Follow up after 20 years showed no significant difference in survival between the group that underwent mastectomy
as opposed to the groups that underwent lumpectomy with or
without radiation. This study did not show any risk of radiation
causing cancer in the contralateral breast which is a common
concern. The findings at 20 years of follow up did indicate that
lumpectomy with irradiation significantly decreases recurrence
when compared to lumpectomy without irradiation. However,
perhaps, if wider margins were removed at the time of breast
conserving surgery, the need for radiation afterwards would be
eliminated. (Fisher, et.al. 2002)

Effects of Radiation following Breast Conserving
Surgery
Breast conserving surgery can be performed on women with
a less advanced stage of breast cancer by removing any microscopic residual of the cancer. However, macroscopic bits of
the tumor can remain in the breast or nearby area; therefore
radiation is commonly used to prevent local recurrence and distant metastases. In one study, 10,801 women were included to
see how radiation can reduce the risk of recurrence and death
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including different variables, such as age, tumor size, and nodal
status. This study differs from previous studies in three ways.
Firstly, it assumes that all recurrence whether it is locoregional
or distant is related to the tumor that preceded it. Therefore all
recurrence is considered as first recurrence. Secondly, previous
studies obtained follow up results for 10 years, and this one
goes up to 15 years. Lastly, previous studies considered death
of unknown causes within the first 10 years to be attributed
to breast cancer, but this study attributes it to other causes.
(EBCTCG, Darby, et.al. 2011).
When radiation was applied after breast conserving surgery, the
10-year risk of recurrence dropped to 19.3% as opposed to
35.0% in women that did not undergo radiotherapy. The risk
reduction in this case is 15.7% for women who had radiotherapy following breast conserving surgery. Three quarters of the
recurrence in those that had no radiation therapy was of a local
nature while fewer than half of those in the radiation group
had a locoregional recurrence. In addition, radiation reduced
the risk of cancer related mortality to 3.8% in 15 years, which
suggests that for every 4 recurrences avoided due to radiation,
one death was prevented.
Radiation halved the risk of annual first recurrence and it reduced cancer related death by a sixth. However, mortality without recurrence (death from other causes) was slightly higher
during the first 10 years in the radiation following breast conserving surgery group than those who did not have radiation.
The higher death rate in the radiation group can be attributed
to the toxicity of the radiation. However, this is not considered
significant because it is such a minuscule percentage. On average, including all the women of all the different groups (node
status, age, endocrine receptor responsiveness, etc.), during a
15-year period, one death was avoided for every four recurrences avoided by year 10.
This study considers any instance of recurrence, no matter
where it occurs, as a first event rather than only considering
locoregional recurrence as a first event as other studies have
done. This gives more accurate results than previous studies.
Different kinds of recurrences cannot be ignored because radiation is assumed to reduce all recurrences. Because this study
gathered data from patients with a wide range of risks and overall, radiation halved the risk of recurrence, it can be assumed
that it will reduce the risk in future patients as well by a half.
(EBCTCG, Darby, et.al. 2011).

Boost
After 50 Gy radiation on the breast, a 16 Gy boost is recommended except for in patients with a low risk for local
recurrence. (Aebi, et.al 2011) As stated previously, radiation
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prevented one death in a 15-year follow up for every four
instances of local recurrence prevented in a 10-year follow
up. However, because of the intensity of the radiation, fibrosis frequently occurred which caused a poor cosmetic result.
(Bartelink, et.al. 2007) In one trial, the boost dose was lowered
from the previously accepted 25 Gy to 16 Gy because of the
high percentage of patient fibrosis which resulted from the intensity of the boost. There were 5,569 breast cancer patients
who were included in the boost vs. no boost study. The patients
were no different from each other with respect to surgery or
whole breast irradiation. Local recurrence in the no boost
group after 10 years was 4% higher than in the boost group.
Incidence of fibrosis at 10 years was 4.4% in the boost group as
opposed to 1.6% in the no boost group. Although a boost of 16
Gy was shown to decrease the rate of local recurrence in this
study, no improvement has been discovered in disease-specific
survival or overall survival. However, this could be because of
the success of salvage mastectomy which was performed on
the no boost group when they began to exhibit signs of local
failure. The risk of fibrosis for those in the boost group is not
of a significant level. (Bartelink, et.al 2015).
The above study was done over a period of 10 years. A different
study was performed which included 20-year follow up for all
patients. This trial was performed to see if a boost dosage of 16
Gy decreased the rate of recurrence. A 5-year follow up study
showed that it does decrease recurrence. A 10-year follow up
showed that when a boost is delivered, the rate of salvage mastectomies decreases. In the 20-year follow up, local recurrence
was 13% in the no boost group as opposed to 9% in the boost
group. Incidence of fibrosis was a little bit higher (about 4%) in
the boost group. The cumulative percentage for salvage mastectomies performed on the boost group was 6.4 vs. 10.3 for
the no boost group. The fact that there was no improvement
in overall survival in the boost group seems to show that the
boost is not needed. However, this must be the result of the
high rate of successful salvage mastectomies performed. The
boost the number of salvage mastectomies by a third. (Bartelink,
et.al 2015)

Effects of Radiation following Mastectomy
Post mastectomy radiation is used to treat women with four
or more positive lymph nodes to ensure complete removal of
any residual tumor foci. However, the role of radiation in treating women post mastectomy with one to three positive lymph
nodes still remains uncertain. As of now, post mastectomy radiation is not given to women who have node-negative disease.
The following study included 8,135 women who had 1 to 3 positive lymph nodes. About 20% of the women had node-negative
disease, 72% had node positive disease, and the nodal status for
the remaining ones was unknown.
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Radiation therapy was shown to significantly decrease the rate
of recurrence and breast cancer death in the group that had
1 to 3 positive lymph nodes. Radiation was not seen to have
any added positive benefit in women who had node negative
disease. Radiation reduced the 10 year risk of recurrence in
women with 1 to 3 positive lymph nodes from 45.7% to 34.2%
which is an overall absolute benefit of 11.5%. Today, radiation
treatments cover more of the high risk areas, such as the chest
wall. In addition, the doses are lower than they used to be so
the risks of radiation have decreased. Therefore, the proportional gains of radiation today are probably greater than the
results of this study. However, within the 20 years in which this
study has been performed, methods of detection and treatment
have improved; therefore the absolute benefits of radiation are
lower than those reported in this study. (EBCTCG, McGale,
et.al 2014).

Intraoperative Radiotherapy
There is new research in the field of intraoperative radiotherapy to treat many different kinds of cancers including breast
cancer. Instead of a few weeks or months of radiation post
breast conserving surgery, patients can be treated with a dose
of radiation at the surgery itself. Although the average time of
radiation has decreased over the last couple of years, it is still
a strain and inconvenience on the women who must travel to
the hospital every day for about 30 days to receive treatment.
Another advantage of intraoperative therapy over mastectomy
is that if recurrence occurs after breast conserving surgery and
a mastectomy is needed, it is easier to perform it with the now
popular method of skin and or nipple sparing procedures if no
radiation was applied to the skin because radiation can cause
necrosis. (Veronesi, et.al. 2013) In addition, intraoperative radiation therapy can target the cancerous tissue while protecting
the normal tissue around the tumor. (Najafipour, et.al, 2015).

the previous location. Within five years of follow up, there was
a significantly greater instance of recurrence in the intraoperative radiation therapy group than in the external radiotherapy
group. Overall survival, however, did not differ significantly between the two groups. Predictions are that in the future, better
methods will be used to differentiate between patients who are
at higher risk of recurrence and therefore need external whole
breast irradiation or intraoperative radiation plus external radiation. (Veronesi, et.al 2013) It must be noted that this study
only measured 5 years which considered short term follow up
in a study of this sort.

Testing for Endocrine and HER-2 Receptivity
Trastuzumab
Overexpression of HER2 protein occurs in 20-25% of breast
cancers, causing high-grade tumors, increased growth rates,
early systemic metastasis, and reduced rates of overall and disease free survival. (Slamon, et.al 2011) Trastuzumab (Herceptin)
is given many times in conjunction with chemotherapy, but
it can also be given alone. Trastuzumab does not cause the
negative side effects that other chemotherapy medications
are known for, such as alopecia, myelosuppression, and severe
nausea. However, Trastuzumab has been known to cause cardiotoxicity in 1.4% of those to whom it was administered to.
(Piccart-Gebhart, et.al 2005) Various studies were performed
to find out how much Trastuzumab actually improved disease
free survival and whether the increase in cardiotoxicity was a
cause for concern.

In one trial, the effects of intraoperative radiation on a number
of different cancers was tested. Intraoperative radiation was
found to increase survival in patients with pancreatic cancer.
When used on patients with early breast cancer, it was found
to decrease life expectancy by less than a day. Although it may
increase operating room load, it is generally a cost effective and
considered a safe method to treat breast cancer. (Najafipour,
et.al, 2015) However, more research must be done to see if this
new method has any real advantage.

One study included 4,482 women. Both groups received
Trastuzumab after undergoing primary treatment (surgery,
chemotherapy, radiation, ect.). One group received it for one
year, the other for two. Patients with a history of cardiac
trouble were excluded from this study. The study shows that
Trastuzumab given after primary treatment reduces the rate of
recurrence by 50%. It does not seem to make a difference what
type of chemotherapy is received. The risk of cardiotoxicity is
low; however, it is possible that this is because there is a short
follow up in this study. In addition, there is a concern that longer term follow up will show that Trastuzumab does not reduce
disease recurrence in the central nervous system.The results of
this study indicate that one year of Trastuzumab should be used
following primary treatment of breast cancer. (Piccart-Gebhart,
et.al 2005).

In another study, 1305 patients were randomized, 654 belonging
to the external radiotherapy group and 651 to the intraoperative group. Only 11% had more than 4 positive nodes. In
this study, ipsilateral breast tumor recurrence was defined as
“the sum of local recurrence plus 2nd ipsilateral tumors.” Local
recurrence was considered the recurrence of the carcinoma at

A study was performed to see whether an anthracycline-based
regimen increased Trastuzumab’s toxicity. There were 3,222
women who were divided into three groups. One group underwent an anthracycline regimen. In the second group, the
patients received anthracycline with Trastuzumab. In the third
group, the patients only received Trastuzumab. All three groups
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underwent an intense cardiac monitoring schedule. A significant benefit was seen in patients who received Trastuzumab
as opposed to patients who did not. There were no apparent differences between the two Trastuzumab goups; however
the trial was not set up to discern a difference between them.
Congestive heart failure occurred more often in the group that
received anthracycline in addition to Trastuzumab. In addition,
treatment time is decreased when anthracycline is not given.
(Slamon, et.al. 2007).

Hormones and their effect on Breast Cancer and
breast cancer treatment
In the Million Women Study conducted in the UK, over 1 million
women between the ages of 50-64 were recruited to have a
breast screening every three years. The women were given
a survey to complete shortly before their screening. (The
questionnaire can be viewed at http://www.millionwomenstudy.org). The purpose of the study was to see if and how
hormone replacement therapy affects breast cancer. In total,
50% of the population had used hormone replacement therapy at some time. The results of the study proved that recent
or current users of hormone replacement therapy are at increased risk of breast cancer. Those using estrogen-progestogen combinations have a four times greater risk than those
using estrogen-only preparations. However, past users of
hormone replacement therapy have almost no increased risk.
In all, hormone replacement therapy results in 5 to 6 more
cancers per 1,000 women with 5 years use and 15-19 extra
cancers per 1,000 women with 10 years use. (Million Women
Study Collaborators, 2003).
The Million Women Study, because of its large number of participants and span of time, has been the source of much controversy. It has been pointed out the women who participated
in the study are not a good sampling of the general population
because women that use hormone replacement therapy are
more likely to be concerned about their risk of cancer and go
for a mammogram. (Eden, 2010) However, the Million Women
Study represented 53% of the population, so although this may
be 53% of the population that is more likely to be affected by
hormone replacement therapy, over half a population is a good
indication of the rest of the population.

Hormone Therapy
Soon after a patient is diagnosed with breast cancer, she is tested to see whether her tumor is hormone receptor positive of
negative, defined by estrogen and/or progesterone receptivity.
Accurate assessment is critical in deciding whether to treat
with hormone therapy; however, accurate results are difficult
to obtain.
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In the past, tumors that showed less than 10% positivity were
not given hormone therapy because they seemed similar to patients who tested negative for hormone receptivity. Recently,
however, The ASCO/CAP guidelines were revised to treat
women in the 1%-9% positivity group with hormone therapy.
Now 3% more women are being treated with hormone therapy. The problem is that although for a small minority of cases,
hormone therapy has a good positive result on those in the
1-9% group, physicians must consider the benefits of endocrine
therapy versus its cost and side effects. (Yi M, et.al 2014) The
goal of this study, as noted above, was to show that perhaps
the benefits of treating the 1-9% group with endocrine therapy
do not outweigh the costs. However, this study has limitations.
They retroactively collected the data and because of that, the
Estrogen receptor status is not known for certain because the
patients obtained their diagnosis outside the facility where this
study was performed. In addition, the study’s limited sample
size makes it very difficult to analyze the data based on results
from adjuvant chemotherapy and endocrine therapy.
A later study shows that even with a very small percentage
of Estrogen receptor positivity, adjuvant hormone therapy cut
breast cancer mortality by a third for fifteen years. Those who
had hormone receptor treatment were found, initially, to have
lower rates of recurrence than those without; however, they do
risk relapse for up to fifteen years despite usage of Tamoxifen
for five years. (EBCTCG, Davies, et.al. 2011).
The suppression of hormones and the target of HER2 receptors is a not a new development in medicine. Two cohorts,
comprised of 7,178 patients, were studied to see whether
current hormone treatment is more effective than that of the
past. One cohort was diagnosed recently, and the other was
diagnosed from 1986-1992. Relapse event was any disease recurrence. In all, 1,700 patients had relapsed in 9 years of follow
up. The result showed that the current treatments are more
effective because they are used for longer and they are more
efficient. However, patients with ER+ tumors do seem to have
a late relapse and ER- tumors have an early relapse in patients
that were recently diagnosed. (Cossetti, et.al 2014).
Another study was performed in 1996 to see whether there
is a difference and how significant of a difference 2 years of
Tamoxifen makes compared to 5 years of treatment . The results showed that 5 years was more effective. They did not test
past 5 years; therefore, they do not know if more than 5 years
would be more effective. (Swedish Breast Cancer Cooperative
Group, 1996).
Premenopausal hormone receptor positive breast cancer is
treated by ovarian ablation or suppression. The ovaries still
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function in premenopausal women and they are the main site
for hormone production. The aromatization of androgens in
the adrenal glands produces hormones in postmenopausal hormone-receptor positive breast cancer. Aromatase Inhibitors
(AI’s) inhibit the production of those hormones. AI’s fall into
two categories: non-steroidal and steroidal AI’s. Across the
board, AIs are superior to Tamoxifen. The ovaries are only
temporarily suppressed when women are premenopausal for
preservation of fertility. (Li, et.al. 2016).

The Premenopause/Post-menopause treatment
methods
Tamoxifen is the standard drug to treat hormone receptor
positive breast cancer. Premenopausal patients, however, are
often resistant to Tamoxifen. Therefore ovarian function suppression medications are combined with Tamoxifen in order to
reduce disease recurrence in pre-menopausal women. Ovarian
function suppression medications increase toxicity, complicating
overall treatment regimens. (Kim et. al, 2016).
Two trials were performed, the Tamoxifen and Exemestane Trial
(TEXT) and the Suppression of Ovarian Function Trial (SOFT),
to determine whether the aromatase inhibitor Exemestane
improved survival in premenopausal women when used in conjunction with Tamoxifen as opposed to women treated with
ovarian suppressors with Tamoxifen. The combined data from
the two studies shows that Exemestane plus ovarian suppression
as opposed to Tamoxifen plus ovarian suppression significantly
improved survival and decreased risk of recurrence. (Pagani
et. al, 2014) However, in the SOFT study, the women who remained premenopausal and had an increased risk of recurrence
and therefore needed adjuvant chemotherapy, the addition of
ovarian suppression treatments improved survival rates (Kim et.
al, 2016) Because these women received additional chemotherapy, it is not clear whether it is the chemotherapy or the ovarian
suppression that increased survival.
A Korean Study was performed to compare ovarian function
suppression with Tamoxifen versus just Tamoxifen in young,
premenopausal women who had undergone chemotherapy.
The main purpose of this study was to compare the 5-year disease-free survival rates between the two groups. The Korean
Breast Cancer Society focused on this age range because although South Korea has an overall smaller number of breast
cancer diagnoses compared to the world at large, 48.7% of
breast cancer diagnoses are in premenopausal women under
the age of 50 which is a much higher percentage of young
women than in other countries.
The advantage of this study over other studies is that there
is repeated evaluation of ovarian function, which allows for

better selection of patients that should be receiving ovarian
function suppression treatments, avoiding unnecessary side effects. Ovarian suppression causes menopausal symptoms which
significantly alter the the quality of life. These symptoms can
lead to a lack of patient compliance and can also destroy physician-patient relationship (Kim et. al, 2016). This study shows
the benefit of Tamoxifen plus ovarian suppression therapy in
premenopausal patients with Estrogen receptor positive breast
cancer treated with chemotherapy. This trial helps determine
the optimal endocrine therapy needed based on ovarian function status of premenopausal patients.

Conclusion
The patient must undergo a mastectomy if reconstruction of
the breast post breast conserving surgery is impossible or not
feasible. However, mastectomy is not as radical as it once was.
Moreover, now there are new skin sparing methods, such as the
nipple areolar sparing method which allows for a more natural reconstruction after surgery. Post mastectomy radiation is
given in women with 4 or more positive lymph nodes, but in
women with 1-3, the question still remains. Studies show that
in women with 1-3 positive lymph nodes, recurrence is reduced
by over 10%.
In about 75% of cases, patients undergo breast conserving surgery. Except in cases of very low risk of recurrence, patients
must have radiation afterwards. However, perhaps better tumor
residue removal will be employed which can eliminate the need
for radiation therapy. After breast conserving surgery, radiation
reduces risk of recurrence within 10 years from 35% to 19%, a
significant difference. Radiation prevents one death for every
four recurrences prevented (a 3.8% decrease). Radiation does
increase toxicity; however, the percentage is so low, that they
give radiation anyways. However they do try to keep dosages
low. A radiation boost after the radiation treatment regimen
decreases recurrence by 4% over a period of 10 years and after
20 years. There is no difference in overall survival between the
group which received a boost and the one that didn’t because
of salvage mastectomies and other retroactive treatments performed. The risk of fibrosis does increase by the same percentage as survival in the boost group.
Trastuzumab is given to those that test positive for HER2 expression. Although it does increase cardiotoxicity in 1.4% of
cases, it has less side effect than other chemotherapy medications. However, the risk of toxicity may be low in this study
because of a short (5 year) follow up. A longer follow up may
show a larger percentage of toxicity.
Hormone replacement therapy increases one’s risk of getting
breast cancer. Those who take an estrogen-progesterone
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combinations have a four times greater risk of developing cancer than those who take estrogen only. Each woman together
with her doctor must decide whether the benefits outweigh the
risks in taking hormone replacement treatment. This treatment
increases the quality of life for post-menopausal women; however if someone has an increased risk of developing breast cancer,
they should not take this treatment. The Million Women Study
does represent most of the population. However, sometimes
large studies cannot take certain factors into because although
they do divide their sample by different characteristics, there
are too many people to be very exact and specific.
New guidelines have been set up, so now women with 1-9%
hormone positive lymph nodes get hormone therapy. However
the study that proved that this change is necessary (from the
previous about 10%) has limitiations. Firstly, they collected the
data retroactively, so they could not be certain that all of it
was correct, and they had a limited sample size. Those that are
hormone receptor positive and take hormone therapy for five
years do initially have decreased recurrence, but they do risk
relapse for up to 15 years.
In the study where a group received hormone therapy from
1986-1992 was compared to a more recent group, it was proven that hormone therapy is more effective now because the
therapies are more efficient and they are used for longer than
they once were. Although those with hormone receptor positivity have a better prognosis, they are at risk for a relapse
albeit much later than those with hormone receptor negative
cancer. Hopefully new research and discoveries will lead to a
more permanent and better prognosis.
Premenopausal women are resistant to Tamoxifen, so it is usually applied together with ovarian suppressors. These suppressors can increase toxicity, but they do improve. As the Korean
study noted, repeated evaluation of ovarian function can allow
for better selection of patients which can avoid unnecessary
side effects which lower quality of life.
All the above research shows that there is no one best method
to treat breast cancer. Treatment must have a multidisciplinary
approach. Each patient must be treated as an individual with all
symptoms and disease specifics taken into account.
There are various limitations that studies have. One limitation
is that studies, by their very nature, must be performed under
certain assumptions, like assuming that death of an unknown
cause within 10 years is disease mortality which may or may
not be the case. In addition, a large sample size can cause a
“one size fits all” attitude. Trials involving breast cancer patients
have an advantage because there are many people who have
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breast cancer. However because of the large study size, at times
there is not enough specification of treatment. One woman
may seem to have the same diagnoses as another, but some
important differences may not be accounted for. For example,
a woman who tests positive for HER2 receptor and has 8.5%
hormone receptor positivity will be given Trastuzumab and hormone therapy, but perhaps she has a risk of heart disease in her
family and the increased cardiotoxicity will be more harmful for
her than the average patient. It is not enough for doctors to be
up to date on different treatment advances, they must create a
treatment plan that takes each individual patient’s needs, background, and overall health into account.
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Abstract
The french paradox is caused by an inconsistency with scientific experimentation:The French have a very high intake of
saturated fat and cholesterol, which is associated with coronary heart disease, yet they have un-commensurately low
levels of deaths due to this disease. It has been proposed that alcohol, as a part of the French diet, is the factor that helps
decrease the risk of heart disease in the French population by 20-30%. Research has been gathered from many medical
journals to create a larger and more accurate perspective to determine if alcohol has any effect on coronary heart
disease. Experiments indicate that alcohol does indeed have protective effects on the cardiovascular system through
various mechanisms including: High-density lipoprotein (HDL) increases, Apolipoprotein A1-A2 increase, Hemostatic
factors, and insulin sensitivity increase.
Introduction
The French Paradox, a term coined by Serge Renaud in 1986,
has stymied scientists for years.The paradox is presented by the
fact that France is one of the world’s highest consumers of saturated fat and cholesterol-containing foods. Yet, as a whole, the
French people have lower rates of coronary heart disease than
the rest of the Western world (cited in Ferrieres, 2004; cited in
Agarwal, 2002). This presents a paradox since it has been firmly established that large amounts of cholesterol and saturated
fat increase the risk for Coronary heart disease (Shestov, et
al, 1993). How could a nation that consumes more cholesterol
and saturated fats than the United States of America still have a
significantly lower CHD mortality rate?
One possible explanation for this conundrum was proposed in
1986: the French have a larger intake of alcohol consumption
than Americans. It was, therefore, hypothesized that alcohol,
through various biological mechanisms, can lower the risk for
Coronary heart disease (Rimm, 1999). The detrimental effects
of alcohol have been tested and proven. However, most of these
terrible effects stem from long term alcohol abuse and binging.
Perhaps viewing alcohol from a moderate intake perspective
will present different data. The purpose of this paper is to research and assess this hypothesis to determine if a moderate intake of alcohol has a deterrent effect on coronary heart disease.

alcohol as well as total abstinence from alcohol. For laypeople,
the term “moderate intake of alcohol” has a wide and subjective
purview that will always fall somewhere between abstinence and
excessive alcohol consumption. For the purposes of the experiments referenced herein, moderate intake of alcohol refers
to 15-30 milligrams of ethanol (the alcohol found in what are
commonly considered alcoholic beverages, such as beer, wine
and spirits) per day.This is the amount typically contained in one
to two alcoholic beverages. Any alcoholic consumption below
or above 15-30 milligrams may have similar effects. However,
this level of consumption it is not within the purview of this
research paper.
When focusing on the intake of a moderate amount of alcohol
(15-30 mg of ethanol), several experiments have found positive
effects that alcohol exerts, directly or indirectly, on coronary
heart disease. Graphically, it is represented as a J or U shaped
curve. Below is a summary of the effects of alcohol on relative
risk of death (Tabl1 1). Some experiments show that moderate
levels of alcohol intake will decrease the risk of coronary heart
disease by as much as 20 to 30 percent ( Rimm et al, 1999b;
Emberson & Bennett, 2006; Pearson, 1996).There are numerous
mechanisms proposed for this decreased risk. Some have greater scientific support than others. This paper will present those
mechanisms that have sufficient scientific ground upon which to
stand. The various mechanisms that will be discussed are:

Method
This is a meta-analysis of more than twenty papers including many
original experiments. The information gathered in this paper has
been collected from numerous sources including databases such
as PROquest and JSTOR. Additionally, a great deal of information
was gathered from medical journals publicly available on the internet or in libraries. All of this information was read, analyzed,
and compared to determine each piece’s respective authority
and veracity. Each article was also assessed in accordance with its
respective levels of diversity and sample size significance.

Results
In this review, the words “moderate intake of alcohol” will be
used. This term obviously excludes excessive consumption of
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High-density lipoprotein increase; Apolipoprotein A-1 and A-2
increase; Change in lipoprotein size; Increase in fibrinolytic activity; Decrease in fibrinogen; Decreases in platelet aggregation;
and Increasing insulin sensitivity.

Apolipoprotein A-1 A-2 Increase
In a process similar to High density lipoprotein increase, moderate intake of alcohol is hypothesized to increase the transport
rates and concentration of Apolipoproteins A-1 and A-2. These
proteins are produced in the liver and are part of the large
complex of HDL that helps start the process of removal of “bad
cholesterol” from the blood stream by HDL ( De Oliveira e
Silva et al, 2000; van der Gaag et al, 2016; Frank & Marcel, 2000).

Effects of Moderate Intake of Alcohol on Coronary Heart Disease

There are two primary ways that Apolipoproteins assist in the
removal of bad cholesterol:
First, in particular, Apolipoprotein A-1 is a cofactor for the enzyme lecithin cholesterol acyltransferase (LCAT) which converts cholesterol into cholesterol esters (http://www.ncbi.nlm.
nih.gov/gene/335; Frank & Marcel, 2000). The cholesterol esters
are more hydrophobic and help form the sphere of HDL that
gets transferred in one of two ways: directly, through specific HDL receptors to the liver; or indirectly through very low
density lipoprotein (VLDL) and intermediate density lipoprotein
(IDL) conversion. Therefore, an increase in the concentration
and transport rates of Apolipoproteins A-1 and A-2 will speed
up the process by which the HDL will esterify and remove cholesterol from the blood.
Second, in addition to its role in speeding up the rate of cholesterol removal by HDL, Apolipoprotein A-1 has also been
associated with prostacyclin stabilizing factor, which is involved
in anticlotting. By stabilizing prostacyclin, better known as
Prostaglandin I2 (PGI-2), platelet aggregation is inhibited which
helps decrease the chance of clots forming. The positive effects
of inhibiting platelet aggregation will be discussed in more detail
later in this paper (Yui et al, 1988).

Change in Lipoprotein Size
Experiments have also shown that ethanol can increase particle
size of HDL and LDL. Small, dense LDL’s have been associated
with a risk of Coronary heart disease of three times that of an
individual with large “fluffy” LDL. Additionally, an increase in the
size of these lipoproteins has been associated with cardioprotection (Mukamal et al, 2007).
All of the above mechanisms hypothesize how alcohol creates a potential downgrade of risk for heart disease based upon
changes in lipid profile. More particularly, these hypotheses are
based upon increases in HDL-Cholesterol and Apolipoprotein
concentrations as well as lipoprotein size.

The Hemostasis Hypothesis
The next set of mechanisms that hypothesize how moderate
alcohol consumption has a possible downgrade on heart disease
are based on hemostasis. Put simply, these hypotheses suggest
that alcohol affects the way the blood clots and breaks down
clots, thereby reducing the risk for coronary heart disease.
One possible hemostatic mechanism proposed is that moderate
intake of alcohol can decrease fibrinogen concentration (Mennen
et al, 1999 Stec et al, 2000). Experiments have shown that the
moderate intake of alcohol decrease the levels of circulating fibrinogen by 18-20 percent (Wang, Barker, & Fuller, 1999). This

decrease can cause a significant reduction of the risk for coronary heart disease. Fibrinogen is a blood soluble plasma protein that is activated by the enzyme thrombin and produces the
protein fibrin. Elevated levels of fibrinogen in the blood can lead
to potentially devastating effects on the heart. First, it can cause
an increase in platelet aggregation. Second, it will increase fibrin
levels which promote coagulation, which leads to an increase in
blood clotting. Third, elevated levels of fibrinogen increase plasma viscosity, which is associated with an increased severity of
coronary heart disease (Junker et al, 1998; Stec et al, 2000), In
some scenarios, these factors can cause acute clot formation and
block arteries, including coronary arteries, leading to myocardial
infarctions. Finally, elevated fibrinogen levels play a role in atherosclerotic plaque build up. A moderate intake of alcohol will
decrease fibrinogen levels thereby decreasing the above factors.
On the antonymic aspect, alcohol has been proven to increase
the levels of fibrinolytic activity (Pikaar et al, 1987; Aikens et
al, 1998; Sierksma et al, 2001). In addition to alcohol decreasing fibrin building, it is also able to increase fibrin catalysis.
Experiments have shown that moderate levels of alcohol can increase levels of plasminogen activator, which converts plasminogen to plasmin, one of the enzymes that catalyzes fibrin clots. As
a result, the hemostatic process of fibrinolysis is increased. By
increasing the fibrinolytic activity in the body, clots are less likely to form thereby reducing strokes and ischemic incidents. In
fact, many medications that treat heart diseases work through
similar mechanisms by inhibiting Plasminogen activator inhibitor-1, which acts exactly as its name indicates -- by inhibiting the
inhibitor, the activator is increased (Vaughan, 2011).
Another hemostatic aspect of moderate alcohol intake is its
effect on platelet aggregation. Experiments have shown that alcohol can decrease platelet aggregation, subsequently decreasing the risk of cardiac incidents (Zhang et al, 2000; Pikaar et
al, 1987; Renaud & Ruf, 1996, Parson,1996). Platelet aggregation
is a pivotal player in controlling and carrying out hemostasis.
Moreover, it is a significant factor when it comes to atherslerotic heart disease. Atherosclerosis starts with the oxidation of
lipoproteins which are responsible for creating lesions on the
arterial wall. These lesions expose the endothelium thereby allowing platelet receptors to open to accepting signals that allow
platelets to begin adhering to one another. Platelets are also responsible for amplifying the signal that attracts leukocytes such
as monocytes and lymphocytes. These cells have been previously proven to advance atherosclerosis through many mechanisms
including the uptake of cholesterol up to the point of rupturing.
Additionally, platelets contain chemokines within them that are
released when platelets are activated. These chemokines are
also factors that play a role in the propagation of ahterslerosis
(Kaplan & Jackson, 2011; Weber, 2005).

11

Eli Derdik

Insulin Sensitivity Increase
Alcohol has been shown to increase insulin sensitivity in insulin resistant individuals. (Sierksma et al, 2003; Joosten et al,
2008; Fachinni, Chen, & Reaven, 1994). There is a correlation
between these individuals and higher risk for coronary heart
disease. The precise mechanisms for this correlation are unknown but hypothesized as follows (Sparks, Sparks, & Adelhi,
2012). In one hypothesis, muscle and fat tissue resistance to
insulin causes an increase in plasma insulin and free fatty acid
concentrations. Subsequently, this deadly combination will lead
to Very low density lipoprotein (VLDL)-triglyceride secretion ,
which leads to higher triglyceride plasma levels. Another possible hypothesis suggested is that in insulin resistant individuals, there is a defect that does not allow insulin to properly
regulate VLDL-triglyceride secretion thereby leading to hyperglyceridemia. In both of these mechanisms, the end result is an
increase in triglycerides found in the plasma which, through an
additional mechanism, is associated with coronary heart disease
(Hokanson, 2002).

Discussion
Many scientists disagree with these hypotheses set forth above.
Some attack the conclusions themselves while others question
the experiments based on external biases and statistical errors.
One proposed argument is that the control group of abstainers
from alcohol in the experiments had been tainted by ex-drinkers who became abstainers due to health risks. These individuals either realized themselves or were directed by medical
providers that they had to stop drinking for their overall health
and/or their potential for a cardiac event. If this were true, then
using these individuals as the control for the experiments would
completely ruin the results as these individuals are much more
prone to having cardiac problems due to their previous consumption. However, this contention has been accounted for in
many experiments. The experiments have made sure that their
control groups consisted of individuals who have never been
excessive drinkers as well as others that have been lifelong
abstainers from alcohol.

did not improve the individual’s risk for cardiac incidents (Keene
et al, 2014). Now, this is strongly contended by many other experiments and it would seem likely that there is some other
explanation for why Dr, Keene did not find any improvement
in his experiments. However, this is a curious experiment that
should be taken into account.
All in all, there is sound evidence and scientific proof to say
with confidence that alcohol exerts some level of cardioprotection by increasing HDL concentrations, in particular the
HDL2 and HDL3 subfractions. The mechanism behind this is
not fully understood. However, the hypotheses reported above
may shed some light on this area. The experiments supporting
the cardioprotective effects of moderate alcohol use have been
performed with significant numbers of subjects representing all
people of all races, sexes and socioeconomic backgrounds.There
have been over 40 experiments proving this point. Granted that
some of these experiments do have some faults and biases with
patients, but taken as a whole, the experiments clearly indicate
a significant cardioprotective trait of alcohol. However, this only
accounts for roughly 50 percent of alcohol’s cardioprotection.
Regarding the other 50 percent of cardioprotection, there is
also sound basis to say that alcohol will decrease circulating
fibrinogen, increase fibrinolytic activity, and decrease platelet
aggregation. All these factors have been proven by proper
scientific experimentation. Although some may contest these
results because a few of the experiments were conducted in
vitro and not on people, the results were sound and the newer
experiments have verified this to be true.
With regard to increasing insulin sensitivity there is a lot unknown about the mechanisms by which insulin resistance harms
the cardiovascular system and how alcohol increases sensitivity.
However, from all the experiments it would seem clear that
there is an increase in the sensitivity even if we are not clear
about how it happens.

Conclusion
Another potential problem that has been raised concerning the
experiments is the determination of what type of people make
up the moderate alcohol intake group. The concern is that perhaps individuals who are moderate drinkers of alcohol come
from healthier homes or have healthier lifestyles. These concerns extend to the possibility that they have potentially better
exercise routines, higher education, and better health insurance.
With regard to the claims of cardioprotection by HDL increases, there is some question as to whether increasing HDL will
even have any impact in cardiac incidents. According to Dr.
Daniel Keene, pharmacologically increasing HDL and its effects
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Based on all the evidence and experimentation is seems evident
that there are benefits to moderate alcohol intake. To go so far
as to recommend alcohol as a remedy or even a supplement to
those in risk of coronary heart disease does not fall under the
purview of this paper. It may be true that alcohol will reduce
the risks for heart disease up to 30 percent. However, we need
to be cognizant of the potential risk and damage that alcohol
may cause on other parts of the body. To summarize, medical
professionals should not be so quick to dismiss alcohol as a
deadly drug, rather they should research and weigh the cost
versus benefit and advise their patients accordingly.

Effects of Moderate Intake of Alcohol on Coronary Heart Disease

It would seem clear that since alcohol has cardioprotective
attributes, the French paradox is not very paradoxical. The
French diet includes a consistent moderate intake of alcohol,
which would explain the lower coronary heart diseases rate in
France. Although this may not be the only explanation for why
the French cardiac mortality rate is much lower, alcohol intake
is proven to be a valid hypothesis.
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Abstract
The legitimacy of psychotherapy can often be thrown into doubt as its mechanisms of action are generally considered
hazy and unquantifiable. One way to support the effectiveness of therapy would be to demonstrate the physical effects
that this treatment option can have on the brain, just like psychotropic medications that physically alter the brain’s
construction leaving no doubt as to the potency of their effects. Beginning with the understanding of therapy as a behavior, this paper first questions the possibility of behavior effecting measurable change on the brain. Examining diverse
samples of both animals and humans repeatedly shows that the excessive exercise of spatial memory and mapping activities, which rely on the hippocampus, correlates with targeted hippocampal growth and modulation.The hippocampus
reliably enlarges when over exercised. With this correlation demonstrated, this paper returns to therapy to find that
Cognitive Behavioral Therapy (CBT), of all psychotherapies, modulates the brain in the very same pattern effected by
targeted spatial and mapping behavior.These twin correlations lend credence to each other and their surprising similarity is best explained by the hippocampus’s chief role in declarative memory. Both spatial memory and CBT rely on skills
and behaviors regulated by declarative memory, lunder the jurisdiction of the hippocampus.This paper aligns the strong
evidence of the spatial memory- hippocampal growth correlation with the CBT- hippocampal growth observation to
show that CBT does indeed leave observable effects on the brain and real impressions on the patient.
Introduction:
Objective
This paper will explore how targeted use of the hippocampus
leads to its morphological modulation and growth, with the
overall goal of demonstrating how targeted behavior can demonstrably alter the brain. Specifically, the hippocampal growth
correlated to its cognitive-map character will be explored. The
correlation between the practice of spatial mapping activities
and hippocampal growth will be examined in animals and humans. With hippocampus growth in response to these specific
activities firmly established, this paper will attempt to correlate
this observation to an area where it can have real-world application: therapy. The therapy that will receive particular focus is
Cognitive Behavioral Therapy (CBT). This focus is due to the
observation that CBT, out of all psychotherapies, specifically
effects brain modulation along the very same lines as spatial
memory and practice of mapping skills.

Figure 1:The human hippocampus, right lateral view
(http://neurowiki.dk/images/8/83/Hippocampus0.png

What Is the Hippocampus?
The hippocampus is a seahorse shaped structure located in the
medial temporal lobe of the brain. It has two lobes that each
process a different type of memory. The right lobe is mainly
responsible for viseo-spatial memory and the left lobe primarily
works with verbal or narrative memory (Burgess, et. al. 2002).
However, this lateralization is general; current research suggests
that the storage and retrieval of both types of memories, especially the spatial subset, are more universally distributed across
the whole hippocampus. This is evidenced by “cells coding for
the same location [in reference to viseo-spacial memory] being
distributed over the entire hippocampus.” (Moser, Moser, 1998).
The hippocampus is considered the center of the declarative
memory system. Declarative memory, also known as explicit
memory, is the type of memory that can be consciously recalled
and put into words, such as for facts and verbal knowledge
(Ullman, 2004). It includes “episodic memories” which are autobiographical and personal, and “semantic memories,” defined
as general knowledge about the world (Burgess et. al. 2002,
Schachter et. al. 2009). As part of its role in declarative memory
“the hippocampus is central to the rapid acquisition of declarative knowledge about the environment, generating a so-called
cognitive map.” (Voermans et. al. 2004).
The cognitive map theory is the most current explanation for
how organisms create and store memories of their environment. This theory “proposes that the hippocampus of rats and
other animals represents their environments, locations within
those environments, and their contents, thus providing the basis
for spatial memory and flexible navigation.” Essentially, the hippocampus builds a personal map of an organism’s environment
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as the organism navigates its way through it. Interaction with
the frontal lobes of the brain “timestamps” each addition to the
cognitive map, creating context and adding episodic character to
the map (Burgess et. al. 2002).
The hippocampus has been observed to work in close conjunction with the caudate nucleus of the basal ganglia, a part of
the brain responsible for forming associations between place
and stimulus, thus leading to habitual behaviors. Both systems
can work together, but non-competitively, in route recognition.
When an organism returns to a previously visited location, the
hippocampus uses its cognitive map to help recognize the location while the caudate contributes by recalling the personal memories of what occurred in this place the last time the
organism was there. The hippocampus and caudate traverse
different paths to come to the same conclusion: place or route
recognition. Each are capable of recognizing a location on their
own, via their alternative methods, but the possibility of enhanced recognition resulting from interaction between the two
has been studied (Voermans et. al. 2004).
This is an example of the current trend in scientific research,
in which many scientists study the interrelations and delocalization of brain function, based on the premise that “because
the cognitive systems of the brain work in an integrated fashion, presumably the different memory systems do not work in
isolation.” (Voermans et. al. 2004). As such, much research has
been done on the interactions and communication between
the hippocampus and various other parts of the brain whereas,
historically, focus had been placed on defining each brain area
and its specific function. This makes focus on the morphology,
function, and effects of one specific brain structure difficult but
this paper will attempt to focus on the hippocampus specifically.

Methods
Information for this paper was obtained through various databases made available through the Touro College library. Relevant
Internet searches, via Google, were also used to help lead to resources. Keywords included hippocampus, declarative memory,
cognitive behavioral therapy, and brain modulation. Textbooks
on therapy were consulted as well.

Discussion:
Animal Studies of the Hippocampus
The clear effects of an organism’s mapping behavior affecting
physical changes on its hippocampus were initially observed in
black-capped chickadees in Ithaca, NY. Chickadees are small,
non-migratory, food-storing birds in the same family as jays and
nutcrackers. These birds “showed a peak in relative hippocampal size in October, at the same time of year that food storing
was reported to be greatest in this population of chickadees.”
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(Sherry, Hoshooley, 2010). This peak was specific to the hippocampus; two other brain areas measured for control did not
undergo any change at all. Additionally, this change was assuredly
due to their increased mapping activity and not the alteration in
day length (photoperiod) that occurs in the fall, as manipulating
the day length experienced by captive birds had no effect on
hippocampus size (Sherry, Hoshooley, 2010). Taking this together with previous studies that lesioned the avian hippocampus
and observed how this specifically “disrupted memory for the
locations of caches, because caching performance, feeding, and
other behavior were not affected” assures the hippocampus’s
central role in cache mapping/memory (Sherry,Vaccarino, 1989).
Therefore, it is safe to conclude that the correlation between
the chickadees’ behavior and their hippocampus size is causal.
The chickadees’ food storing activity, which involves tracking
down nuts and seeds, hiding these finds in multiple caches, and
most importantly recalling the location of each cache, exercises
and expands the hippocampus.
In fact, the research team in this study worried that their observations may not be readily replicable because “in captivity, it
may not be possible for birds to engage in enough food storing
and cache retrieval to produce the changes in hippocampal size
and neurogenesis observed in the wild.” (Sherry, Hoshooley,
2010). This concern insinuates that once a certain threshold of
practice of this behavior is reached, the hippocampal change is
inevitable. It also shows that certainly it is some excessive level
of practice of these activities, food storing and cache retrieval,
that directly enlarges the hippocampus.
In a remarkably parallel finding, the hippocampi of Northeastern
red squirrels, creators and hoarders of multiple caches of nuts,
in an activity self-descriptively named “scatterhoarding,” are
larger than the hippocampi of their close cousins, the gray
squirrels of the West Coast. The non-hoarding gray squirrels
have no winter to contend with and so have no need to utilize
the spatial mapping and recall skills specific to the hippocampus
to scatterhoard for the future when food will not be available
(Johnson et. al. 2010).
Notably, red squirrel hippocampus size has even been shown to
fluctuate along with their hibernation patterns. When the squirrels are up and about, busily finding, hoarding, and creating mental
maps of their caches, their hippocampi are larger than when their
body temperature decreases to the point of initiating torpor, or
hibernation, and thus cessation of all such activities (Millesi et. al.
2001). Like the chickadees, the red squirrels are clearly modulating their own hippocampi through their behavior.
Homing pigeons, known specifically for their mapping and
spatial skills, are a natural species to look for the hippocampal
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Figure 2: Coronal section through brain of homing pigeon with area
of study, hippocampus, outlined. (Cnotka et. al. 2008)
growth observed in chickadees and squirrels. Citing studies
similar to those discussed above, researcher Cnotka and her
team hinge their study on the fact that “the hippocampus plays
a critical role in processing spatial information both in birds and
in mammals.” (Cnotka et. al. 2008). And indeed, when these
researchers examined the brains of the pigeonsthey found that
homing pigeons possess disproportionately larger hippocampi
for their body mass (Figure 2). A separate research team compounded this research by finding “morphological and histological differences in hippocampal tissue in homing and non-homing
pigeons” (Shapiro, Wieraszko, 1996).
Additionally, comparing carrier pigeons that are allowed to fly,
explore their barns, and map out new routes with pigeons that
are confined to their cages, revealed the explorer pigeons to
have measurably larger hippocampi (Cnotka et. al. 2008). The
comparison between the explorer pigeons and the cage-confined pigeons directly parallels the above comparison between
the red squirrels and gray squirrels. Both directly prove that
when an animal stresses its hippocampus, the hippocampus will
remodulate and enlarge.

Neurogenesis
Although it has been firmly established that animals who exercise
their hippocampus directly affect their hippocampi’s growth, the
cause of this phenomenon has not been determined.The team of
researchers who conducted the study on homing pigeons admit
just that. They write, “in our study we have not determined what
is responsible for this increase in volume, but it would be interesting to see why the hippocampus might be larger. Existing cells
could increase their cell body size or build up larger dendritic
arbors, new neurons or glia could be added, or there could be
increased vascularization.” (Cnotka et. al. 2008).
Meanwhile, the researchers who observed the hippocampus
growth in New York chickadees were able to squarely implicate

neurogenesis as the mechanism of growth. They did this by administering to wild birds “injections of tritiated thymidine, [3H]
thymidine, which is incorporated into the nucleus of mitotic
cells” (Sherry, Hoshooley, 2010). [3H]thymidine is a commonly
used radioactive cell marker that newly forming cells incorporate into their DNA, thus differentiating the new cells from preexisting cells (Toyohara et. al. 2002). The researchers then released the chickadees back into the wild.When they recaptured
the birds, they found that “birds given [3H]thymidine in October
had more labelled hippocampal cells when captured six weeks
later than birds injected in August or February/March.” (Sherry,
Hoshooley, 2010). Evidently the birds generated more cells in
their hippocampi in October, when their scatterhoarding activity levels were high, than in the months when they were not
exercising their hippocampi excessively.
Neurogenesis would seem to be the most likely explanation for
hippocampus growth but the possibility of new brain cells being
created “on demand” should not be taken for granted. This is
because “in most brain regions, the generation of neurons is
generally confined to a discrete developmental period,” and so
growth would really not be possible at any time for most areas.
Eriksson et. al., (1998), originally demonstrated the presence of
progenitor cells, from which newborn neurons are generated
and so the prerequisites for new cell growth, only in specific
parts of the brain. Among these parts was the hippocampus.
He showed this by injecting human cancer patients with “a thymidine analog, BrdU [that] is incorporated into the DNA of
dividing cells” and then after the patients died, dissecting their
brains to find labelled cells in the denate gyrus of the hippocampus (Eriksson et. al. 1998). These labelled cells indicate the
presence of new neurons, and so progenitor cells, specifically in
the hippocampus.This finding is crucial to correlating the animal
studies to humans and offers the mechanistic explanation for
how the hippocampus gets bigger. It shows that new neurons
can indeed be grown in the hippocampus and that this growth
can be initiated at any time – including whenever mapping skills
are exercised. Eriksson’s study essentially opened the door to
neurogenesis and, as he ends off his report, “the potential to
regulate human neurogenesis should prove to be an interesting
area of investigation.” (Eriksson et. al. 1998). The data in this
paper enthusiastically supports this proposition.

Neuromodulation
In contrast, another research team focused on “the plastic processes that underlie long term potentiation” as the mechanism
by which an organism can remodel its “mental map,” or hippocampus.This team defines long-term potentiation as “a long-lasting, activity-dependent enhancement of synaptic strength that
has been extensively studied in the hippocampus.” (Kentros et.
al. 1998). In their study, they observed how rats build their
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mental maps by encoding each cell in their hippocampus with
a different aspect of the place they are in. These programmable cells were appropriately named “place cells.” It is then the
“conjoint activity of place cells [that is] thought to be the basis
of a map of the environment that the animal uses for solving
spatial problems.” (Kentros et. al. 1998). With this proposition
for the construction of the mental map in place, the researchers
then demonstrated that place cells, and the connections and
interactions between them, can be reprogrammed based on the
rat’s activity. Essentially, the team demonstrated the ability of the
hippocampus to remodulate, in addition to expand, in response
to excessive use (Kentros et. al. 1998).
Taken together, notable hippocampal neurogenesis and neuromodulation correlates with the specific exercise of the hippocampus via practice of hippocampus-centric behaviors, namely
those that rely on spacial mapping and recall activity.

Onward to the Humans
Having examined how the hippocampus specific behaviors of a
wide range of animal species cause direct growth of the hippocampus, and accounting for this growth with evidence for neurogenesis and neuromodulation in the hippocampus, this paper
turns to the likelihood of this causation occurring in humans as
well. Are human brains, specifically the hippocampi, as manipulatable and malleable as those of rats, squirrels, chickadees, and
pigeons?
Blithely referencing the sum of the extensive work that we have
examined thus far, researcher Eleanor Maguire states, “the volume of the hippocampus in nonhumans is known to vary as a
function of the demands placed on spatial memory.” (Maguire
et. al. 2006). With this firmly established, Maguire and her

co-workers performed a landmark study comparing the brains
of London taxi drivers with the brains of London bus drivers.
London is famous for its convoluted cityscape and so its taxi
drivers are required to spend about two to four years studying
its design and navigating its intricacies in order to be ready to
pass the test required to get licensed as professional drivers.The
taxi drivers’ process to proficiency is rigorous and heavily reliant
on the hippocampus. Just as it was observed with regard to the
chickadees, squirrels, and pigeons, Maguire and her team report,
“...years of navigation experience correlated with hippocampal
gray matter volume only in taxi drivers [and not in London’s bus
drivers], with right posterior gray matter volume increasing and
anterior gray matter volume decreasing with more navigation
experience.” (Maguire et. al. 2006). Since London bus drivers
matched with London taxi drivers in “driving experience and
levels of stress, but differed in that they follow a constrained set
of routes,” they provided the perfect comparison group to the
taxi drivers who must learn and then navigate “25,000 streets
and the locations of thousands of places of interest.” (Maguire
et. al. 2006, Woollett, Maguire, 2012) Therefore, comparing the
taxi drivers, who must continuously re-navigate and calculate intricately mapped out routes, to bus drivers, who merely retrace
a limited set of preset routes, shows that it is specifically the
mapping activity that remodels and expands the hippocampus.
Maguire confirms for animals and revolutionarily proves that
for humans as well, that to modulate the hippocampus “the key
factor seems to be utilizing a complex spatial representation
over years of navigation.” (Maguire et. al. 2006)
The clear growth of the hippocampi of London taxi drivers
in response to their spatial mapping behaviors highlights that
humans are indeed capable of modulating their own brains.
People who spend years stressing their hippocampi will reliably enlarge them. The London taxi drivers study also shows
that, surprisingly enough, changing one’s own brain is really not that hard. This opens for consideration the reach of
self-induced brain manipulation. To what extent can humans
modulate their own brains, through what activities, and to
what benefit?

The Relevance to Therapy

Figure 3: Hippocampal activation upon naviagtion through novel
environments. (Maguire et. al. 2002
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Answering these questions is of particular pertinence to psychologists, specifically those who practice therapy. This is because, “if psychotherapy is regarded as a form of learning, then
the learning process that occurs in psychotherapy may produce
alterations [in the brain].” (Gabbard, 2000). Researchers seek
to highlight the physical, observable effects of therapy on the
human brain to help prove the therapy’s efficacy. And indeed,
multiple fascinating observations have been made.

From Squirrels to Cognitive Behavioral Therapy (CBT):
The Modulation of the Hippocampus

In 1992, a study contrasting different forms of treatment for depression found that “behavior therapy and fluoxetine [a common
antidepressant] appear to produce similar decreases in cerebral metabolic rates in the head of the right caudate nucleus.”
(Gabbard, 2000). The caudate nucleus is part of the basal ganglia
and responsible for “the acquisition of place-appropriate responses leading to habitual behavior,” (Voermans et. al. 2004). While it
does function in a memory system separate from the hippocampus, the two do have comparable enough roles that in the event
of degeneration of one, the other can compensate (as detailed
earlier in this paper). According to this study, “both memory systems support navigational memory, albeit based on the processing
of different representations. It has been hypothesized that both
systems work in parallel, receiving similar input information, but
processing this information according to principles that emphasize different relationships among the elements of a given event
or situation” (Voermans et. al. 2004). Importantly, the basal ganglia,
like the hippocampus, does possess progenitor cells for growth by
neurogenesis (Erikkson et. al. 1998).
The similarity between the roles of the basal ganglia and the
hippocampus help the modulation of one stand in as evidence
for the possibility of the modulation of the other. Similar functions means that similar activities will affect their size and shape.
With the overwhelming evidence that this paper has examined
for hippocampus-centric activities modulating the hippocampus,
it follows that similar activities, only different in that they are
reliant on the caudate, would modulate the caudate. If this is so
then we can consider how the activities that the researchers
found here to modulate the caudate, Behavior Therapy, might be
similar to the activities that modulate the hippocampus (spatial
memory and mapping behaviors).
Another research team comparing the effects of different mental health treatment forms showed that “cognitive behavioral
therapy appears to cause biological changes in people with panic
disorder.” (Gabbard, 2000). These researchers first observed
that individuals with panic disorders inappropriately release lactate in response to certain stimuli. This lactate then serves to
trigger the panic attack. The researchers treated the individuals
with CBT and tested the CBT’s effectiveness by injecting them
with the triggering lactate. The team saw that, after treatment,
“the induction of panic by lactate... [was] effectively reversed
through successful cognitive therapy. In other words, panic disorder sufferers in whom, before starting therapy, attacks were
precipitated by injection of lactate no longer responded in that
manner after therapy.” (Shear et. al. 1991). While this study does
not bring the physically observable effects of the therapy studied
down to the level of the brain, it does provide another exhibit
of therapy, an action, inducing physiologic, measurable effects.

A similar set of results, proving that performing the actions
proscribed by therapy induces physiologic responses, comes
from a research group who measured the variation of certain
hormone levels of depressed patients in conjunction with CBT.
They “observed that in a group of outpatients with mild major
depression, responders to cognitive behavior therapy had significantly greater decreases in T4 levels and free T4 index than
nonresponders” (Joffe et. al. 1996). The researchers propose
that this is part of the whole “cascade of biological events that
effect a therapeutic response in depression” (Joffe et. al. 1996).
Here the physiological effects of therapy are found in hormone
level variation, but it is assumed that digging a bit deeper would
reveal modulation to the brain.

The Specific Effect of Cognitive Behavioral
Therapy
Notably, these studies all tend to refer specifically, out of all
the forms of therapy available, to Cognitive Behavioral Therapy
(CBT). It seems that CBT is different from other forms of therapy and that it is especially effective in inducing measurable morphological brain change.
A practical guide for clinicians to employ CBT helps define this
treatment method: “CBT is based on two central tenets: 1) our
cognitions have a controlling influence on our emotions and
behavior; and 2) how we act or behave can strongly affect our
thought patterns and emotions” (Wright et. al. 2006). The cognitive portion of CBT works to resolve cognitive errors that
contribute to an individual’s disorder, such as overgeneralization
and magnification, and the behavioral component consists of
the patient learning and performing actual tasks such as breathing modification and journaling “ (Wright et. al. 2006). CBT’s
in-practice structure consists of four basic steps that reflect
these principles: 1. relabel unwanted thoughts as symptoms of a
brain disorder, 2. reattribute these thoughts to the dysfunctional
brain, 3. change behavioral responses even though the thoughts
are still there, and 3. revalue the thoughts as less important
(Beauregard, 2014). Based on the evidence thus far of actual
behaviors modulating the brain center they rely on, it makes
sense that the action centric, goal oriented CBT would be the
type of therapy most likely to induce brain changes.
Dr. Aaron Beck, the founding father of CBT, stressed the importance of patient action and involvement in his or her own therapy. The structure of the patient - therapist relationship, termed
“collaborative empiricism,” expects the patient to work as an
equal partner to the therapist in solving his or her problems. The
patient is assigned behavioral tasks and homework assignments
to personally, actively accomplish (Wright et. al. 2006). More than
the therapy “being done” on the passive patient until the patient’s
problems are fixed, in the CBT model the patient is taught how to
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remodel his or her own beliefs in conjunction with being told to
perform self-driven actions. It is through fastidious participation
and performance of these actions that the patient is “fixed.”
Evidently, the actions proscribed by CBT rely on the hippocampus because, as this paper began to describe, multiple studies
correlate the effectiveness of CBT with enlargement or modulation of the hippocampus. This relationship has been observed
in patients treated with CBT for panic disorder (Beauregard,
2014), social phobia (Goldapple et. al. 2004), obsessive-compulsive disorder (Goldapple et. al. 2004), post-traumatic stress
disorder (Levy-Gigi, Keri, 2014), spider phobia (Paquette et. al.
2003), and depression (DeRubeis et. al. 2008). And so, just as
the London taxi drivers’ spatial mapping behaviors modulated
their hippocampi, the active CBT patient evidently relies on the
hippocampus when he or she performs the CBT-assigned tasks
and thereby enlarges his/her hippocampus.

CBT for Depression
An illustration of CBT’s effect on the brain can be found in
a clinical study comparing the effects of CBT and paroxetine
(a standard antidepressant) on the depressed brain. Based on
the premise established by multiple clinical trials “in patients
with both mild and severe major depression consistently
demonstrate similar rates of response to cognitive behavior
therapy (CBT) and antidepressant pharmacotherapy,” a team of
researchers hypothesized that, while the observable effects of
these two treatments are practically identical, their mechanisms
of action are likely very different (Goldapple et. al. 2004). After
administering a full course of CBT to a sample of depressed patients, the researchers imaged the patients’ brains (Figure 5) and
indeed found a pattern very distinct from that of paroxetine.
They found that “areas of increased metabolism before to after
treatment included the hippocampus and dorsal midcingulate”
and that the changes effected by CBT were actually in the inverse direction of those caused by paroxetine (Goldapple et. al.
2004). CBT treatment effected “regional changes [that] involve
sites similar, and in some cases identical, to those seen previously
with paroxetine and other pharmacotherapies, but the changes
were in the opposite direction.” (Goldapple et. al. 2004). Where
paroxetine decreased hippocampus size and connectivity, CBT
enlarged it. Therefore, it is seen that modulating the hippocampus is a unique, effective method for treating depression that is
distinctly accomplished by CBT. Notably, CBT was seen here to
both expand and remodulate the hippocampus.
However, it seems that opposite conclusions were observed
in a separate imaging study. Here, “MDD [Major Depressive
Disorder] participants displayed a greater activation in the subgenual cingulate cortex, medial PFC, and left anterior hippocampus/amygdala before treatment, and a reduction in these brain
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regions after long-term psychodynamic therapy.” (Beauregard,
2014). Essentially, the research team here saw therapeutic intervention shrink the hippocampus! A possible explanation
for this opposite observation is the use of a different therapy,
not CBT in particular, as intervention. Perhaps its mechanism
is like that of paroxetine, which helps alleviate depression but
via a pathway that modulates the brain into a pattern inverse
to that of CBT (Goldapple et. al. 2004). Therefore, rather than
confounding conclusions formed thus far, this contradictory observation can help reinforce the special effect CBT alone has on
the hippocampus.

CBT for PTSD
A separate research team headed by Levy-Gigi examined the effects of CBT on the brains of patients suffering from PTSD.They
found that “morphological changes associated with psychotherapy were confined to the hippocampal formation and cingulate
cortex.” (Levy-Gigi, Keri, 2014). PTSD is especially relevant as it
has long been specifically correlated with smaller hippocampal
size. Researchers in 1997 “showed that the left hippocampal
volume in adults with post-traumatic stress disorder who had
experienced childhood physical and sexual abuse was dramatically reduced when compared to that in matched controls.”
(Gabbard, 2000). Therefore a treatment that directly enlarges
the hippocampus would likely be especially effective.
Indeed, Levi-Gigi’s team reports that “the most noteworthy
finding of this study was that clinical improvement during CBT
in PTSD was associated with increased hippocampal size and
elevated FKBP5 gene expression, a cellular regulator of the
glucocorticoid receptor.” (Levy-Gigi, Keri, 2014). First, confirmation of the way CBT enlarges the hippocampus is proffered.
Second is the introduction of the gene FKBP5, a “regulator
protein of the cortisol receptor and [since] abnormal cortisol
secretion is linked to hippocampal atrophy, it is reasonable to
hypothesize that the amelioration of FKBP5 gene expression
had a causal role in the normalization of hippocampal volume.”
(Levy-Gigi, Keri, 2014). This hypothesis says that elevated levels
of this particular gene, FKBP5, can be aligned with and seen as
confirmation for hippocampal enlargement.
Levy-Gigi and her associates also returned to the previous discussion on what exactly is behind the hippocampal enlargement
observed, considering how “possible mechanisms may be enhanced neurogenesis, increased neuronal size, and enrichment
of dendritic arborization.” (Levy-Gigi, Keri, 2014). According to
the evidence examined previously, it is likely that the progenitor cells observed in the hippocampus, and so neurogenesis, is
the mechanism behind the hippocampal growth observed here.
Neuromodulation, or the reconnectivity and recharacterization
of hippocampal cells, likely occurred as well.

From Squirrels to Cognitive Behavioral Therapy (CBT):
The Modulation of the Hippocampus

CBT for Spider Phobia
Anxiety disorders, such as phobias, respond well to CBT intervention. This is because anxiety disorders typically include and/
or come from cognitive errors that CBT can specifically target
and solve (Wright, 2006). One specific phobia studied in conjunction to CBT is spider phobia. The team behind the spider
phobia study says that “although several psychological models
have been proposed to explain the therapeutic effects of CBT,
little is known regarding the neurobiological mechanisms underlying this form of psychotherapy.” (Paquette et. al. 2003). To
investigate this matter they administered CBT to a sample of
spider phobic females, all of whom were deemed responders
to this intervention. However, when the researchers examined
the brains of their spider phobic subjects (via fMRI) before and
after CBT, they found a decrease in hippocampus activity. Before
intervention they found an overactivation of the hippocampus
and after intervention they found this overactivity greatly decreased. This finding directly confounds the extensive research
examined and discussed thus far. Therefore, the generalizability
and validity of this study must be questioned.

The Connection Between Declarative Memory,
the Hippocampus, and CBT
As laid out in the beginning of this paper, the hippocampus is
considered to be the center of declarative memory, which is the
collection of conscious memories people are capable of articulating. The foil to declarative memory is procedural memory,
the contents of which are implicit, operating outside of conscious awareness (Gabbard, 2000). New research has begun
to understand the effects of talk/ interpersonal therapy and
psychoanalysis to be in the procedural, implicit realm. Sigmund
Freud, father of psychoanalysis, himself alluded to implicit memory years before the concept was defined when he “stressed
that what the patient does not remember will be repeated in
the relationship between patient and analyst.” This concept is
defined as “transference,” and in light of modern psychology can
be seen as stemming from implicit memory (Gabbard, 2000).
The patient in therapy will be implicitly affected by the therapist
and his or her relationship to the therapist. Characteristic of
this, he or she will not be able to explicitly articulate the effects
of the psychoanalysis or psychotherapy even though he or she
will exhibit behavioral change.
Illustrating this concept is the lament of psychiatrist Gabbard:
“therapists are often disappointed when they see former patients and ask them what they feel was of most benefit to them
during the years they were in psychotherapy. Much to the dismay of the therapist, patients often do not remember any of
the psychodynamic formulations or interpretations that the
therapist carefully constructed to provide insight. Instead, they
remember a joke the therapist told, a belly laugh they shared,

a moving moment of emotional connection, or a glance exchanged between therapist and patient when a special form of
closeness was felt.” (Gabbard, 2000).
Psychologist Lyons-Ruth interprets these moments in therapy
as a form of “implicit relational knowing when something emotionally reparative transpires without involving the realm of insight or cognitive understanding.” (Lyons-Ruth et. al. 1998). She
and her colleagues believe such moments are a crucial part of
the mode of therapeutic action. Alteration of implicit/ procedural memory and the manipulation of the manifestations of these
types of non-declarative memories, such as transference, seems
to be characteristic of all therapies besides for CBT.
CBT is unique in that it specifically targets explicit memory,
rather than implicit memory. CBT does not attempt to grope its
way through the murky depths of the subconscious, non-declarative, implicit realm. Rather, as illustrated above, CBT’s two
central focuses are on understanding and controlling cognition
alongside altering behaviors in order to affect emotions and
thoughts. Both these actions are necessarily declarative as they
rely on the patient’s explicit understanding, self-motivation, and
complicity.
The hippocampus is the center of the declarative memory system and, stemming from this role, is its spatial mapping responsibilities. Therefore, the linkage between the identical effects of
spatial memory/ mapping skills and CBT on the hippocampus
is their reliance on declarative memory! Both make excessive
use of the hippocampus and so enlarge it. The scatterhoarding
squirrels, the homing pigeons exploring their barns, and the taxi
drivers navigating London make use of the same exact memory modality and brain system as the traumatized, phobic, or
depressed patient carrying out CBT-proscribed actions. Both
groups over-rely on the hippocampus, in its declarative memory role, and so the same pattern of hippocampus enlargement
emerges in both.
The diverse areas of research explored in this paper converge
on the central point that exercising the hippocampus, via exaggerated practice of the skills and behaviors that it is responsible
for, effects its measurable modulation and growth. The pointed
use of the hippocampus’s cognitive map function by the blackcapped chickadees, the red-tailed squirrels, the homing pigeons,
and the rats enlarged the hippocampus in each species. When
the London taxi drivers exaggeratedly employed their parallel
cognitive maps to navigate the city, they enlarged their hippocampi as well. Intensified use of the hippocampus in terms of its
explicit memory responsibilities by CBT patients modulated the
hippocampus along the very same lines.The search for an underlying feature to relate these actions leads to the very definition
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of the hippocampus: the center of declarative memory. All of the
parties discussed in this paper evidently over-employ declarative
memory, and so the hippocampus.

Further Research and Conclusion
Based on the observations and correlations in this paper, further
research could examine if or how other areas of the brain could
be modulated. The declarative memory - hippocampal growth
correlation is so clear and definitive that there must be similar
trends in other areas of the brain. This paper has already observed that similar modulation is possible in the caudate nucleus. Perhaps identifying the specific skill that a different brain area
is responsible for and then excessively practicing this skill would
modulate or enlarge the corresponding brain area as well.
Further research could also examine whether the correlations
in this paper could be looked at in reverse. Could invasively
entering the brain and somehow forcibly enlarging the hippocampus effect an increase in spatial/mapping memory or explicit
memory? And, assuming this enlargement were possible, could
it be used as therapeutic intervention for the same patients that
typically benefit from CBT?
Viewing the relationship in reverse has already been ventured
towards by Maguire, the researcher who studied the hippocampal enlargement of London taxi drivers. She proposed “examination of the characteristics of those who succeed at taxi
driver training, and [asking] whether innate pretraining cognitive
factors and/or hippocampal volume are predictive of successful
qualification.” (Maguire et. al. 2006). In other words, do individuals with naturally larger or more malleable hippocampi, and so
an inborn propensity for spatial memory, gravitate towards jobs
that benefit from this characteristic, such as taxi driving?
The researchers who studied the effects of CBT on PTSD also
mentioned viewing the correlation they observed in reverse.
They proposed the “possibility that small hippocampal size is a
premorbid vulnerability factor for PTSD” (Levy-Gigi, Keri 2014),
looking at the hippocampus size first and the effects that follow
after. If a smaller hippocampus could predispose an individual
to disorders such as PTSD, then perhaps a larger than average
hippocampus could protect them from this and other hippocampus-centric mental disorders. While still strictly conjecture,
research on and validation of this theory might then lead to
hippocampal enlargement becoming standard intervention for
individuals deemed at risk for mental disorders correlated to
the hippocampus. Having observed diverse correlations and
multiple angles, this paper concludes with the vast potential for
practical implications that may arise as researchers begin aligning and synthesizing some of these ideas.
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Abstract
Jet lag is a resulting disorder of flight travel across several time zones. Circadian rhythms, the approximately 24 hour
system that our bodies follow, become distorted following such a trip, as the body’s internal biological clock has not yet
caught up to the current local time zone. Time cues and other external factors are necessary to adjust the clocks and
reverse the negative effects of jet lag.
Introduction
Long flights across several time zones can result in jet lag, similar to what is known as travel fatigue. The effects of this jet
lag are caused by the tight space of the aircraft, limit of food
options, dehydration from the dry air, as well as climate and
lighting changes.The consequences of such jet lag increases with
every additional time zone crossed, as the internal body clock
is unable to adjust properly. This can result in the inability to
sleep at night and improperly timed daily functions. Circadian
rhythms, the internal bodily processes that follow an approximately 24 hour biological clock, require an adjustment period
to correct the negative effects of jet lag. Natural clocks follow
a morning-night schedule which allows a person to function
during daytime and reboot at night. Jet lag can cause a disorder
in this natural system. Prolonged and repeated travel over time
zones have been linked to health problems such as depression,
irregular menstrual cycles, diabetes, fluctuating melatonin secretion, as well as other issues. Upon arrival to the new destination,
the traveler should attempt to regulate his biological clock to
the local time zone. Planning ahead will assist the traveler to
maintain a healthy balance of the body’s internal functions.. The
goal of this paper is to understand what jet lag is, how it occurs,
and how the internal biological clock can be adjusted to relieve
or avoid the symptoms.

such as: indigestion, loss of appetite, among others. Comparing
the studies can be challenging due to the lack of jet lag symptoms. Yet, fatigue, difficulty concentrating, decreased alertness
during the day, weakness, and lethargy have been found as consistent effects (Waterhouse et al, 1997).
The word ‘circadian’ originates in the Latin ‘circa dia,’ which
means ‘about a day,’ because circadian rhythms do not equal
exactly 24 hours, but vary in that range by each organism.These
unalterable rhythms are caused by the constant ticking of the
body’s biological clock in the brain and other organs, and therefore keep many aspects of our body in sync - specifically behavior, metabolism, and physiology (Rosbash, 2003). Jet lag results
from these circadian rhythms breaking out of their natural harmony when the body clock is unadjusted from traveling a great
distance. Our sleep/wake cycles seem to be the most disturbed
by the journey.

Discussion

Crossing three or more time zones is what generally causes
the desynchronization associated with jet lag. The more time
zones crossed, the more severe the jet lag will be. Jet lag will
not occur from traveling north or south. Interestingly, it will be
worse from eastward travel than westward since traveling west
extends the day, thereby allowing for easier correction. After
a flight east, travelers are not tired during the local nighttime,
which is daytime for their unadjusted body clock, but they get
tired as the new day dawns, as it is nighttime for their body.
After a flight to the west, people are more tired in the new
evening at their destination and yet they awaken early. Although
this also a challenging transition, the traveler will be able to go
about his day and settle in (Waterhouse et al, 2007). In one
study, subjects flew between Europe and the United States, over
a 6 hour time difference, and those who traveled on a westward flight adjusted back to peak performance in about 2-4
days. Meanwhile, those who traveled eastward required 9 days
to recover, because instead of shortening the day by 6 hours,
most of the travelers’ internal clocks were delayed by 18 hours
(Coleman and Kim, 1998).

Jet lag, also known as circadian dyschronism, is a temporary
syndrome characterized by various physiological and psychological effects that occur following flights across several time
zones, most likely resulting from circadian misalignment in the
body. An assortment of symptoms have been linked to jet lag,
including fatigue, coexisting with insomnia, irritability, disorientation, headaches, loss of concentration, gastrointestinal problems,

The body clock is located on the suprachiasmatic nucleus
(SCN), which is connected directly to the retina and receives
information about light from the eyes, as well as having receptors for melatonin type 2.Without external inputs and rhythmic
time prompts, the body clock and its daily rhythms can continue, but with a period not exactly 24 hours, as circadian means

Methods
Research articles were obtained from the Touro Library database (tourolib.org), which lead the student to various sites
including ProQuest, PubMed, among others. The articles were
compiled from an assortment of science journals and experimental studies that discussed the definition of jet lag and its
symptoms, the explanation of a body clock and its makeup, with
testing and trials to prove the connection between the two.
Each article was reviewed intensely, and the findings were subsequently arranged into a comprehensive paper in order to fully
describe the term jet lag.
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about 24 hours. Regardless of the exact amount of time, for the
body clock to function properly it must be adjusted to the solar
day via recurring signals in the environment, known as zeitgebers - time-givers.
A zeitgeber’s effect on the body clock depends on the time
at which it presents; a zeitgeber can produce a phase advance,
phase delay, or no phase shift. A phase-curve response is the
relationship between the time the zeitgeber is presented and
the phase shift. The chief zeitgeber is the light-dark cycle and
the secretion of melatonin when a person is asleep at night.
The product of one’s environment and lifestyle, the exogenous
component, together with the body clock, the endogenous
component, form a healthy rhythm when they are in sync.
However, the span of days after a time zone transition causes
the rhythm to falter, because while the exogenous component
has changed, the endogenous component has not yet caught up
to it. Theoretical statistics evaluate rhythms before and after a
time zone transition, showing the loss of synchronization. The
external light is being sent through the retina and is telling the
body that it is daytime, but the internal body clock still feels as
if it is meant to be nighttime, and therefore jet lag reigns. Table
1 advises when exposure or avoidance of bright light will assist
in correcting the body clock upon arrival at the new time zone.
It is based on the observation that light in the morning of body
time will advance the clock, and in the evening of body time will
delay it. These times may not coincide with actual day or night,
and so wearing sunglasses or seeking a light box that mimics the
sun may be necessary to keep the biological clock in its sync
(Waterhouse et al, 1997).

De Mairan put a mimosa plant into a cupboard to observe its
reactions when kept in the dark. He noticed that the leaves
still continued to open and close rhythmically, seemingly by its
own internal interpretation of night and day. His clear-cut finding from this was that the plant had an endogenous component
with an internal biological clock (Foster and Kreitzman, 2014).
Baron and Reid describe circadian misalignment very clearly:
“The term ‘circadian misalignment’ can describe a variety of
circumstances both in the laboratory and natural environment.
In the Oxford Dictionary (2010), ‘misalignment’ refers to ‘the
incorrect arrangement or position of something in relation to
something else.’ One of the most common types of misalignment studied is misalignment of the sleep/wake cycle in relation
to the biological night. Other types of misalignment include
misalignment of feeding rhythms to the sleep/wake or light/
dark cycle, or internal misalignment of central and peripheral
rhythms. Figure 1 presents a schematic depiction of the organization of the central and peripheral circadian rhythms. This
diagram includes zeitgebers (light, melatonin and activity) as well
as the potential causes of chronic circadian misalignment.
Figure 1

Table 1. Use of bright light to adjust body clock on first day after time
zone transition:
Bad local times for exposure
to bright light

Good local times for exposure
to bright light

Time zones
to the west
4h
8h
12 h

0100-0700* (1:00 - 7:00 am)
2100-0300* (9:00 pm - 3:00 am)
1700-2300* (5:00 - 11:00 pm)

1800-2400+ (6:00 pm - 12:00 am)
1400-2000+ (2:00 - 8:00 pm)
1000-1600+ (10:00 am - 4:00 pm)

Time zones
to the east
4h
8h
12 h

0200-0800+ (2:00 - 8:00 am)
0600-1200+(6:00 am - 12:00 pm)
@

0900-1500* (9:00 am - 3:00 pm)
1300-1900* (1:00 - 7:00 pm)
@

*Will advance to body clock. +Will delay the body clock.
@Treat as 12-14 h to the west, since the body clock adjusts to delays more easily than
to advances.Source:Waterhouse et al, 1997

This concept of an endogenous clock following circadian
rhythms has been around for centuries. A French astronomer
named Jean Jacques d’Ortous de Mairan conducted a simple
experiment on a mimosa plant, which he knew to be a heliotrope. He saw that it was also responsive to the sun by raising
its leaves during the day and drooping upon the fall of darkness.

The timing of melatonin onset under dim light conditions (dim
light melatonin onset or DLMO) and the core body temperature minimum are often used as markers of circadian timing.
The timing of these circadian markers in relation to sleep/wake
behaviors is commonly referred to as phase angle, and has also
been used as a measure of circadian alignment. For example,
the duration between circadian markers (DLMO or core body
temperature minimum) and sleep timing (onset, midpoint or
wake time) has been evaluated. Individuals with evening chronotype (preference for later timing of sleep and activity) have been
shown in some studies to have a shorter phase angle between
circadian markers and sleep, indicating that they sleep and wake
earlier in their circadian phase. One of the most significant and
immediate consequences of misalignment of the sleep/wake
cycle to the biological night is sleep disturbance and/or daytime sleepiness. Insomnia, difficulty waking in the morning and

25

Shayna Melool

sleepiness caused by circadian misalignment are typical symptoms that lead patients to seek care in sleep clinics for circadian disorders. However, the physiological and psychological
consequences are much broader than sleep/wake disturbance.
These include changes in feeding patterns, metabolic function
and risk for mood disorders. Other types of disruption include
internal misalignment of rhythms, such as timing of central versus peripheral clocks. For example, research in animal models
has demonstrated that altering availability of food timing shifts
peripheral (e.g. hepatic) but not central rhythms.” (Baron and
Reid, 2014).
There are many bodily processes controlled by day-night
rhythms, such as blood pressure control, feeding behaviors, and
lipid and carbohydrate metabolism, among others.The circadian
clock, a continuous internal system of transcriptional loops, is
what controls this regulatory biological movement, and these
looping pathways balance each other out. In example, transcription factors such as Clock and Bmal1 control the assembly of
proteins like Per and Cry, which then regulate the assembly of
Bmal1, resulting in the levels of Bmal1, Clock, Per and Cry fluctuating regularly. Various input signals, zeitgebers like light and
hormones, can change these loops and ‘reset the clock’ so to
speak (Staels, 2006). In another study of two groups of travelers,
after a flight with a 6 hour difference one group remained inside
a lab for a week while the other group spent time outside. The
group that went out adapted to the new time zone in half the
time that the indoor group needed. Local time cues, like lightdark cycles and meal times, among others, are what allowed the
second group to synchronize quicker (Coleman and Kim, 1998).
The concept of “social jet lag” has been mentioned in current
research as well.This is a form of persistent circadian disruption
that corresponds to the time difference between routine sleep
cycles during the work/school week and free time on weekends.
It is a weekly discrepancy in the internal body clock, which can
be comparable to journeying across three to four time zones
twice a week for someone who wakes up at 6:00 AM during the
week and sleeps until 9:00 or 10:00 AM on the weekend. There
has been discovered an association in the affirmative between
the extent of this “social jet lag” and body mass index, suggesting yet again that the interference of circadian cycles contributes to weight gain, among other possible issues (Summa and
Turek, 2015).
It all seems to come down to the body clock and its adjustment.
But what does that truly mean? What is this clock? It was first
believed that there was a single master clock in the suprachiasmatic nucleus in the brain which regulated numerous biological
processes within the body. It was later discovered that there are
additional peripheral clock genes in the liver, kidneys, pancreas,
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heart, and other tissues. We now know that these clocks manage the activity of three to ten percent of genes in various tissues, and in some cases maybe even as much as 50%. If any of
these clocks fall out of sync with the master clock, which is
possible from sleeping at the wrong times, the frenzy within the
body can lead to obesity, diabetes, depression, and many other
complicated disorders.The clock gene in the heart sends signals
in the early morning to prepare the heart for the harshness
of awakening, an explanation as to why so many heart attacks
occur at dawn hours. The peripheral clock in the liver functions
strongly with the metabolism, contributing to the regulation
of normal blood glucose levels over the course of the day to
make certain there is a steady flow of energy for brain function
and body processes. There is still a system required to combat
excess blood glucose due to eating, with insulin the primary
hormone in charge of that regulation by starting the removal of glucose from the bloodstream. Insulin is produced in the
pancreas, where there is another biological clock that is vital
to sustaining normal blood sugar levels. Any disruption of that
clock can damage pancreatic function and result in diabetes, a
metabolic disorder in which the body produces too little insulin
and causes irregularities in blood glucose levels. An experiment
was done by Marcheva and Bass in which pancreatic tissue from
mice with mutations in circadian clock genes were isolated and
examined. They observed that the amount of insulin secreted in
response to a glucose stimulation decreased dramatically. They
then bred mice with their pancreatic clocks deleted, and these
offspring mice developed diabetes early in life and showed a
drastic reduction in insulin secretion. Another experiment with
mice allowed the scientists to observe a connection with Nighteating Syndrome, a disorder in which people would consume
an excessive amount of food at night and develop obesity and/
or metabolic syndrome. It was thought that this condition may
be resultant of a deficiency in managing the circadian timing
of hunger, causing patients a predisposition to weight gain and
metabolic misalignment. These examples just provide further
evidence for the fact that the multiple clocks throughout the
body are required to maintain equilibrium by synchronizing
their timing, all based on the leading master clock (Foster and
Kreitzman(2014),. any disruption causes a multitude of health
issues, including heart and stomach issues, neurological diseases and psychiatric illnesses among others (Summa and Turek,
2015). Due to the fact that circadian rhythms don’t follow an
exact 24 hour schedule, they have the ability to ‘reset,’ or shift,
the phase in response to environmental time cues. The central
clock in the SCN is mainly reset by light, owing to its direct
pathway to the retina. The peripheral clocks, as mentioned
above, are controlled by various signals from the SCN clock.
For example, melatonin synthesis in the pineal gland, mentioned
in depth below, is mainly affected by the light-reliant SCN clock,
with nocturnal secretion (Wu et al, 2011).

Jet Lag and the Biological Clock

The core body temperature (CBT) and melatonin secretion,
as mentioned above, both play key roles in the body’s natural ability to follow a healthy sleep/wake cycle. Professor Jim
Waterhouse wrote in the British medical journal The Lancet
that “the ease of getting to sleep and staying asleep depends not
only on the previous wake time, but also on associations with
the circadian rhythm of core temperature. Sleep is easiest to initiate when core temperature is falling rapidly or is at its lowest
and most difficult when body temperature is rising rapidly or is
high. Waking is the opposite of sleep initiation, because it happens when core temperature is rising or is high.” (Waterhouse
et al, 2007). In healthy people, core temperature will reach a
low point between 3:00 and 5:00 AM, during which time most
people are asleep, and steadily begins to increase at about 6:00
AM, reaching a climax at midday when most people are awake
(Brody, 2007). CBT measurement is a standard physiological
method for studying circadian rhythms, because its rhythm has
been determined to be the most reliable endogenous circadian
oscillator. Hamilos et al performed an experiment of CBT in
patients with Chronic Fatigue Syndrome and documented that
“the rhythm of CBT should be a valid benchmark for which
to compare other circadian rhythms for desynchronizations”
(Hamilos et al, 2001). There has also been a parallel seen between core body temperature and mental performance - performance rises with rising temperature throughout the early
hours of the day, allowing for peak performance, and as it gets
later, tasks that require central processing and short term memory decline due to the falling evening temperatures. There have
also been changes in mood and performance observed under
different groupings of the time of day and the amount of time
awake, with more deterioration in mental performance with
sleep loss (Waterhouse et al, 2007). Melatonin, produced mainly
by the pineal gland and then secreted into the bloodstream, is
a hormone that is secreted mostly at nighttime, when it is dark,
seeming to stimulate the body to sleep. When there is trouble
sleeping, oral ingestion of the chronobiotic drug melatonin can
assist in inducing sleep. A phase response curve, which describes
the relationship between a stimulus and a response, is the resulting reaction to melatonin ingestion, shows that taking it in
the morning will cause a delay in circadian rhythms, and taking
it at night will cause an advance in them. This phase response
curve is about 12 hours out of phase, with the phase response
curve of light, which would cause a phase advance in the morning and a phase delay at night (Brown et al, 2009). It seems that
the circadian clock regulates the timing of melatonin secretion,
although darkness is necessary as well because light will inhibit
the secretion. After a long flight, the SCN-generated night-time
cue will be set to the home nighttime before the clock adjusts,
and thus if a traveler will enter a dimly lit room when it is nighttime at their home, melatonin secretion can occur and cause
sleepiness (Sack, 2009). But taking melatonin in the evening and

remaining in somewhat darkness can aid in falling asleep, which
can additionally help acclimate the body to the local sleep/wake
schedule. A word of warning for female travelers: interaction of
melatonin and menstrual hormones can lead to a stop of the
menstrual cycle. Female athletes can even be at a health risk
from this, since many of them already have stalled cycles due to
“overtraining” (Reilly et al, 1996).
In reference to athletes, there was a study done on elite athletes
that recorded sleep loss and mood changes after long distance
flights. Athletes that traveled more than five time zones to the
west showed shifts in performance, including grip strength and
back and leg endurance, which were in phase with their unadjusted body clocks. A similar result was seen in a group of
Olympic athletes who journeyed over ten time zones to the
east. It was even observed that for several days after an east
or west flight over six to eight time zones, the athletes had distorted grip strength and weak performances in training sessions
(Waterhouse et al, 2007).
Now that is it understood what jet lag is and the extent of its
affects, counting the misalignment of the internal body clock,
what can be done to alleviate the dyschronism symptoms?
There are a number of ways to attempt to prevent jet lag, as
well as suggestions for adjusting the body clock to combat the
desynchronization once it emerges.
Trip planning can play a major part in prevention of jet lag. If possible and extra stress would not be caused, stopovers should
be included in the flight plan. Breaking up the number of time
zones being crossed by having a stopover can greatly diminish
the likelihood of jet lag. Keeping hydrated is also necessary to
counteract the dry air of the flight cabin (Waterhouse et al,
1997). Also, unless it is nighttime at the destination, sleep should
be avoided during the flight, as it can anchor the rhythms to the
home time zone. Staying on home time by remaining concurrent
with one’s circadian rhythms won’t allow the internal clock to
be disrupted; however it seems to make sense only for short
trips. Supposedly, this approach was employed by President
Lyndon B. Johnson when he met with Vietnamese leaders. This
may be difficult, but if possible it can help avoid majority of jet
lag symptoms. Conversely, coordinating with the local time of
the planned travel location, from the get go can adjust the clock
quicker and avert negative effects of the journey. This can be
done by eating meals by the local schedule, going out in the
daytime, going to bed at a reasonable time for the local environment, etc. A sleeping pill may be required the first night to assist
in an easy transition, but hopefully after that the adjustment will
continue smoothly (Coleman and Kim, 1998). Melatonin, which
we have seen to be a somewhat ‘darkness signal,’ can be helpful
in aiding clock acclimation, since it has the ability to induce sleep
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when necessary. However, the dosage is unclear, and it would
seem that the timing of administration is more relevant than
the actual amount. In addition, a boost in caffeine consumption
may combat daytime tiredness; however caution is required so
as not to aggravate insomnia. Exercise has been proposed to
alleviate jet lag symptoms, but it has not been studied in clinical
trials (Sack, 2010).

Conclusion
From the research obtained, it is evident that jet lag has no
exact, scientific definition, but that it is a lack of synchronization of the body’s internal clocks and the external environment.
It can take a few days following flight travel over several time
zones for the body’s circadian rhythms to realign. Repeated travel over an extended period of time can have the same long term
consequences as those of shift workers - extended desynchrony
with persisting symptoms that exacerbate with age. Resetting
the clock requires zeitgebers, the most integral of which by far
is the fluctuation of light and darkness. Adjusting is the primary
goal to adequately offset jet lag. To do this, travelers should set
up a specific itinerary of predetermined sleep and activity times,
meal schedules and exposure to light versus remaining in dim
lighting. The quicker the circadian system acclimates to the new
time zone, the shorter the symptomatic period of jet lag will be.
Assistance from the hormone melatonin may be necessary, a
chronobiotic which adjusts the timing of the central body clock.
Recently the drug called modafinil, meant to resist the tendency
to fall asleep, has been registered for use in shift work sleep
disorder, and although no records deal with its use in jet lag,
the two have similarities and so perhaps this drug would aid
in preserving daytime alertness (Arendt, 2009). Each individual
must know his body and research the best methods for him to
avoid or resolve jet lag.
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Abstract
Treatment options for those suffering from Parkinson’s Disease are as diverse as its symptoms.With the advent of modern
technology there are new and innovative treatments that are becoming available, such as Deep Brain Stimulation (DBS).
Prior to exploring treatment options one must t understand the various causes of the disease. Treatment of the various
motor and non-motor symptoms can include a combination of medication and surgical therapies.Among surgical interventions DBS is the treatment of choice. It has the fewest side effects and provides the greatest symptomatic relief.
Introduction
Parkinson’s disease was first formally written about in 1817, by
a prestigious English doctor, James Parkinson. He published a
short pamphlet about the disease titled, “An Essay on Shaking
Palsy”. In the beginning of his paper he describes the symptoms
of the disease as “involuntary tremulous motion, with lessened
muscular power parts not in action and even when supported;
with a propensity to bend, with trunk forwards and to pass
from a walking to running pace; the senses and intellect being
uninjured”. (Elis, 2013) Parkinson was not the one who discovered the disease as there are sources referencing the disease
dating back to the ancient Egypt and Mesopotamia. (Raudino,
2012) As time, technology, and science advanced, scientists and
medical professionals were able to further understand the causes and symptoms of the disease. Treatment options for those
suffering from Parkinson’s are as diverse as its symptoms. With
the advent of modern technology, there are new and innovative treatments that are becoming available. One of these new
treatments is Deep Brain Stimulation (DBS). As with all new
treatments, one has to assess its effectiveness, its side effects
and how it compares with old methods of treatment.This paper
will address these issues in relation to DBS and its treatment
for Parkinson’s disease.

Methods
This systematic review was composed after reviewing relevant
journal articles about the subject matter.Articles used discussed
causes of the disease, current treatment methods and alternative surgical interventions. Articles were obtained using search
engines like Proquest and MedLine and articles from published
journals.

Background
Prior to exploring treatment options, one must thoroughly
understand the disease and its causes. Parkinson’s has many
different causes, some rooted in genetics, others in chemical
imbalances. The genetic cause for this disease has been shown
to include five different genes. (Pchelina, et. al. 2014) The first of
these genetic proteins is ⍺-synuclein, a neuronal protein which
serves an unknown function. These proteins aggregate in the
Lewy bodies, causing researchers to conclude that they play
a major role in the protein composition of the Lewy bodies.

Although mutations within ⍺-synuclein are relatively rare; even
patients with sporadic PD seem to exhibit protein aggregates in
the Lewy bodies, leading researchers to believe that ⍺-synuclein
plays a major role in both genetic and sporadic forms of PD.
Several independent family studies done on groups of people
with PD show that ⍺-synuclein mutations are a rare cause of
PD. The largest analyses done on ⍺-synuclein and PD indicated
that allele length variability is associated with an increased risk
for PD. (Pihlstrøm, Toft, 2011).
Mutations in the gene encoding parkin, a 465 amino acid chain
protein is one of the causes of autosomal recessive PD. Parkin
mutations in familial PD suggest that the ubiquitin-protease system has an important role in the disease. (Pickrel,Youle, 2015)
Mitochondrial abnormalities are also thought to cause the disease. These abnormalities lead to a failure of cellular energy
production and increased free radicals. The newest gene discovered which confirmed these hypotheses is the PINK1 gene.
(Pickrel,Youle, 2015).
Another gene associated with Parkinson’s is the DJ-1 protein.
Although its exact function is unknown, it is thought to help
with proper protein folding. DJ-1 protein may be linked to abnormalities in the protein control system. Other studies show
that DJ-1 mutations may lead to increased levels of oxidative
stress. (Pchelina, et. al. 2014).
PD is not caused by genetic factors, although genetic factors
increase one’s risk for developing the disorder. Sporadic PD
is when there are multiple genetic alterations which increase
the risk of developing PD, but they do not cause PD. One such
risk factor is prevalent among Ashkenazi Jews carrying the GBA
gene mutation. Those who do have a GBA mutation are seven
times more likely to develop the disease when compared to
healthy control groups. (Feany, 2004).
The most common cause for PD is from the progressive loss
of dopaminergic neurons in the substantia nigra pars compacta. Motor symptoms appear when approximately 50%–60% of
these neurons degenerate, causing a 70%–80% depletion of dopamine levels in the dorsal striatum. (Pickrel,Youle, 2015).
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Discussion
Parkinson’s disease is associated with a wide variety of symptoms, both motor and non-motor. The four cardinal motor
symptoms associated with the disease are; Rest tremor, bradykinesia, rigidity and loss of postural reflexes. The rest tremors
seen in PD are usually found in the distal extremities, but they
can also be seen in the lips, chin and jaw. Bradykinesia can be
described as slow movement and it is a hallmark of basal ganglia
disorders. Although Parkinson’s patients seem to have impaired
motor programes, when provided an external stimulus many of
them exhibit normal movement. This phenomenon is known as
kinesia paradoxica. Rigidity is often one of the first symptoms of
the disease, but it is often misdiagnosed as arthritis or bursitis.
Neck and trunk rigidity leads to postural deformities. Additional
postural issues include, extreme neck flexion, trunk flexion and/
or scoliosis. (Jankovic, 2008).
Non-motor symptoms associated with the disease include;
autonomic dysfunction, cognitive abnormalities and sleep
issues, among others. Autonomic dysfunction features can include, orthostatic hypotension, sweating dysfunction, sphincter dysfunction and erectile dysfunction. Neurocognitive
dysfunction was tested on 537 PD patients using the
Neuropsychiatric Inventory. Eighty-nine per cent of patients
exhibited symptoms for at least one of the Neuropsychiatric
Inventory. The results of the Neuropsychiatric Inventory
were as follows: Fifty-eight percent of patients showed symptoms of depression, 54% showed apathy symptoms, 49%
exhibited anxiety symptoms and 44% showed signs of hallucinations. (Jankovic, 2008).
Sleep abnormalities often seen in PD were thought to be a side
effect of the medications patients were given. More recently,
some physicians are beginning to view it as a part of the disease.
Researchers began looking at the hypothalamic hypocretin system, a system that regulates sleep/wake cycles, to see how this
system differs in Parkinson’s patients. They have found that patients with PD had almost 50% fewer hypocretin neurons than
the healthy control group. (Fronczek, et. al. 2007).
There are no known preventions that will stop PD, however
there are some substances which have an inverse relationship
with PD. Caffeine has been found to reduce one’s risk for PD.
MPTP, one of the toxins associated with PD was injected onto
the striatum of mice. This led to an 85% decrease in dopamine
levels in the area. However when the mice were given moderate
amounts of caffeine, there was only a 60% decrease in dopamine
levels. This study leads to the conclusion that caffeine may help
mitigate some of the symptoms of PD, however this relationship
is not causal. (Holden, 2001).
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Nicotine, found in cigarettes, decreases the risk for developing the disease. It also inhibits the MPTP pathway, ensuring that
more dopamine receptors remain intact. Additionally, nicotine
has been shown to reduce the activity of Monoamine Oxidase,
which causes the oxidation of dopamine. Coffee drinkers have a
30% decreased risk of developing PD, while smokers have greater than a 30% reduction risk. (Martyn, Gale, 2003).
There is no known cure for Parkinson’s Disease, however,
there are a full array of medications and treatments to slow
progression of the disease and to relieve some of its symptoms,
both motor and non-motor. Drug therapy is the mainstay of
treatment. Surgical intervention, such as deep brain stimulation is recommended in severe cases. Physiotherapy, speech
therapy and occupational therapy have all been shown to help
Parkinson’s patients as well, particularly in advanced stages of
the disease. (Rajput, Rajput, 2006).
The three main drugs being given to Parkinson’s patients are,
Levodopa, monoamine oxidase B (MAO-B) inhibitors and dopamine agonists (DAs). MAO-B inhibitors are given to patients
with mild motor symptoms, usually in the early stages of the
disease. When administered in conjunction with Rasagiline, patients dropped 3-4 points on the Unified Parkinson’s Disease
Rating Scale. When taken with other drugs, such as SSRIs,
some patients began exhibiting serotonin syndrome symptoms.
Dopamine Antagonists act directly on striatal dopamine receptors and have a greater effect on motor symptoms than MAO-B
inhibitors. DAs are often prescribed as a first order treatment
in patients who are young at age of onset. Side effects of DAs
include; nausea, headaches, sleep attacks and Impulsive Control
Disorder, among others. DAs are usually supplemented with
levodopa in the later stages of PD. Levodopa, also known as the
gold standard in PD treatment, is the first order treatment given
to elderly Parkinson’s patients. Levodopa is most successful at
eliminating PD motor symptoms, however, it has many side effects. (Sprenger, Poewe, 2013).
Some side effects of levodopa include nausea and dyskinesia.
Being on the drug long-term causes up to ⅓ of patients to develop dyskinesias. Between doses patients can experience painful muscle spasms and the reemergence of other PD symptoms.
The National Health Service of England recommends keeping
the dose of levodopa as low as possible to prevent motor complications. The Movement Disorder Society recommends taking
levodopa with a DA to prevent long-term motor side effects.
(LeWitt, 2008).
The most common surgical intervention for Parkinson’s patients
is Deep Brain Stimulation (DBS). Prior to the discovery of this
treatment, surgical treatment for movement disorders involved
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ablations. More specifically pallidotomy, thalamotomy, and more
recently, subthalamatomies. Thalamotomy relieved many of the
tremors and dopa-induced dyskinesia, however it often left patients with speech and cognitive deficiencies. Unilateral pallidotomy have been shown to significantly improve contralateral
tremor, rigidity, bradykinesia, and dyskinesias. Side effect of pallidotomy include, weight gain, reduction in verbal fluency, and a
higher incidence of recurrent depression in patients who have a
prior history of the disease. Appropriate anatomical and careful
physiological screening prior to placement of the lesions may
decrease incidences of cognitive or neuropsychological damage.
Subthalamatomies have been experimented with as a cheaper
alternative to DBS. Preliminary findings indicate that there are
fewer cognitive and speech side effects than in pallidotomy and
thalamotomy. However postoperative chorea occurred in more
than half of patients who underwent this procedure. This remains a concern with subthalamotomy. Additional research is
necessary to ascertain whether this treatment is a viable alternative to DBS. (Walter,Vitek, 2004).
Deep brain stimulation is a highly effective surgical therapy
for PD and other movement disorders (fig. 1). To qualify as a

Once a patient is found to be a viable candidate for surgery,
they undergo basic preliminary testing. The main test involves
a patient skipping a dose of levodopa at night. The patient then
goes to the neurologist so he can assess the patient’s symptoms without medication. Afterwards, the patient then takes
his dose of levodopa, so the neurologist can see how it affects
the patient’s symptoms. Symptoms that do not improve with
medication, usually will not improve with DBS either, hence the
significance of this test (Farris, Giroux, 2011).
Once cleared for surgery the patient will undergo the procedure. The procedure involves the implantation of electrodes
in the subthalamic nucleus, two lead coated wires and a neurostimulator, which is technologically similar to a pacemaker.
(Farris, Giroux, 2011) Prior to the implantation of the electrodes, patients undergo stereotactic imaging to locate the
subthalamic nucleus. Surgery for implantation of electrode and
lead is usually done under local anesthesia, so the surgeon can
determine the best location for the electrode within the subthalamic nucleus. Using microelectrodes, the surgeon will stimulate different areas to figure out where the patient will have the
greatest symptomatic relief. Once the best tract is found the
surgeon will replace the microelectrodes with the lead through
various means. After this is done, the patient is closed up and
the second part of the procedure takes place at a later date.
(Benabid, et. al. 2009).
The second part of the procedure involves placing the neurostimulator in the subcutaneous pouch in the subclavicular area.
This is done under general anesthesia. Once the neurostimulator is inserted and connected to the lead, the programming of
the stimulator begins. Programming of the neurostimulator will
usually begin a week after surgery.Voltage is increased gradually,
while the patient is tested by the neurologist. Once an appropriate setting has been found for the patient, PD medication dosages are lowered to prevent dyskinesias. (Benabid, et. al. 2009).

Figure 1.This drawing depicts the components of DBS
candidate for surgery, patients must be first undergo testing
by a competent neuropsychologist and neurologist. A neurologist will review the patient’s medical history and ensure that
reasonable medical intervention has been applied. The patient
will then meet with a neuropsychologist to discuss goals and
expectations of the surgery. If a patient has unrealistic expectations, they are no longer an appropriate candidate for surgery.
(Benabid, et. al. 2009).

Deep brain stimulation offers many advantages to ablations,
although it is not a risk-free procedure. When performing
ablations, the lesions placed on the brain are permanent and
irreversible. With DBS, the neurostimulator can be turned off,
or reprogrammed in case of complications. In cases of adverse
effects, the neurostimulator can even be explanted. Some of
the adverse effects of the implantation of the electrodes and
leads in DBS include hemorrhaging, seizures and/or infection.
Although these side effects are relatively rare (4%), it is important to know about them. With regard to the neurostimulator,
battery depletion is an issue. Batteries have a median life of four
years, but in patients with high voltage stimulation, they may last
only one year. (Grill, 2005).
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Studies done on the short and long term effects of the procedure on Parkinson symptoms show significant improvement
in many of them. Following DBS of the subthalamic nucleus,
levodopa dosages decreased on average 55.9%. Rigidity and
bradykinesia symptoms decreased by 63% and 52% respectively
after twelve months. Parkinsonian tremors decreased by 61%
following subthalamic nucleus DBS. However, stimulation targeting the dorsal border of the subthalamic nucleus produced
an 86% improvement in tremor symptoms. Gait and balance
issues caused by PD are less likely to be helped by DBS. In a
one year follow up study, patients were found to have the same
gait and balance scores as their preoperative scores with drug
treatment. (Fasano, et. Al. 2012).
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Conclusion
Deep Brain Stimulation has been proven to be the most effective surgical intervention for those suffering from Parkinson’s
Disease. As with most medical issues, invasive surgery is not
the first choice for treatment, but if necessary DBS is the gold
standard in invasive treatments for PD. It provides relief to many
of the motor symptoms associated with the disorder. Although
success varies, it has developed into the most viable surgical
treatment for PD.
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Abstract
Staphylococcus aureus is a pathogen responsible for common skin infections, such as impetigo, cellulitis, folliculitis, and
abscess and it is the most common cause for skin and soft tissue infections (SSTI). Humans are carriers of this microorganism and are responsible for facilitating its spread around the world. Over time it has developed resistance to multiple
antibiotics, such as penicillin and methicillin, which has made S. aureus a persistent problem in the healthcare world
today. Its methicillin resistance has given it the more commonly known name methicillin-resistant S. aureus (MRSA).
MRSA was initially discovered solely in the healthcare environment and thus became known as healthcare-associated
MRSA (HA-MRSA). With time, MRSA began to affect people with no previous exposure to a healthcare facility and
was therefore called community-associated MRSA (CA-MRSA). Incision and drainage are often the first and best treatment option used against SSTI caused by MRSA. Antimicrobial therapy is also employed. Vancomycin is currently the
leading drug, however other antibiotics such as linezolid, daptomycin, clindamycin, and trimethoprim-sulfamethoxazole
are sometimes used due to a growing number of reports of vancomycin resistance. This paper examines the different
options for the treatment of SSTI caused by MRSA by comparing different antibiotics, their mechanisms of action and
resistance, dosages and administration, as well as adverse effects. No definite conclusion can be made as to the best or
most effective treatment option for MRSA. Rather, each reporting of SSTI caused by MRSA needs to be evaluated on
a case by case basis to determine the most appropriate choice of therapy. The various aspects of MRSA and therapy
choices employed to combat it have been researched by the author using the Touro database, Google Scholar, and
PubMed for various links to journals and articles that these databases provide.
Introduction
Staphylococcus aureus is a gram positive pathogen and the most
common cause of skin and soft-tissue infection (SSTI) in the
world. A study done in 2008-2009, spanning more than nineteen
European countries and more than 3000 cases of complicated skin and soft tissue infections (cSSTI), found that about one
third of these cases were due to S. aureus (Russo, et al., 2016).
S. aureus is responsible for common skin infections such as impetigo, cellulitis, folliculitis, carbuncles, abscess, pyomyositis, and
necrotizing fasciitis, as well as more deep-rooted infections that
lead to blood stream infections, nosocomial pneumonia, and
infection of wounds and surgical sites (Popovich, et al., 2008).
S. aureus is so prevalent that about 25% of humans are consistent carriers of this microorganism, while 50% are observably
intermittent carriers. Colonies of S. aureus can be found in the
anterior nares and other areas of skin throughout the body.
Penicillin was the first antibiotic used to treat S. aureus infections; however, within a few years S. aureus developed resistance
to this “miracle drug”. A specific strain of S. aureus started to
produce an enzyme capable of destroying penicillin, called penicillinase. The plasmid that produced the penicillinase quickly
spread among the different strains of S. aureus. To combat this
new development, methicillin, which is a semisynthetic β-lactamase-resistant penicillin, was created in 1959. After only two
short years, the first case of methicillin-resistant staphylococcus
aureus (MRSA) was reported. This case of bacterial resistance
was the result of a more complex mechanism than found in
the penicillin resistant strain of S. aureus. Methicillin works by
blocking the protein penicillin binding protein (PBP), found in S.
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aureus that is associated with the construction and maintenance
of the cell wall. Instead of using these PBP proteins, resistant
strains of S. aureus acquired a new protein, PBP2a, which has the
same function as PBP but is not susceptible to methicillin. PBP2a
is encoded by the gene mecA, located on the chromosome,
unlike the penicillinase gene which is found on the plasmid. This
mecA gene is a distinguishing characteristic of MRSA and the
presence of PBP2a means that S. aureus is resistant not only
to methicillin, but to all β-lactam antibiotics, including synthetic
penicillin, cephalosporin and carbapenem (Mastofsky, et al, 2011;
Pantosti,Veniti, 2009; Popovich, Hota,2008).

HA-MRSA
MRSA has become a worldwide problem and is common
throughout hospitals as well as smaller healthcare facilities.
Since its origins in the 1960s, the spread of healthcare-associated MRSA has become a public health concern (Mastofsky et
al, 2011; Pantosti, Veniti, 2009). The common strains of MRSA
found today originated from a few clones that developed independently of each other (Gardam, 2000). MRSA is spread by
direct contact and most often in a healthcare setting where
contamination can spread through the hands of healthcare providers (Okado et al, 2016). This spread of infection has led to
the definition of HA-MRSA which is an annotation for healthcare-associated MRSA or for hospital-acquired MRSA. Patients
with compromised immune system or those that have had extended hospital stays are more susceptible to the contraction of
MRSA. In addition, use of antibiotics and undergoing surgery are
factors that can contribute to MRSA infection. Once a patient
has acquired HA-MRSA it is extremely difficult to eradicate and
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the person can be a carrier for an extended period of time
(Gardam 2000). A patient can be a carrier for HA-MRSA for
longer than six months, long after his discharge from the hospital (Pantosti,Veniti, 2009).
In order to reduce the prevalence of HA-MRSA and to stop
the spread of this nosocomial pathogen, hospitals take on two
different approaches. The first recommendation is prevention
based and includes barrier precautions, hand washing and environmental cleaning for MRSA patients. The second approach
is an implementation of an antibiotic stewardship program. The
purpose of the program is to control antibiotic prescribing in
order to reduce the adverse effects of antibiotics, such as drug
resistance and more specifically decreasing the spread of infection caused by multi-drug resistant bacteria. A 10-year program
implemented in Saint-Joseph Hospital in Paris, France focused
on applying a combination of these two aspects to decrease the
prevalence of HA-MRSA found in their hospital. The program,
implemented from 2000-2009, showed an 84% decrease in HAMRSA colonization throughout the hospital. Researchers found
that there was an increase in the use of alcohol based hand rubs
(ABHR) from 6.8 L to 27.5 L per 1000 patient-days. Additionally,
antibiotic use, measured with the Defined Daily Dose (DDD)
per 1000 patient-days decreased by 31%. The implementation
of this program and its results were significant in that it was
conducted in a region known to be endemic for MRSA. From
2000-2009, France had MRSA rates greater than 25%, an alarmingly high rate (Chalfine et al, 2012).

CA-MRSA
In the 1990s a new strain of MRSA emerged. Known as community-associated methicillin resistant staphylococcus aureus
(CA-MRSA) This new epidemiology has the capability of causing
infections in otherwise healthy individuals who have had no previous exposure to a healthcare setting. These reported cases of
CA-MRSA have statistically worse clinical outcomes than those
of HA-MRSA (Mostofsky et al, 2011; Pantosti,Veniti, 2009). CAMRSA is a more infectious form of S. aureus than HA-MRSA and
can carry the genes that encode Panton-Valentine leucocidin
(PVL) which is “associated with tissue necrosis and a greater
severity of disease” (Russo et al, 2016). However, in most cases
CA-MRSA causes skin and soft tissue infections (SSTI) such
as furuncles, abscesses, impetigo, and cellulitis (Pantosi,Veniti,
2009). CA-MRSA is the most common cause for patients presenting with SSTI in emergency departments around the United
States (Albrecht et al., 2015),
CA-MRSA has a number of distinguishing characteristics that
differentiate it from HA-MRSA. Firstly, CA-MRSA, unlike HAMRSA, is vulnerable to most non-β-lactam antibiotics and contains what is known as SCCmec element of type IV and type

V. SCCmec stands for staphylococcal cassette chromosome
mec and is the mobile genetic element for S. aureus that is
responsible for its resistance to methicillin and other β-lactam antibiotics. This SCCmec element is encoded by the gene
mecA and is divided into subtypes I-VIII (The Working Group
etc., 2009). Conversely, HA-MRSA is multidrug-resistant to
non-β-lactam antibiotics and contains SCCmec type I, II, III. A
second difference, as mentioned above, is that CA-MRSA contains PVL, which is a strong virulence factor (Mostofsky et al,
2011; Pantosti,Veniti, 2009).
With the growing number of MRSA cases reported each year,
the clearly defined lines between HA-MRSA and CA-MRSA are
being blurred. Asymptomatic colonization of MRSA can persist
for years and a HA-MRSA can be easily misconstrued for CAMRSA. Cases have been reported of community-onset HAMRSA, as well as nosocomial CA-MRSA infections (Mostofsky
et al, 2011). The definitions abound as to how to clearly classify
and differentiate between HA-MRSA and CA-MRSA. There are
many uncertainties as to how to define prior hospitalization and
length of time since hospitalization. This question is crucial as it
determines if one is still a carrier of MRSA or not.The common
definition of prior hospitalization is “hospitalization within six
months to one year of current admission”. Sometimes, MRSA
acquired from long term care facilities and nursing homes is
not considered healthcare associated, but rather CA-MRSA,
skewing the statistics (Gardam,2009). One way to differentiate
between the two strains it to test the isolate’s susceptibility to
non-β-lactam antibiotics, as this is one key difference between
HA-MRSA and CA-MRSA (Popovich et al, 2008).
There are many different treatment options available to treat
MRSA infections, including incision and drainage, oral antibiotics,
parenteral antibiotics, and topical therapies. More than one mode
of therapy can be used. Treatment options can be administered
on both an inpatient and outpatient basis (Popovich et al, 2008).
The purpose of this paper is to review some of the current and
leading parenteral and oral treatment options used to best treat
SSTIs caused by both HA-MRSA and CA-MRSA. It will explore
and compare different antibiotics, their uses, benefits and side
effects in an effort to understand the most effective way to treat
MRSA.

Methods
This study was performed through the analyzation of various
original and peer reviewed articles which were accessed using
databases such as the Touro Database, PubMed, and Google
Scholar. The research collected in this study was used to understand MRSA, its effects and the best way to treat it when found
as the cause of SSTIs.
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Discussion
There are many different treatment options for MRSA that are
currently in use or in development. Some are administered orally or parenterally, while others are administered topically.
Incision and Drainage
The most important part in the treatment of complicated SSTI
(cSSTI) is the incision and drainage of the infection site. This
procedure is common in the case of furuncle, soft tissue abscesses and other purulent SSTI. An estimated 80% of patients
presenting in the emergency departments with acute, purulent
SSTI require drainage. Most patients with infections caused by
CA-MRSA are cured via incision and drainage alone and do not
require any antibiotics. Thus, incision and drainage, where appropriate, is the first step to treating cSSTI caused by MRSA
(Ruhe et al., 2007; Stryjewski et al., 2008).
However, there is still much to learn regarding the effectiveness of incision and drainage of infection sites. A study done on
children with SSTI, with an infected site of greater than 5 cm,
showed that pediatric patients are more likely to experience
failure of incision and drainage alone and antibiotic therapy is
usually necessary. Additionally, patients with other risk factors
such as systemic illness, comorbidities, as well as multiple areas
of SSTI are more likely to need antibiotic therapy in addition to
or in place of incision and drainage (Popovich et al., 2008).
Vancomycin
Vancomycin is the standard drug used today to treat SSTI
caused by MRSA (Stryjewski et al., 2008). Since its introduction
in 1958, it has been used to combat gram positive bacteria with
great success. Vancomycin is administered parenterally on an
inpatient basis.Vancomycin, a glycopeptide, works against MRSA
by inhibiting the bacteria’s cell wall synthesis. It interacts with a
peptide precursor of the peptidoglycan at an important site of
attachment and thereby inhibits peptidoglycan polymerase and
transpeptidation mechanisms. Penicillin is also bactericidal by
hindering biosynthesis of cell wall; however, vancomycin inhibits
an earlier stage of the peptidoglycan synthesis thereby eliminating cross-resistance (Wilhelm et al., 1999).
The clinical practice guidelines set by the Infectious Diseases
Society of America states that the recommended dose for the
average adult with normal renal function for intravenous vancomycin is 15-20mg/kg/dose every 8-12 hours. Dosage amount
should not exceed 2000 mg regardless of a patient’s weight.
For more serious cases, in which a patient is systemically ill and
has a suspected MRSA infection, the dosage level may be elevated to 25-30 mg/kg/dose. However, in such a case, one must
be cautious for red man syndrome, a reaction associated with
a high dosage of vancomycin that can cause anaphylaxis. As a
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precaution, infusion time can be lengthened to two hours and
an antihistamine can be administered prior to the loading dose.
Antibiotics can be administered on an empirical basis until culture
results are obtained (Liu et al., 2011). For patients who have problems with renal function, careful monitoring should be ensured
while administering vancomycin, as vancomycin can sometimes
be associated with nephrotoxicity (Wilhelm et al., 1999).
As with the development of resistance to β-lactam antibiotics
which led to the new subset of S. aureus, specifically MRSA, new
reports have come out of vancomycin resistance. The levels of
resistance range from intermediate susceptibility to full resistance of vancomycin (Pantosti et al., 2009). These new strains of
S. aureus resistant to vancomycin are known as vancomycin-intermediate S. aureus (VISA) and as vancomycin-resistant S. aureus
(VRSA) (Popovich et al., 2008). There is even a third category of
vancomycin resistant bacteria known as hetero-VISA, that seems
to be vancomycin susceptible when routinely tested, but contain
a minority of cells that have intermediate vancomycin susceptibility. Upon exposure to vancomycin, these hetero-VISA bacteria
can multiply in number and spread (Pantosti et al., 2009).
VRSA developed from a prolonged use of vancomycin in response to chronic MRSA infection. Over time, the bacteria
changed from MRSA to VRSA by the plasmid exchange of vanA,
the gene for vancomycin resistance, possibly from a co-infecting vancomycin-resistant enterococcus (Pantosti et al., 2009).
A minimum inhibitory concentration (MIC) to vancomycin has
been observed nationwide in MRSA isolates. This phenomenon,
known as the MIC creep, has led to the lowering of the MIC
breakpoint for vancomycin in 2006 to ≤ 2 µg/ml for susceptible, 4-8 µg/ml for intermediate, and ≥16 µg/ml for resistant. As
a result, higher dosage amounts are being recommended for
therapy, yet there is no substantial data to prove its efficacy and
a higher dosage may cause greater toxicity, especially nephrotoxicity (Popovich et al., 2008).
S. aureus that displays a decrease in vancomycin susceptibility
generally has phenotypic features that are different than the
strains of both original S. aureus and MRSA.The main phenotypic change of vancomycin-susceptible S. aureus (VSSA) to cause
resistance is a general thickening of the cell wall. Involved in this
alteration of cell wall structure is an overexpression of PBP2
and PBP2a, increased level of abnormal muropeptide protein,
increased amount of D-alanyl-D-alanine residue, and reduction
of peptidoglycan cross-linkage (Sirichoat et al., 2016).
Linezolid
Many test results have shown Linezolid to be a comparable drug,
in terms of results, to vancomycin. Linezolid is an oxazolidinone
antibiotic that was first discovered in the 1990s and approved
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for use in standard medicine in 2000 (Dumitrescu, Lina., 2014).
Linezolid is the first antibiotic of this class to be brought to
market. Oxazolidinone represents a new systemic antimicrobial
class. Linezolid works by blocking protein function in the cell.
It binds to the 50s subunit of the pathogenic cell which prevents it from complexing with the 30s subunit, mRNA, initiation
factors, and formylmethionyl-tRNA. This inhibition prevents
the formation of the protein initiation complex, preventing
the translation step of protein synthesis. Other drugs that are
classified as protein synthesis inhibitors, such as macrolides and
tetracyclines, have different mechanisms, as each allows the
process of mRNA translation to begin, while stopping peptide
elongation. This mode of action of linezolid seems to work particularly well against staphylococcal infections. Additionally, its
target site is unique and does not interfere with the mechanism
for other protein synthesis inhibitors. Linezolid is bacteriostatic
(Livermore, 2003).
Reported cases of linezolid resistance have been rare and a
number of reasons for the low level of resistance have been
proposed. First, linezolid is an entirely synthetic compound, so
it is unlikely that naturally occurring mechanisms of resistance,
such as those found in antibiotic producing organisms will be
employed. Second, oxazolidinones inhibit ribosomal protein
synthesis while other antibiotics of similar ribosomal protein
synthesis mechanisms do not propose cross-resistance to
linezolid. Additionally, linezolid acts by binding to the 23s rRNA
of the 50s ribosomal subunit. There are multiple copies of the
gene that code for 23s rRNA in each cell. For resistance to
occur, mutations would be necessary in each of the copies of
the gene. Because of the fear of resistance, caution should be
employed when there is a long and repeated use of antibiotics
(Meka, Gold, 2004).
Linezolid is administered either intravenously or orally. It has
100% oral bioavailability and therefore allows for rapid transition from parenteral form to an oral one, possibly resulting in
early discharge from the hospital. This can result in decreased
length of stay and a decrease in overall cost of treatment. MRSA
can be treated with oral linezolid exclusively. Outcomes were
the same for patients treated only with oral linezolid compared
to intravenous vancomycin despite the difference in routes of
administration and antibiotic (Dumitresu, Lima, 2014; Weiglet
et al., 2005). Standard dosage of linezolid is 600 mg every 12
hours. For uncomplicated SSTI the recommended dose is 400
mg every 12 hours. Because of its 100% bioavailability, dosage amount is not dependent on the route it is administered
(Moellering 2003).
Linezolid can cause some minor side effects, including gastrointestinal discomfort such as nausea, vomiting and diarrhea,

and dermatological effects, like rash and itchiness. Most reported adverse effects ceased with the cessation of therapy.
When therapy exceeded 14 days, 12.6% of patients studied,
experienced hematologic effects such as decreases in platelet
count, hemoglobin level, hematocrit and white blood cell count
(Birmingham et al., 2003). Linezolid can also cause reversible
myelosuppression when administration of antibiotics exceeds
14 days (Weigelt et al., 2005).
In clinical studies linezolid has performed comparably to vancomycin in treating cSSTI caused by MRSA, with possible advantage.
A study showed that “linezolid [was] superior … to vancomycin
in the MRSA subset. The difference between linezolid and vancomycin results was most dramatic in patients with abscesses and
surgical-site infections caused by MRSA”. Linezolid is more effective in treating SSTI caused by MRSA due to the enhanced penetration of linezolid into the skin and tissue (Weigelt et al.2005).
Linezolid has also shown to be less nephrotoxic than vancomycin
(Dumitrescu et al., 2014). In a study comparing the treatment of
cSSTI caused by MRSA with linezolid and vancomycin in diabetic
and non-diabetic patients, similar results indicated no significant
difference in therapy of diabetic patients. However, for non-diabetic patients, results showed a greater success rate for patients
treated with linezolid (Lipsky et al., 2011). Other studies have
shown no significant benefit of using linezolid over vancomycin.
Szczypinska et al. claims that by examining length of stay (LOS)
as the determining factor of efficacy of an antibiotic, no significant difference was found between vancomycin and linezolid. As
of now, linezolid is used as a secondary choice to vancomycin in
cases of vancomycin resistance, despite the proven success and
efficacy of linezolid in treating MRSA, in order to prevent the rise
of linezolid resistance (2013).
Daptomycin
Daptomycin is another viable antibiotic for the treatment of
SSTI caused by MRSA that was brought to market in 2003
(Popovich et al., 2008). Cell death is caused by rapidly depolarizing the bacterial membrane. The lipophilic tail of daptomycin,
a cyclic lipopeptide compound, inserts itself into the bacterial
cytoplasmic membrane, in this case MRSA, and causes a rapid
depolarization of the membrane. This ultimately leads to a loss
of DNA, RNA, and protein synthesis. Daptomycin is bactericidal
at all of the bacterial growth stages, including the stationary
phase (Aikawa et al., 2013; Gonzalez-Ruiz et al., 2016; Seaton,
2008).
Daptomycin resistance is rare but is a growing concern in the
healthcare field (Hayden et al., 2005). The mechanism of resistance is unknown but it has been suggested that the mechanism
of resistance may be due to irregular dltA transcription factor
which “may result in a change of the bacterial cell membrane
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fluidity and therefore lead to a reduced affinity of daptomycin to
its target site” (Gonzalez-Ruiz et al., 2016). It has been hypothesized that the mechanism for daptomycin resistance is similar
to that of vancomycin by VISA. Daptomycin is similar in size and
weight to vancomycin and may not be able to penetrate the cell
wall to reach the cell membrane, which daptomycin interacts
with, if the cell wall thickens as it does in VISA. Daptomycin
would never have the opportunity to reach the bacterial cytoplasmic membrane in the face of such an obstacle, resulting
in daptomycin resistance (Cui et. al. 2006). Resistance to daptomycin without previous exposure has so far proved to be
extremely rare, with an observation of only 0.04% of 10,000
cultures tested shown to have an MIC of 2 µg (Gonzalez-Ruiz
et al., 2016).
The recommended dose of daptomycin to treat cSSTI is 4 mg/kg/
day to be administered parenterally with a 30-minute IV infusion.
Course of treatment for daptomycin is 7-14 days. Daptomycin
use has not been approved for pediatric patients (Gonzalez-Ruiz
et al., 2016; Seaton, 2008). Daptomycin is administered only once
daily to reduce the risk of elevated creatine phosphokinase (CPK)
levels and skeletal muscle toxicity. Elevated CPK levels were resolved upon discontinuation of daptomycin treatment. The most
common adverse effects reported are constipation, nausea, and
headache (Gonzalez-Ruiz et al., 2016).
In some cases, such as difficult-to-treat infections like recurrent
MRSA due to vancomycin resistance, a higher dosage of daptomycin (≥6 mg/kg/day) may be recommended. A higher dosage
of daptomycin would allow for rapid clearing of bacteria and
would lower the risk for emerging resistance. Daptomycin has
also been used in combination with other antimicrobial therapies to prevent the rise of resistance. Such combination therapies should be considered for patients who are at high risk
of developing resistance to daptomycin alone. Daptomycin and
linezolid combination therapy was synergistic in its effect and
was bactericidal for MRSA. Daptomycin has also been used with
rifampin, trimethoprim-sulfamethoxide, fosfomycin, and tigecycline (Gonzalez-Ruiz et al., 2016).
Many studies have been performed measuring the efficacy of
daptomycin compared with that of vancomycin. Most show
daptomycin and vancomycin to be comparable and a selection should be made based upon physician and patient preference, resistance factors and economic cost/ benefit analysis
(Gonzalez-Ruiz et al., 2016; Kauf et al. 2015). Patients treated
with daptomycin showed a greater probability of clinical success by day 2 than those receiving vancomycin therapy, however
length of stay for patients from both antibiotic groups averaged
to be the same- four days.Vancomycin is also significantly cheaper than daptomycin (Kauf et al. 2015).
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Clindamycin
Clindamycin is especially useful in treating MRSA in an outpatient
setting (Frei et al., 2010). Clindamycin is a lincosamide drug and
belongs to the class of antibiotics known as macrolides, lincosamides and streptogramin B (MLS). Although similar in function
to macrolides, lincosamides and streptogramin B are structurally
different. Clindamycin works by binding to the large ribosomal
subunit, which is the center responsible for catalyzing the formation of peptide bonds during protein elongation. Clindamycin
blocks this ribosomal tunnel, allowing peptide elongation to continue until it reaches a point of steric hindrance caused by the
clindamycin.This inhibition will lead to eventual dissociation of the
peptidyl-tRNA from the ribosome. Once a peptide has reached
a certain length on the ribosome, clindamycin loses its ability to
inhibit protein synthesis (Tenson et al., 2003).
Resistance to clindamycin therapy is a cause for concern. The
resistance mechanism involves modification of the drug binding
site on the ribosome. The mechanism is the same for all MSL
antibiotics, and is known as MSLB resistance. MSL drugs bind
to the 23s rRNA-binding site. The erm gene is responsible for
the methylation of the 23s rRNA-binding site. In the presence
of the erm gene, resistance can be expressed constitutively as
well as when induced into production. Because of the presence
of the erm gene, resistance can occur during the course of clindamycin therapy (Lewis II et al., 2005; Popovich et al., 2008).
In testing for clindamycin resistance, MRSA strains may appear
susceptible, but can later develop resistance. To test for inducible resistance, a D-zone test is used.This a double-disk diffusion
test in which two disks, a clindamycin disk and an erythromycin
disk are placed on a plate growing S. aureus. The strain is inducible resistant if the zone of inhibition around the clindamycin
disk facing the erythromycin disk is blunted, forming a D shape.
Rates of inducible clindamycin resistance varies by region in the
United States. Use of clindamycin should be determined by local
rates (Popovich et al., 2008).
Clindamycin can be administered parenterally or orally for SSTI.
When administered intravenously, the appropriate dosage is 600
mg every 8 hours. For oral administration, patients should be
given 300-450 mg four times daily. Courses of treatment range
from 10-14 days (Popovich et al., 2008). Clindamycin has a 90%
oral bioavailability and can penetrate well into skin and skin
structure. It is also less costly than some newer drugs used to
treat SSTI caused by MRSA (Lewis II et al., 2005). Clindamycin
may also inhibit the PVL gene that is common in CA-MRSA
(Forcade et al. 2011).
Clindamycin is commonly associated with gastrointestinal side
effects. Most common were reports of diarrhea and pseudomembranous colitis (PMC). In a study comparing gastrointestinal
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effects caused by clindamycin and ampicillin, another medication
known to have gastrointestinal side effects, it was found that
29.8% of patients developed diarrhea following clindamycin therapy. Patients were evaluated for side effects for six weeks following discontinuance of clindamycin therapy (Lusk et al. 1977).
The findings of a study involving a retrospective chart review
to compare the efficacy of vancomycin to the efficacy of clindamycin indicated that vancomycin and clindamycin had similar
treatment results (Frei et al. 2010). In some cases, clindamycin is
used in conjunction with vancomycin as a combination antimicrobial therapy. However, it has been reported that clindamycin
often “antagonizes the antistaphylococcol activity of vancomycin” (Deresinski, 2009).
Trimethoprim-Sulfamethoxazole
Trimethoprim-Sulfamethoxazole (TMP-SMX) is another antibiotic that is used for the treatment of MRSA. TMP-SMX is
the most commonly prescribed oral antibiotic for outpatient
treatment of CA-MRSA infections, in addition to clindamycin
(Forcade et al., 2011; Johnson, Decker, 2008). TMP-SMX is a
two part drug consisting of one part trimethoprim to five
parts sulfamethoxazole. The interaction of these two drugs
inhibits the bacterial synthesis of tetrahydrofolic acid, which
is used in the production of bacterial nucleic acid. TMP-SMX
inhibits two consecutive steps in the formation of folic acid.
Sulfonamides inhibit dihydropteroate synthetase (DHPS),
which is responsible for para-aminobenzoic acid to be catalyzed into dihydrofolate. TMP inhibits dihydrofolate reductase
(DHFR) which causes dihydrofolate to be catalyzed into tetrahydrofolate (Huovinen, 2001; Michalek et al., 2015). TMPSMX has also been shown to have anti-inflammatory and
immunomodulatory effects, enhancing its antimicrobial capabilities (Michalek et al., 2015).
Resistance to TMP-SMX can be found against both drugs,
trimethoprim and sulfonamides, with different mechanisms
against each. Resistance of S. aureus to TMP is suspected of
being caused by a single amino acid change in the dhfr gene, altering DHFR. A single amino acid mutation in the dhps gene is
responsible for sulfonamide resistance of S. aureus (Huovinen,
2001). However, a study performed in three cities in the
United States in 2005, showed that 97% of CA-MRSA isolates
were susceptible to TMP-SMX (Johnson et al., 2008; Popovich
et al, 2008).
TMP-SMX is most commonly administered orally with the
standard dose of 160/800 mg twice daily for 7-15 days. TMPSMX can also be administered intravenously with a dosage of
trimethoprim (80 mg)/sulfamethoxazole (400 mg) per 5 ml to
be given as 5 mg/kg every 6-12 hours (Michalek et al., 2015;

Popovich et al., 2008). TMP-SMX has a high bioavailability, at
around 85% for both complexes (Stein et al., 2016). Some recommend a higher dosage, 320/1600 mg twice daily for 7-15 days,
of oral TMP-SMX to treat SSTI caused by MRSA. Yet Cadena
et al. found that patients treated with the two different doses
had similar clinical results. For the treatment of SSTI caused by
MRSA, a higher dose may not be necessary (2011).A lower dose
may also minimize gastrointestinal adverse effects (Michalek et
al., 2015). In studies testing TMP-SMX patients were found to
have side effects of diarrhea, nausea, vomiting, pruritus, and rash
(Miller et al., 2015).
Studies comparing TMP-SMX to clindamycin, show TMP-SMX to
be a comparable treatment option (Frei et al., 2010; Miller et al.,
2015). TMP-SMX can be used in combination with clindamycin
to treat pediatric patients (Stein et al., 2016).TMP-SMX bactericidal activity against MRSA was greater than that of linezolid, rifampicin, and clindamycin, other popular oral antibiotics used to
treat MRSA. The use of TMP-SMX is economically beneficial as
well. When compared to linezolid, at $1352 for a 10-day course
of treatment, TMP-SMX is significantly cheaper, costing only
$18 for a 10 day course. These numbers are average wholesale
numbers in the United States (Kaka et al. 2006). According to
Johnson et al. studies comparing the effectiveness of TMP-SMX
to vancomycin, the leading drug, are lacking (2008). However, all
VISA strains in the United States are susceptible to TMP-SMX,
and TMP-SMX has been used, in combination with other drugs,
in its treatment (Cosgrove et al., 2004).

Conclusion
Staphylococcus aureus is the leading cause for SSTI in the world.
In an effort to combat this growing concern, many antimicrobial
agents have been used. The method of defense was penicillin
and then methicillin which lead to what is commonly known
as MRSA. Initially found only in hospitals and other healthcare
facilities, MRSA soon spread to the community at large. Patients
with no previous healthcare exposure were now susceptible to
MRSA. These infections are typically manifested as SSTI in the
form of impetigo, cellulitis, folliculitis, and abscess.
With the rise of methicillin resistance, and subsequently resistance to all β-lactam antibiotics, new treatment options
were needed. Vancomycin became the treatment option of
choice. However, vancomycin resistance was soon reported as
well, though not to the extent of methicillin resistance. Other
antibiotics are also used to combat SSTI caused by MRSA.
Daptomycin, a newer drug that is administered intravenously, shows great promise. Linezolid, can be administered both
parenterally and orally, and therefore has potential to shorten
hospital stay. Clindamycin and TMP-SMX are both popular oral
drugs used in outpatient treatment of MRSA.
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Regardless of the effectiveness and benefits of these non-β-lactam antibiotics, vancomycin remains the “gold standard” of
treatment therapy for MRSA. Fear of developing resistance
to alternative drugs limits the extent of their use and keeps
vancomycin as the leading choice. Healthcare professionals and
researchers need to remain alert to any signs of resistance of
antimicrobial agents to prevent its spread and to help stop the
increased presence of MRSA in hospitals and the community.
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Abstract
This paper seeks to review how previous research on bacteriophage therapy can be utilized to improve the treatment
of MRSA infections. Due to the growing phenomenon of antibiotic resistance, scientists are looking to utilize the natural
antibacterial qualities of bacterial viruses called phages to fight MRSA infections. In order to improve the therapeutic
methods of combatting MRSA, one must first understand the mechanics of how phages infect bacterial cells and lyse
them with their proteins. The narrow host range of bacteriophages causes the infection of only the pathogenic bacteria
and maintains the state of the normal flora. Research suggests that the combination of antibiotics and bacteriophage
therapy is a more effective means of combatting MRSA than the utilization of each individual treatment on its own.
The next step in developing this treatment option is isolating and classifying each specific bacteriophage and determining its host range. Matching the phages and their corresponding bacteria may seem like a daunting process; however,
researchers discovered that phages are naturally located near the bacterial strain that they infect. An additional aspect
of the ongoing research is the determination of what causes some phages to be more effective than others. Scientists
note that not only does the phage have an inherent strength which is derived from its genetic makeup but, its strength
in combating infections is also affected by the host’s immunity. New findings lead researchers to believe that there may
be a more direct method of treating MRSA infections. Although the phage in its entirety can be used to lyse bacterial
cells, scientist have isolated a protein found within the phages that can lyse bacterial cells. Scientists hope to harness its
power for a more sinuous treatment of infections.
Abbreviations
CDG- Chronic Granulomatous Disease
ICA- Inter-Cellular Adhesion
MRSA- Methicillin Resistant Staphylococcus Aureus
PAS- Phage-Antibiotic Synergy
SA- Staphylococcus Aureus
VRSA- Vancomycin Resistant Staphylococcus Aureus

Introduction
One of the growing challenges in healthcare is the rising occurrence of antibiotic resistance. Many pathogens have developed
resistance to an array of drugs; the discovery of new antibiotics
has not been keeping up with the rate of the evolving antibiotic
resistant bacteria. Many are concerned that the medical world
may return to the times when small infections will be lethal.
For example, Methicillin Resistant Staphylococcus Aureus (MRSA)
is an example of a bacterial strain that is resistant to every antibiotic except for Vancomycin. This bug is responsible for most
hospital acquired infections., and these bacteria can colonize anywhere from surgical sites, lungs, blood, heart, skin and even brains.
(Jensen et al., 2015). Unfortunately, there has been a recent discovery of Vancomycin Resistant Staphylococcus Aureus (VRSA).
The emergence of VRSA and its dangers have lead scientists and
medical doctors to worry about the future of medicine.
Felix d’Herelle co-discovered bacteriophages in the early 1920s.
Bacteriophage therapy utilizes the killing powers of nature’s predators for bacteria; bacteriophages. Interest in phage therapy, and
its associated research diminished once Flemings discovered the
curative powers of penicillin. However, Russia and many Eastern
European countries have continued studying this topic. The growing need for alternative treatments for bacterial infections gives rise
to a resurgence of interest in this novel topic (Pincus et al., 2015).
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A bacteriophage is a virus that binds to receptors that are only
found in bacterial cells. Bacteriophages infect bacterial cells,
reproduce and then lyse their host bacteria. Then the original phage’s offspring then spreads and infects more bacterial
cells. Bacteriophages have a specific receptor site and are thus
antibacterial to a narrow range of bacterial cells. In addition,
their specificity prevents them from infecting human cells.
Bacteriophage therapy seeks to harness these powers and use
them to treat human infections (Jensen et al., 2015).
Scientists are hopeful that bacteriophage therapy will successfully treat infections caused by many pathogens, specifically the
hard to treat MRSA infections. Since research on this topic is
fairly new, clinical trials need to be run prior to its institution in
standard medicine. This paper will review some of the different
experiments and their outcomes.The author wishes to determine
how these experiments will impact the future of phage therapy.

Phage Infection Mechanism
Bacteriophages are viruses that infect bacterial cells. They are
found all over the planet.The phages infect bacterial cells by binding the tips of their tails to receptor molecules on the bacterial
cell. The viral DNA is then injected into the host cell. The virus
now directs the creation of more phages, which can be created in
less than thirty minutes.The phage bursts out of the bacterial cell,
thereby killing the bacteria.The released phage’s offspring continue to infect more bacterial cells (Pastagia et al., 2013).
Bacteriophages produce two proteins in order to lyse the cell: Holin,
creates a pore in the bacterial cytoplasmic membrane, and Lysin interacts with the peptidoglycan in the cell wall. Lysin cleaves to the
peptidoglycan bonds and ruptures the cell wall. Unable to withstand
the osmotic pressure, the cell wall bursts (Wang et al., 2000).The released phages can then continue the cycle of infecting bacterial cells.

Phage Therapy as a MRSA Treatment

Narrow Host Range
As a bacterial virus, bacteriophages can be extremely host specific. Consequentially, they exhibit some major advantages in
comparison to broad spectrum antibiotics. For instance, using
phages to rid the body of infections does not pose a problem to
the normal flora, whereas antibiotic treatments impact normal
flora.The downside to the phage specificity is the rapid ability of
the bacterial viruses to develop resistance, thus increasing the
risk that the therapeutic effect is merely transient.
One way to circumvent this problem is to create a personalized
phage cocktail specifically for each patient. This would entail
culturing every infection, and then creating a specific mixture
of bacteriophage from a phage library. This would ensure that
the specific viruses could be combined in accordance with the
different infectious pathogens present in the patient. In order
for this to be a viable treatment option, the hospital would need
to have a broad range of bacteriophage present at all times. One
group of researchers studied how probable it is to have a wide
resource of phages to treat infections.
The researchers purchased many strains of antibiotic resistant
bacteria from both a lab and a hospital. In order to isolate the
bacteriophages, they filtered sewage waste and then centrifuged
the supernatant. Finally, the bacterial viruses were purified three
times by plating and re-plating the plaques.
After multiple attempts, the researchers discovered that only one
out of 117 strains of bacteriophages were effective against MRSA.
After obtaining more samples of the bacterial viruses from other
sources, the researchers still had difficulty isolating effective phage.
The study resulted in the realization that it is not feasible to treat
MRSA infections on demand; isolating effective strains presents
significant challenges. In order to treat these infections, pre-made
wide range cocktails would have to be available. It is important
to note that on demand discovery of phages does seem possible
for other bacterial pathogens such as Pseudomonas aeruginosa,
Salmonella, and E. coli.Treating these infections with personalized
cocktails is a viable option (Mattila et al., 2015).

Combination of Phage and Antibiotic Therapy
One way to use bacteriophage to combat infections is to combine phage therapy with antibiotic therapy. The combination of
phages and antibiotics so far seems to be synergistic; the interactions between the two antibacterial agents provide a combined
effect that is greater than the sum of the individual effects. One
phenomenon that has been noted is called phage-antibiotic synergy (PAS). Research shows that administering sub-lethal doses
of antibiotics brings about this effect, regardless of whether the
pathogen is a multi-resistant or naïve bacteria or whether an
old or new antibiotic is used.

Evidence suggests that a high dosage of antibiotics leads to a
tremendous evolutionary advantage for antibiotic resistant
pathogens. So, combining phage and antibiotics may be the solution to the medical dilemma. A lower dosage can be used to
target naïve bacteria, and the bacteriophage can simultaneously
inhibit the growth of the antibiotic resistant strains (TorresBarceló et al., 2016).

Concerns in PAS Treatment
There are some concerns about the negative effects that can
occur as a result of this two-fold treatment. Although there is
no research that provides a basis for these fears, in order to
ensure the complete safety of all patients, it is imperative to
keep these concerns in mind. One major concern is regarding
the possibility of breeding double resistant strains of a pathogen.
This fear is an outgrowth of a similar phenomenon that has
been noted for some antibiotic combination therapy (TorresBarceló et al., 2016).
Researchers must also be mindful of specific antibiotic-phage
combinations that inhibit the effectiveness of each individual
component. For example, phages can block the bacteria’s ability
to absorb the antibiotic, or the antibiotic may affect the host
in a way that limits the phage’s ability to infect the bacteria or
to produce sufficient offspring. Thorough screening of all the
various combination before treatment can easily eliminate this
concern (Torres-Barceló et al., 2016).
Finally, researchers caution that PAS may increase the virulence
factors of certain infections. This phenomenon can be seen in
the instance of quorum sensing, the communication between
different bacteria cells, which can coordinate the production of
some virulence factors. It has been observed that certain exposure to either phages or antibiotics has produced increased
virulence. However, the bacterial viruses that target quorum
sensing receptors can inhibit this response. Although there is
little or no research indicating that these concerns are obstacles
to the use of bacteriophage therapy, proper research must be
done before combining antibiotics and phage therapy in treatment of infections (Torres-Barceló et al., 2016).

Isolation and Host-Range Determination of
Bacteriophage
n order to harness the therapeutic powers of phages, the therapeutic index must be carefully studied and documented. One
group of researchers bought bacterial cells from labs and public
facilities. They isolated the methicillin resistant strains on agar
plates. The next step required that they isolate the virulent
phages. Upon obtaining samples from the environment, the researchers purified the samples by filtration and centrifugation
three times (Jensen et al., 2015).
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In the study they discovered 12 bacteriophages that exhibit lytic
activity against SA and MRSA. In order to determine the host
range, they took spectrophotometric assays of the cultures of
phage-treated bacteria and performed spot testing. After further testing the cocktails on fabric and on glass, they found that
the bacteriophage viruses were able to reduce the colony count
on cultures of fabric and glass. Interestingly, the phage cocktails
showed greater lytic activity against human MRSA then against
non-human Staphylococcus Aureus (SA) and against methicillin-susceptible SA. In conclusion, they isolated 6 unique lytic
phages that show strong lysis of MRSA (Jensen et al., 2015). The
information gathered from this research now opens the door
to further studying of these specific bacteriophages. In order to
advance the applications of this study in medicine, the efficiency
of these phages need to be clinically tested in humans.

Phage Treatment Viability
In order for the bacteriophage to be therapeutically useful,
there must to be a way to store it in pharmacies. In order to
examine phage viability, researchers stored phage in the freezer,
refrigerator, and at room temperature. They concluded that the
phage was most stable at room temperature, and was almost
100% viable after 60 days (Pincus et al., 2015). This is a positive
discovery for the future of phage therapy, as the shelf life seems
to be suitable for pharmaceutical storage and sale.

Isolation of Phages and Host Range
Determination
Another area of life in which MRSA affects humans is its ability
to infect livestock. Generally, animals are not harmed by these
infections. However, they can be responsible for the transfer of
infectious bacteria to humans, and this transmission has been
documented. In particular, farmers and vegetarians who experience greater exposure to livestock are at a higher risk for this
kind of infection. One group of researchers isolated three bacteriophages that were found in pig farms and tested the effectiveness of their antibacterial qualities (Kraushaar et al., 2013).
The methods used in the experiment are as follows. Researchers
purchased bacterial strains, specifically MRSA CC398 strain 101355, from a laboratory. The phages were taken from a variety
of sources including dust swabs, nasal swabs, and fecal swabs
from four German pig farms.They then centrifuged, filtered, and
tested the phages on MRSA lawn. The host range was tested on
agar plates of 86 different MRSA strains CC398 strains and 34
other MRSA strains. The researchers also analyzed the DNA of
the phages. None of the analyzed phages contained known virulence or resistant genes. Hence, the study could be conducted
without concern that the phages would eventually cause more
harm than good to the human host.

44

The MRSA strains belonging to complex 398 are commonly
found on pig farms. These researchers aimed to combat livestock-associated MRSA infections by discovering the phages
that naturally inhibit this pathogen. They screened 91 samples.
Twenty percent of the samples exhibited lytic activity. An interesting phenomenon was noted in the course of this process.
One of the farms was negative for both MRSA and anti-MRSA
bacteriophages. This discovery is important, because it connotes that phages are found in proximity to the bacteria that
they infect. Thus, researchers can assume that if they have a
bacterial pathogen it is likely that phage can be isolated from
that environment (Kraushaar et al., 2013). This can simplify the
process for future research as the knowledge of where to find
the right phages is now known.

Genetics’ Effect on Phage Efficiency
The researchers studied three phages that are genetically related.
The three PSa phages interestingly infect the same wide range
of bacteria. Twenty- four MRSA strains were infected by these
phages. These phages all have a receptor that researchers believe
may be lipoteichoic acid. Of the three PSa types, type two and
type three reduced the numbers of a specific MRSA strain more
efficiently than type one. This aspect was observed with wider
clearings on agar plates, but the plaques produced by type two
and type three were ten times more reductive that the plaques
produced by type one. The genotyping of the three phage’s genes
indicates that this property is a result of the differences in the
lysis genes (Kraushaar et al., 2013). Further examination of the
genes that favor greater bacterial lysis would be the next step in
producing antibacterial cocktails for human medicine.
Another interesting result of this experiment was the discovery
of mutant bacteria that were resistant to the phages used in the
study. Even when the three different phages were combined in
one cocktail, they still did not harm the mutant cells. This discovery is important as it highlights the necessity of combining more
diverse phages in a cocktail to prevent resistance to similar phages (Kraushaar et al., 2013). This is another area of research that
can be expounded upon based on the findings of this experiment.

Phage Therapy and Host Immuntiy
An important aspect of phage therapy research is the determination of specific bacteriophage’s therapeutic index. Additionally,
it is vital to explore if the bacterial virus is equally effective in all
human hosts or if different factors contribute to the optimal productivity of the bacteriophage. One study explored the efficiency
of phage SATA-8505 and its ability to prevent and treat infections
caused by the MRSA strain USA300. The therapeutic index was
examined in vitro with human cells and in vivo in mice. This specific strain was selected due to earlier research that proved its
efficiency in combating MRSA USA300 (Pincus et al., 20).
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All materials for the experiment, MRSA strain USA300, bacteriophage SATA-8505, and the phages were obtained from
laboratories. Using agar plates, the researchers were able to
confirm that phage SATA-8505 has the ability to kill MRSA
USA300. This phenomenon was seen when they observed the
colony morphology of culture plates two to four hours after
phage inoculation.
Once it was clear that the phages were effective killing agents of
MRSA, the researchers inoculated the mice with MRSA pathogens immediately after they injected bacteriophages into the
skin. They then measured the diameters of the skin lesions for
six consecutive days. The mice that were treated with an equal
concentration of phages and bacteria displayed smaller skin lesions than the control group.The researchers also used Chronic
Granulomatous Disease (CDG) immuno-deficient mice. CDG
patients are more susceptible to MRSA infections due to their
problematic neutrophil response. Interestingly, the CDG mice
developed bigger skin lesions than the healthy mice; usually
CDG patients develop MRSA infections on deep tissue, such
as the liver. (Pincus et al, 2015). This could be a positive sign, for
despite the fact that the skin lesions were big, the infections
resembled those of healthy patients. One may think that due
to the large lesion size, the CDG mice did not benefit from
the phage therapy. Upon further examination, one may conclude
that these mice improved relative to their own individual states
of immunity and infection.
Unfortunately, the phage treatment does not seem to be a
magical injection. Both groups of mice exhibited an increased
lesional inflammatory cytokines. The fact that the actual lesion
size was reduced while the bacterial count and cytokine response did not decrease led the researchers to hypothesize that
although the administered dose of phage reduced the ability of
the bacteria to inflict toxin-generated damage, it did not affect
the viability of USA300 (Pincus et al., 2015). These researchers
did a complete project. In order to completely understand this
phenomenon, they repeated the experiment while changing the
phage dosage and the original bacterial count. They discovered
that an increase in phage administration brought about an increase in the inflammatory response in the CDG mice.This may
indicate why bigger lesions that are produced when a higher
dosage of phage is administered.
This discovery highlights the importance of phage dosage, especially in immunocompromised patients.The scientists noted that
although the phage worked at certain concentrations, when the
dosage was increased, negative side effects, such as an inflammation of the infectious site, were observed. Further research is
required in order to configure the optimal dosage for treating
patients while incurring minimal or no harm. The researchers

make a point in warning clinicians that before phage therapy is
used on any immuno-deficient individual, the dosage must be
reconfigured. Extrapolating data from healthy individuals would
not work for the CDG patients who were more affected by
increases in dosage.
Once researchers noted that the phages induced an inflammatory response in mice, they investigated whether a similar
response could be noted in human cells. When human blood
cells were exposed to dosages of phage, the human cells did
not produce inflammatory responses. The response of human
keratinocytes was also investigated. When compared to the diluent treatment, phage induced a small, yet significant, cytokine
response (Pincus et al 2015). This is a potential roadblock in the
implementation of phage therapy. The only way this treatment
could work is if the scientists find a way to inhibit the human
body’s negative response to the phage itself.
The next step involved investigation of the impact of phage SATA8505 on human blood in both healthy and immuno-deficient individuals. Unfortunately, the phage did not seem to affect bacterial
growth or colony morphology. The bacteria cells that were exposed to phage in blood and were then re-cultured grew just as
well as bacteria that were unexposed to bacteriophage. The researches further investigated the phage and bacterium used and
found that the bacterial cells were killed by the phage in a culture
plate. This negates the possibility that a phage-resistant strain of
MRSA was used to inoculate the blood sample. In order to elucidate why the bacteria is unaffected by phage in the presence of
human blood, further research is necessary.
The last part of this research included the study of the efficiency of SATA 8505 on Vancomycin Resistant Staphhylococcus
Aruerus (VRSA). The researchers determined that this phage
is incapable of killing out the VRSA strains (Pincus et al., 2015).
This observation highlights the strain-specificity aspect of phage
therapy, since the phage worked fairly well on the MRSA but did
not affect the VRSA growth.

Strain Specificity
The strain specificity of phage has both positive and negative
aspects to it. While it is true that phage therapy successfully
avoids destroying normal flora, one must first determine the
exact strain of the infection prior to beginning the treatment.
Unfortunately, this determination often takes time, and while
treating MRSA infection, time is often of essence. Therefore,
phage therapy may not yet serve as the first line treatment
against infections (Pincus et al., 2015).
Thus, possibility of using phage cocktails holds much promise. Similar to multivalent vaccines, phage cocktails combine
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a few different strains of bacteriophage. This would increase
the chances that one of the strains would cover the unknown
pathogen in the human host. Although this solution seems scientifically sound, there is a financial drawback. Each phage used in
the cocktail must be separately tested in isolated therapy. Then
research must be conducted on the combination to ensure that
the combined effects are positive or synergistic. The added cost
of all this research may be an issue (Pincus et al., 2015).

Phage Lysins: Pathogen Directed Treatment
One major drawback to phage therapy is the bacteria’s ability to
develop resistance to phage attachment. Recently researchers
have developed ways to purify the lysins from the bacteriophages. The lysins can be used on their own as an antibacterial agent
by causing bacterial lysis on contact. The use of lysins is generally limited to bacterial organisms with a cell wall, although researchers are searching for lysins with Gram-negative bacterial
activity (Pastagia et al., 2013).

Lysin Mechanism
The lysins have two main functions: substrate recognition and
enzymatic hydrolysis. The N-terminal domain enzymatically
severs specific peptidoglycan bonds. This can be accomplished
in multiple ways. They can hydrolyze the glyosidic bonds in the
glycan strand of the cell wall, or the enzymes can hydrolyze
the cross-bridge. The enzymes may also cleave the amide bond
which is located between the glycan moiety and the main peptide. There is a level of specificity of lysin binding which is based
on binding ligands and the specificity of cell wall binding domains.
Additionally, the lysins bind to their substrates with an affinity
constant similar to antibodies (Ka = 6x108). This suggests that
lysins do not disengage from the receptors after they bind and
cleave, just like antibodies. This also explains the speed of lysin
action. Their high affinity constant accounts for their speedy
identification of their target bacterial cells (Pastagia et al., 2013).

Lysin Clinical Potential
The primary benefit of phage lysins is that, to date there has
been no documentation of bacterial resistance to phage lysins.
Additionally, bacteria with thick capsules and bacteria in biofilms
do not inhibit lysin activity. These reasons are enough to aim
research toward harnessing bacteriophage lysin antibacterial
potential.
Lysins generally exhibit bactericidal activity against the bacterial
host of the phages they were harvested from. Like bacteriophages, lysins are strain specific, and therefore do not affect normal
flora. One specific lysin, chimeric lysin (ClyS) has been proven
to kill MRSA strains along with other staphylococci. Some lysins have been proven to affect a broader range of bacterium
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(Pastagia et al 2013). These kinds of lysins would be a great first
defense method against infections in which the exact strain of
pathogenic bacteria is unknown.

Phage Lysin and MRSA Biofilm Eradication
Phage lysins have potential to fight biofilms, a serious health
problem. All biofilms are harder to treat than planktonic bacteria; specific biofilms of antibiotic resistant pathogens, such
as MRSA are even more difficult. Biofilms exhibit antibiotic
resistance up to 1000 times more than planktonic bacterial
cells (Chopra et al., 2015). These biofilm infections develop in
patients that have prosthetic objects implanted in their bodies. Phage lysins seem to be the optimal way to combat MRSA
infections because of the speed of their bactericidal activity, the
small chances of bacterial resistance, and the low probability
of it affecting the normal flora. Additionally, the usage of lysins
allows for all the positive aspects of phage therapy without the
negative possibilities such as resistant mutations.
Lysins generally exhibit bactericidal activity against the bacterial
host of the phages they were harvested from. Like bacteriophages, lysins are specific to bacterial strains and therefore do not
affect normal flora. One specific lysin, chimeric lysin (ClyS), has
been proven to kill MRSA strains along with other staphylococci. Some lysins have been proven to affect a broader range of
bacterium (Pastagia et al 2013 and sources within). These kinds
of lysins would be a great first defense method against bacterial infections when exact strain of the pathogenic bacterium is
unknown.
Research was conducted on the efficiency of phage lysins in
eradicating MRSA biofilms. The object of this study was to evaluate the success of a phage lysin in eradicating old and new
biofilms alone and in conjunction with antibiotics. The MRSA
bacteria strain and the antibiotic, Minocycline, were obtained
commercially. The phage lysin was extracted from phage MR-10
that had been previously been characterized by the same research group. In order to isolate and confirm their results, the
team followed a published method for isolating phage enzymes
(Chopra et al., 2015). This method of obtaining the phage lysin
left some room for potential error. The research team may have
made some errors in isolating the original phage, and the methods that they used originally are not documented in their paper.
Thus, the whole project could have operated with impure or
misnomered materials. Conversely, the method they utilized to
isolate the enzyme leaves little room for error because they
followed a proven method of isolating the endolysin. They did
not rely solely on their observations and research. Additionally,
they confirmed their results with SDS-PAGE analysis after every
purification step (Chopra et al., 2015).

Phage Therapy as a MRSA Treatment

The biofilms were grown in the lab, and their morphological
characteristics were identified by scanning with electron microscopy. The biofilms were developed on coverslips. Two different types of biofilms were formed; ica-positive and ica-negative. For the first part of the research, both types of biofilms
were treated with the endolysin. The ica-negative biofilms were
initially treated with 9 µg/ml. After three hours no significant
reduction was observed. Even once they increased the duration
of the treatment, there was no significant reduction. However,
when the ica- negative biofilms were treated with 18µg/ml of
lysin a statistically significant reduction was observed after six
hours. This seemed to be the highest effective dosage for any
increase in phage lysin concentration did not create a significant
decrease in bacterial count. Contrarily, the ica-positive MRSA
biofilm showed a reduction in bacterial cell count with an application of 36µg/mL of phage lysin after six hours. Increasing the
duration to 24 hours did not make a difference in the bacterial
reduction (Chopra et al., 2015). Although the two biofilms
were very similar, the difference in the intra-cellular adhesion
clearly affected the optimum concentration of lysin needed to
eradicate the biofilms.

Phage Lysin and Antibiotics
The next step in this research was to examine the combined
effects of phage lysin with antibiotics in treatment of biofilms.
They were subjected to both minocycline (a tetracycline antibiotic,) and MR-10 endolysin. A significant decrease was observed
in the first three days of the treatment. After that there was no
more significant reduction in both forms of the biofilms The
researchers also conducted this experiment on old biofilm This
strong unit did not exhibit significant reduction in the cell count.
They researchers theorize that this observation is a result of
the two antibiotic agents acting primarily on the top layer of the
thick biofilm. Other literature clearly states that antibiotics cannot penetrate deep into the biofilm because of the complicated
nature of the biofilm matrix. Since the lysins are one time use
enzymes, it is possible that they acted on the same cells as the
antibiotic at different receptor sites. This could be the reason
for the lack of reduction in the very thick biofilms (Chopin et al.,
2015). Based on this theory, one way to combat thick biofilms
would be continuous application of lysins. Once they kill out
the upper layers, the new lysins can kill the cells in the deeper
layers of the matrix.

the controls and each other, the second method of sequential
treatment delivered the strongest significant decrease in bacterial cell count. Figure 1 below compares the difference in total
bacterial cell concentration from the control group and the two
separate sequential treatments. Using the Live/Dead backlight
kit, the researcher’s stained the biofilms to see the total live and
dead cells in the biofilm. After the second sequential treatment
the staining confirmed that the majority of the live cells were
killed (Chopin et al., 2015).
The positive results of biofilm treatment with three hours of
minocycline followed by overnight incubation with endolysin
MR-10 has a two-fold explanation. First, the antibiotic, minocycline eradicated the metabolically active cells. According to
literature, the active cells are in the upper layers in the biofilm.
Since the antibiotics cannot penetrate the layers and it is only
affective on active cells, using it first ensured that there were
active cells in the biofilm that the antibiotics could access. Next,
the endolysins were applied. These lysins are small, low molecular weight proteins. Additionally, they act on both growing and
stationary cells. Therefore, adding the lysins second enabled the
smaller molecules to penetrate the biofilm and act on the metabolically inactive cells (Chopin et al., 2015). This reasoning also
explains why the first sequential treatment was not nearly as
successful. The endolysins probably killed the uppermost cells
first, so subsequent treatment with antibiotics did not have a
very strong additive benefit. By the time the antibiotic was applied there was not much more metabolically active cells present in the uppermost layer where the antibiotics were able to
access. Therefore, they did not do as much as they could when
they were applied first.
MRSA biofilms are another manifestation of the dangers posed
by this antibiotic resistant bacterium strain. Instead of using
the whole bacteriophage, this study provided solid research
that supports the idea that an isolated enzyme from the phage
will work in eradicating these biofilms. Since the lysins attack
the peptidoglycan of the bacterial cell, it is a great solution for
the hard to treat metabolically inactive cells found in biofilms.
With the foundation of this research, many more studies can be
conducted in order to isolate other endolysins for all sorts of
biofilm infections.

Conclusion
The next step of this research team was to study how sequential treatment of phage lysin in conjunction with minocycline
would affect the biofilms. There were two different sequences
studied with different results. The first time the researchers applied endolysin for six hours and then added minocycline before
incubating overnight. The next time they applied the minocycline first and then the phage endolysin. In comparison to both

Although many are discouraged by the growth of MRSA infections and the lack of treatment options, research suggests
that bacteriophages may serve as the solution to this medical
dilemma. Researchers have explored multiple aspects of bacteriophages and they have classified numerous strains of anti-MRSA phages. In order for the medical world to harness the
natural powers of these viruses, more clinical studies must be
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performed. Scientists must first continue to experiment on animals, in order to rule out all possibilities of the occurrence of
negative side effects of phage inoculation. After the preliminary
experimentation on animals has been completed, human trials
can establish phages as tried and true medicinal option. If scientists continue to diligently explore this topic, there may be
reason to believe that the world will be rid of the inherent
dangers of multi-resistant pathogens.
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Abstract
Macular degeneration is the leading cause of vision loss in Americans sixty years and older. Currently, it is an incurable
disease. Stem cell therapy is the idea of transplanting stem cells to replace damaged cells in the body. As the demand
for transplantable organs far outweighs the supply, stem cells are an encouraging alternative to replace damaged cells.
Can stem cell therapy be the first cure for macular degeneration? Many experiments have been done on transplanting
stem cells into the eyes of rats with macular degeneration yielding promising results. The first transplantation of retinal
pigmented epithelial stem cells into humans to treat macular degeneration was done in 2012. Stem cells were differentiated and inserted into two patients suffering from macular degeneration. Both patients that partook in the study
displayed significant visual improvement, and no abnormal growth was observed. In another study, the use of retinal
epithelial cells vs. the use of other types of eye cells to treat macular degeneration was studied. Each cell type has the
same potential for use in stem cell therapy. Stem cell therapy is a hopeful option for treatment of macular degeneration.
Further research is needed before it can be used as a widespread cure.
Introduction
Two important characteristics distinguish stem cells from other
cells. Firstly, they are unspecialized cells that have the ability to
renew themselves through cell division, and secondly under
certain conditions they can be induced to become tissue or
organ-specific cells with special functions.
Until recently, scientists have mainly worked with embryonic
stem cells and somatic stem cells. Embryonic stem cells are
from the blastocyst of the embryo. The blastocyst is composed
of an inner cell mass of stem cells that differentiate into different types of cells, giving rise to the entire body of the organism.
Embryonic stem cells are donated for research purposes by
eggs that have been fertilized in vitro, and they are not derived
from eggs fertilized in a women’s body. The donated stem cells
are transferred to a culture dish that contains a nutrient broth
called a culture medium where they divide and spread over the
surface of the culture dish. When stem cells are grown under
specific conditions, they can remain unspecialized. If the stem cells
are allowed to clump together to form embryoid bodies, spontaneously they will begin to differentiate. Scientists can modify the
stem cells by inserting specific genes or by changing the chemical
make-up of the culture. Figure 1 illustrates the process of modifying stem cells to become gene specific stem cells.
Figure 1: Stem cells
clump together to
form embryoid bodies,
and spontaneously
they will begin to
differentiate.The stem
cells can be modified
by inserting specific
genes. (Bethesda,
2016)

Adult stem cells are different from embryonic stem cells because they are found in mature tissues or organs. Adult stem
cells are undifferentiated cells that can develop into specific
cells of the tissue or organ where it is found. Adult stem cells
are found in a specialized region called the stem cell niche.
When needed the stem cells will divide and differentiate. This
can occur when there is tissue damage or under normal wear
and tear conditions – the stem cells will divide in order to replenish the supply of cells.There are various types of adult stem
cells that can differentiate into numerous types of cells hematopoietic stem cells (develop into blood cells), mesenchymal stem
cells (develop into bone cells, cartilage cells and fat cells), and
neural stem cells (develop into cells of the nervous system).
Human induced pluripotent stem cells are an additional type of
stem cell. This stem cell is an adult cell that has been genetically
reprogrammed to express the characteristics of an embryonic
stem cell. The method used to reprogram these cells help researchers learn more about the possibility of reprogramming
damaged or diseased cells in the human body.
Human stem cells have many uses in research and clinic. The
most important use being cell-based therapy. Cell-based therapy
is the potential to direct the differentiation of stem cells in order
to transplant them as replacement cells or tissue. Today, tissue
and organs are being donated, but the need for transplantable
organs and tissue far outweighs the supply. Cell-based therapy
can offer a renewable source of replacement cells which can be
used to treat different diseases. (Bethesda, 2016).
There are several drawbacks of using transplanted stem cells to treat
disease including rejection and long-term side effects are not known.
Therefore, a lot of research is still being done before stem cell therapy is used as an established treatment for disease. (Ladock, 2016).
One disease scientists believe stem cell therapy can treat is macular degeneration. Macular degeneration is the most common
cause of vision loss affecting more than 10 million Americans.
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The retina is the part of the eye that records the images we see
and sends them via the optic nerve to the brain. The macula is
located in the central area of the retina and is responsible for
focusing central vision, seeing fine details, and recognizing faces
Figure 2: Anatomy of the human eye showing the location
of the macula. (ISSCR, 2015)

retina that is responsible for central vision. Researchers have
been studying the possibility of using stem cells to treat macular degeneration. The macula is made up of photoreceptor
cells called rods and cones. Rods and cones respond to light by
sending electrical impulses to the brain through the optic nerve.
The brain then interprets these impulses. Behind the rods and
cones is a layer of cells called retinal pigmented epithelial cells.
(ISSCR, 2015).

Functions of Retinal Pigmented Epithelium

and color. The anatomy of the human eye is illustrated in figure
2 with the location of the macula shown. Macular degeneration
is a disease which causes the deterioration of the cells of the
macula. At the present time it is an incurable disease.
Age-related macular degeneration is the most common cause of
blindness in people over the age of 60 years old.Age-related macular degeneration gets progressively worse as one ages. It starts
with the dysfunction and death of retinal pigment epithelial (RPE)
cells. It continues with photoreceptor loss, and insufficiencies
in high acuity vision. There are 3 stages of age-related macular
degeneration. Early age-related macular degeneration is the first
stage where vision loss is not experienced. It can be diagnosed by
the presence of small yellow droplets beneath the retina called
drusen. The second stage is called intermediate age-related macular degeneration where some vision loss may be experienced. A
comprehensive eye exam will look for drusen or pigment change
in the retina. The last stage is called late age-related macular degeneration.At this stage vision loss is noticeable. (Buchholz, 2009)
It is known that the causes of macular degeneration are both
genetic and environmental, but the exact cause is not known.
Age is the biggest risk; there is more of a chance one will develop macular degeneration as one ages. (Akpek, 2013).

Methods
Literature for this article was obtained primarily using Touro
College Online library. Other databases such as PubMed were
used. Additionally, Google Scholar was valuable for finding necessary and relevant articles.

Discussion
Only 5.5 millimeters in diameter, the macula is a part of the
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Retinal pigmented epithelial cells have many functions in the
eye. Firstly, these cells are responsible for transport in two
directions. In one direction they transport glucose and other
nutrients from the blood to the rods and cones. In the other
direction the transport electrolytes and water from the subretinal area to the choroid. Another function of retinal pigmented
epithelial cells is to absorb and filter entering light. The retina
is made up of various pigments that are sensitive to different
wavelengths of light. Additionally, retinal pigmented epithelial
cells are responsible for phagocytosis. (Simó Et. Al. 2010)
The eye is an excellent part of the body for researchers to test
stem cell therapy on because the eye is well contained by its
many barriers. It is hard for the stem cells to move to other
parts of the body. Additionally, researchers can assess the differences between a treated and untreated eye on the same patient.
There is equipment available that allows one to see the interior
and exterior of a person’s eye.
The focus of scientists has been on using retinal pigmented
epithelial cells for stem cell therapy. This is because it is a lot
harder to ensure the proper placement of rods and cones in a
patient’s eye. Rods and cones connect with nerve fibers, and it is
extremely complex to correctly integrate these photoreceptor
cells with the nerve fibers. Retinal pigmented epithelial cells do
not connect to nerve fibers; therefore they are a better option
for stem cell therapy.
It is the goal of scientists to be able to transplant retinal pigmented epithelial cells before the disease has progressed such that
the photoreceptor cells have died. In this way, the transplanted
retinal pigmented epithelial cells can take on some function of
the damaged retinal pigmented epithelial cells and prevent the
rod and cone cells from dying, thereby stopping the progression
of the disease. (ISSCR, 2015).

Delivery of Stem Cells into the Eye
The following method was used to deliver retinal epithelial
cells into rats. The rat was put under anesthesia. A sharp sterilized needle was inserted to make a hole right beneath the
limbus, which is the border between the cornea and the sclera
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of the eye. The tip of the syringe was inserted into the hole,
injecting the retinal pigmented epithelial cells. The syringe was
then taken out slowly, and eye moisturizing drops were given.
(Westenskow Et. Al. 2015).
A study of rats with macular degeneration, treated with human
embryonic stem cells has shown evidence of rescued photoreceptors and vision loss prevention. Three different levels of
pigmented cells were used; light, medium and heavy. Different
amount of cells were used in each group of rats. Visual acuity
improved in the groups of rats treated with a dose of between
5,000 – 100,000 retinal pigmented epithelial cells. The cells injected into the rats sustained visual function for at least 60 days.
The cells survived in the rats for at least 220 days. All the groups
of rats showed deterioration of visual acuity over time. There
is no evidence that showed any group having a slower deterioration over time. The deterioration of the visual acuity of the
rats in this study may be related to the inadequate use of immunosuppressive drugs to treat the rats. Another hypothesis of
why the cells didn’t last is that cell transplantation may need to
be repeated several times in order to sustain their therapeutic
effect. The study confirmed the long-term safety of retinal pigmented epithelial cells for treatment of macular degeneration
in rats. It is a promising step in the research of stem cell therapy
to treat specific types of macular degeneration in humans. (Lu
Et. Al. 2009).
In one study researchers tested whether human embryonic
stem cells can safely be used to treat patients with macular
degeneration. Although human embryonic stem cells were first
discovered in 1998, this was the first study to report transplanting human embryonic stem cells into human patients. The
study tested for signs of hyperproliferation, carcinogenicity,
abnormal tissue formation, and rejection. Two patients were
selected for the study. One patient had dry age-related macular
degeneration and the other had Stargardt’s macular dystrophy
(most common pediatric macular degeneration). (Schwartz Et.
Al. 2012).
In the experiment human embryonic stem cell culture MA09
(classification of human embryonic stem cells) were used to
generate a master cell bank. (Schwartz Et. Al. 2012) Cell line
MA09 has contact with the environment before transplanted
into the patient and therefore is classified as a xenotransplantation. Xenotransplantation is any procedure that involves the
transplantation, infusion, or implantation to humans of nonhuman live cells. (Samdani, 2014) After embryoid bodies were
formed and there was multiplication of the cells, retinal pigment
epithelial patches were isolated. Embryoid bodies are the first
phase of embryonic stem cell differentiation. There are various
ways to form embryoid bodies, but it has been a challenge to

form embryoid bodies uniform in size. (Xu Et. Al. 2011) The
retinal pigmented epithelial cells were tested for pathogens and
phagocytosis. They were also tested for RPE and hESC markers.
Human embryonic retinal pigment cells were successfully cultured. The cells showed typical retinal pigmented epithelial cell
behavior by losing their pigmented cobblestone morphology
during proliferation and re-differentiating into a monolayer of
polygonal cuboidal pigmented epithelium.
One hundred and fifty nanoliters of retinal pigmented epithelial
cells were injected into the patients’ eyes through a cannula that
delivered a dose of 500,000 viable retinal pigmented epithelial
cells into the subretinal space. Immunosuppressive drugs; tacrolimus and mycophenolate mofetil were given to each patient a
week before the surgery and continued for six weeks after the
surgery. Tacrolimus was not given after week six and the mycophenolate mofetil was continued for an additional six weeks.
(Schwartz Et. Al. 2012).
There was no hyperproliferation or abnormal growth in either
of the patients following surgery as determined by biomicroscopic and ophthalmoscopic clinical examinations. (Schwartz Et.
Al. 2012).
Anatomical evidence showed survival of human embryonic
stem cells in the patient with Stargardt’s macular dystrophy.The
transplanted cells were localized to exactly the correct anatomical location. Increased pigmentation was seen in the retinal
pigmented epithelial cells beginning from week one after the
surgery up until month three after the surgery.
The patient with age-related macular degeneration did not take
the immunosuppressive drugs after the operation; therefore
anatomical evidence was difficult to confirm.
Both patients displayed functional visual improvement. The
Figure 3: A
series of images
showing the
macula before
the operation
until after the
operation.
Increased RPE
are seen post
operation.
(Schwartz Et.
Al. 2012)
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patient with Stargardt’s macular dystrophy was able to read study
letters of 20/500 immediately following surgery. By week six, the
patient was reading letters of 20/320 which remained stable
through the postoperative period. The patient with age-related
macular degeneration showed mild visual improvements.
The series of images in figure 4 illustrate the area in the eye called
the macula from before the operation until after the operation.
Increased retinal pigmented epithelial cells are seen post operation.
In this study human embryonic stem cells were safely transplanted into 2 patients. (Schwartz Et. Al. 2012).
A second study compared the effectiveness of using human induced pluripotent cells with using human embryonic stem cells.
Both types of stem cells have the ability to differentiate, but it is
unclear if they both have the same potential for use in stem cell
therapy. The results were determined by finding differentiating
ocular cells called retinal pigmented epithelium (RPE).
Transcription factors, protein arrangement, and gene expression
were looked at when comparing the two types of stem cells.
The study concluded that human induced pluripotent stem
cells are a feasible candidate for cellular therapy since they have
similar cellular function and possess proper gene expression.
(Buchholz Et. Al. 2009).

Where we are now

must be performed.
Scar tissue is present in the damaged eyes of patients with macular degeneration. When new cells are transplanted there is a
barrier between the host retina and the grafted cells. This can
affect the way the light is transmitted, and the way the patients
will see. Treating patients before scar tissue has formed, or discovering ways to get rid of scar tissue is crucial before stem
cells can be transplanted. (Barnstable).

Conclusion
There is promising research for use of retinal pigmented epithelial cells to treat macular degeneration. Continued research
is needed before stem cell therapy can be used as a widespread
treatment for macular degeneration. It is a goal of researchers
to treat patients earlier on in the progression of the disease,
before complete visual function has been lost.
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Abstract
With Zika virus spreading worldwide, a lot of attention is drawn to researching its pathogenesis and etiology. It has
also been noticed by various research groups and such health agencies such as CDC and WHO that there might be a
connection between ZIKV and microcephaly, due to the spiking number of cases of microcephaly reported in areas with
affected patients. Temporal and geographical data from the affected ZIKV areas, including Brazil and French Polynesia,
suggests a connection between microcephaly and the virus. Tests of amniotic fluids of pregnant women with reported
Zika virus infection and microcephalic fetuses revealed the presence of viral RNA. Zika was also found in placenta and
fetal brain tissue collected from two miscarriages and two newborns. Evidence presented in this review is sufficient to
prove an existent causal relationship between Zika virus and prenatal and neonatal microcephaly.
Introduction
Zika virus (ZIKV) is an emerging disease that has gone from
a mild endemic, circulating only locally in Africa and parts of
Asia, to a worldwide pandemic, spreading rapidly throughout
the Americas. (Lupton, 2016; Paixão, et. al. 2016).
ZIKV is an arbovirus which belongs to the genus Flavivirus, family Flavivirdae. It is known to be transmitted by mosquitoes of
the Aedes species – such as Ae. luteocephalus, Ae. aegypti, Ae.
africanus, Ae. alboictus, and Ae. hensilli, which are usually found
in areas with warm climate; however, Ae. albopictus inhabits as
far north as the Great Lakes in the U.S. (Fellner, 2016) Ae. aegypti is considered to be the most efficient vector for ZIKV, which
creates a bigger threat of spread of the virus, because this specie
is characterized by an easy adaptation to human environments,
indoor and daytime feeding, preference of feeding on humans,
and an ability to breed in extremely small amounts of water.
(Bell, et. al. 2016) As all other flaviviruses, including Dengue
virus, Yellow fever virus, West Nile virus, Japanese encephalitis
virus, Tick-Borne encephalitis virus, ZIKV carries a positive single-stranded RNA, which encodes a polyprotein that is then
processed into three structural proteins: the envelope, the
capsid, and the precursor of membrane. It also encodes seven
nonstructural proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and NS5. (Al-Quahtani, et. al. 2016).
ZIKV was discovered in 1947, in Uganda’s Zika forest, near
Entebbe, during regular surveillance for sylvatic yellow fever
in Macacamulatta rhesus monkeys. (Paixão, et. al. 2016) Shortly
after, in 1952, the first case of ZIKV infection in humans was
reported in Uganda and the United Republic of Tanzania.
For the next 4 decades, ZIKV had spread to equatorial Asia
(India, Pakistan, Malaysia, Indonesia, etc.), but infections were
mild, sporadic, and without large epidemics. (Al-Quahtani, et.
al. 2016) However, in 2007 the first major outbreak of ZIKV
infection occurred on Yap Island in the Federated States of
Micronesia, where well-nigh 75% of population was infected
with the virus. (Fellner, 2016; Al-Quahtani, et. al. 2016) Next
major epidemic of ZIKV was reported in 2013 in French
Polynesia. The most recent outbreak of ZIKV happened in
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Brazil in 2015, with first confirmed case reported in May 2015.
(Al-Quahtani, et. al. 2016).
Due to an increasing number of microcephaly cases being reported in the ZIKV affected areas, WHO and Brazilian Ministry
of Health have confirmed possibility of a link between ZIKV
outbreaks and such severe fetal neurological defects as microcephaly and recommended that all pregnant women residing
in or traveling to the affected areas should take precautions to
avoid contact with possible vectors. (Calvet, et. al. 2016) Having
a virus as a cause of birth defects is not surprising (for example, cytomegalovirus or rubella virus can be a source of microcephaly and other anomalies), but there has never been a time
when a virus caused an epidemic of congenital birth anomalies.
(Rasmussen, et. al. 2016) The CDC has advised that all infants,
whose mothers traveled or resided in areas affected by ZIKV
during pregnancy, should be suspected for congenital ZIKV infection if either intracranial calcifications or microcephaly were
detected at birth or prenatally or if mother’s ZIKV testing results were positive. (Fleming-Dutra, et. al. 2016) Can there really
be a connection between Zika virus and neonatal microcephaly?

Methods
This systematic review was composed after reviewing and
evaluating clinical data reports of Zika virus outbreaks in Haiti,
French Polynesia, Philippines, and Cambodia, case-studies of infants and fetuses with presumed or confirmed ZIKV infection,
and review articles; this data was obtained via searching engines
as MEDLINE and ProQuest, or directly from published sources.

Discussion
Zika Virus: Diagnosis and Treatment
ZIKV infection starts in dendritic cells near the site of inoculation (if mosquito-mediated), which is followed by spreading to
lymph-nodes and the bloodstream. (Al-Quahtani, et. al. 2016)
Replication of flavaviral RNA occurs in both cellular cytoplasm
and nucleus. Infectious ZIKV appears in human blood as early as
day 1 of illness onset, and can stay in blood as late as day 11 after
onset. (Hayes, 2009) The incubation period for ZIKV has been
determined to be 3-12 days. The outcome of infection depends
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on competition between viral replication and the host immune
response. (Al-Quahtani, et. al. 2016) Usually, human infections
with ZIKV are mild, and lethal outcomes are rare; common
symptoms include fever, arthralgia and muscle pain, conjunctivitis, rash, and headaches, lasting up to one week. (Pastula, et. al.
2016) However, 80% of ZIKV are asymptomatic, which makes it
extremely hard to diagnose and treat.
In addition to diagnosis based on epidemiological circumstances and clinical symptoms, there are not so many laboratory
diagnostic tests available, because ZIKV as a pandemic is very
recent. Existent assays for ZIKV diagnosis include use of reverse
transcriptase-polymerase chain reaction (RT-PCR) to detect
viral nucleic acid in the blood and other body fluids, such as
saliva or urine. This test is useful only if performed on serum
collected within day one to day three of symptom onset or
on saliva or urine collected up to day five of symptom onset.
Serological tests using enzyme-linked immunosorbent assays
(ELISA) are able to detect the presence of anti-Zika virus immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies,
which develop in human organism by the end of the first week
of infection. (Al-Qahtani, et. al. 2016; Fellner, 2016) However, as
specific as these two test are (compared to NAT or reduction
neutralization assay, for example), cross-reaction with related
flaviviruses, such as West Nile and yellow fever, and dengue, is
very common; therefore, additional tests should be performed
to exclude those options.

Microcephaly
Microcephaly (micro- small; cephal- head) is a congenital condition which is diagnosed when newborn children have a smaller brain and skull compared to those of others of the same
sex and age (See Fig. 1). (NINDS, 2016) Microcephaly can be a
Figure 1
Microcephaly in
an Infant (Bottom)
Compared With an
Infant With a Normal
Head Size (Top)
Source: CDC

result of both environmental and genetic causes. Most common
environmental factors that lead to microcephaly in infants are
radiation, lead and mercury intoxication, in utero exposure to
alcohol and drugs, and infections, such as TORCHES. (Calvet,
et. al. 2016; Teixeira, et. al. 2016) Common genetic causes are
autosomal recessive microcephaly, Aicardi-Goutières syndrome,
Rett syndrome, and chromosomal trisomy. (Calvet, et. al. 2016)
Frequently, microcephaly is associated with mental retardation,
Down’s syndrome, and neurometabolic syndromes.
There is no treatment available in order to return a baby’s head
to a normal size and shape; and all treatment techniques focus
on decreasing the impact of accompanying disabilities. (NINDS,
2016) Therefore, understanding whether there’s indeed a relationship between maternal infection with ZIKV and congenital
microcephaly and the mechanism, in which the virus affects prenatal development, is extremely important for decreasing the
number of microcephaly cases.

Evidence for a Link between ZIKV and Microcephaly
After the emergence of ZIKV in Brazil in 2015, a 20-fold average
annual increase of microcephaly cases was reported. In 2015,
there has been 1248 new suspected cases – prevalence of 99.7
per 100 000 livebirths. (Ventura, et. al. 2016) On November 28,
2015 Brazil declared congenital ZIKV to be responsible for the
microcephaly epidemic. The very first alert was raised by the
State Secretariat of Health of Pernambuco, Brazil in October
2015 after analyzing the obvious spike in microcephaly cases:
from January to July 2015 there had only been 6 cases reported,
6 cases in August, 11 in September, and 39 in October. Mothers
of 38 newborns were interviewed, 24 of whom reported having
a rash during pregnancy.They also reported not to have had any
common exposure to pesticides, drugs, alcohol abuse, radiation,
or any other possible teratogenic factors. (Teixeira, et. al. 2016)
As ZIKV has spread to other states in Brazil, 49th epidemiologic
week had the highest rate of cases of microcephaly reported –
900 cases in a week; women delivering then would have been in
the first trimester of pregnancy during the peak of ZIKV outbreak. (Kleber de Olivera, et. al. 2015; Teixeira, et. al. 2016) This
observation suggests a very strong association, both geographic
and temporal, between ZIKV and microcephaly epidemics.
In addition, a retrospective study, using serologic and statistical data, of 2013-2014 outbreak of ZIKV disease in French
Polynesia identified that 1% of mothers infected with ZIKV in
the first trimester, had given birth to neonates with microcephaly, which suggests a prevalence to be 50 times as high as the
estimated baseline. (Rasmussen, et. al. 2016) Yet, this study was
based on small numbers of patients, fetuses were not tested for
ZIKV, and other brain anomalies were not included in the study.
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Eight-eight pregnant women in Brazil, who reported having an
onset rash for the previous 5 days, were tested and evaluated
for ZIKV RNA. There were 72 with positive test results and
16 negative. Ultrasonography of 42 of those testing positively
and the 16 negative ones revealed fetal brain anomalies were
present in 29% of the former and 0% of the latter. (Rasmussen,
et. al. 2016) Yet, this study is very limited by lack of tests for
other viruses in mothers’ serum and amniotic fluid for ZIKV
or other viruses. Also, there were no postnatal observations of
the patients.
Link between congenital ZIKV and microcephaly is strongly supported by histopathologic evaluation of 4 formalin-fixed,
paraffin-embedded tissue samples from two newborns, born
at 36 and 38 weeks of gestation, who died shortly after birth
and had microcephaly, parenchymal calcification, microglial nodules, gliosis, brain cell necrosis, and two miscarriages (lost at 11
and 13 weeks gestation) with chorionic villi with calcification,
fibrosis, and focal villitis. All four mothers reported having clinical signs of Zika during the first trimester of pregnancy – fever
and rash. Laboratory testing was performed by the CDC; the
samples included brain tissues from both newborns, placenta of
one newborn, and products of conception from the two miscarriages. These samples were tested by ZIKV RT-PCR and all four
cases turned out positive for NS5 and envelope genes. Further
sequence analysis revealed the highest matches with ZIKV strains
isolated from Brazil in 2015. The same samples were also tested
for viral antigens by immunohistochemistry using a mouse polyclonal anti-Zika virus antibodies, and viral antigens were found
in glial cells and neurons of one newborn and in chorionic villi
of one of the miscarriages. RT-PCR for dengue was performed
and tests results were negative, which eliminates the possibility
of cross-reaction of the virus. (Martines, et. al. 2016) Also, the
mothers’ tests for rubella, herpes simplex, HIV, toxoplasmosis,
and cytomegalovirus were negative, which points at ZIKV infection as the cause of microcephaly and fetal demise.
Another piece of evidence that supports the suggestion that
ZIKV can negatively affect fetal CNS and cause microcephaly
was obtained by a research team at Hospital Geral Roberto
Santos in Salvador, Brazil. There, tissues and fragments of a female fetus, delivered after fetal demise in the 32nd week of
gestation, were examined and tested for congenital ZIKV. Fetus
had signs of microcephaly and arthrogryposis. Samples of cerebral cortex, medulla oblongata, cerebrospinal and amniotic
fluids tested positive by ZIKV-specific RT-PCR, which targets
viral NS5. Samples from other organs, such as extracts from the
heart, lungs, and liver, didn’t test positive and appeared to be
undamaged. Also, the mother’s tests for HIV, HTLV, hepatitis C,
toxoplasmosis, rubella virus, and cytomegalovirus during the 4th
gestational week were negative, which leaves responsibility for
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fetal brain anomalies to the virus. (Sarno, et. al. 2016) However,
this study is limited by not performing histopathological analysis
of the sample tissues.
In addition, a different group of researchers tested the amniotic
fluid of two pregnant women with microcephalic fetuses. Both
women had normal fetal ultrasounds in the first trimester, but
ultrasounds done later on in weeks 25 and 27 revealed severe
microcephaly (head circumference below the third percentile), hypoplasia of the cerebellar vermis, and posterior fossa
enlargement in one fetus and asymmetry of hemispheres, and
hypoplastic cerebellum with the cerebellar vermis completely
missing. Both mothers did not report being on any medications
during pregnancy, alcohol and drug use, or smoking. Tests for
autoimmune and immunodeficiency diseases, and TORCHES
were negative as well. However, they both reported having
ZIKV infection symptoms at 10 and 18 weeks of gestation, respectively; also, they haven’t reported travelling outside of Brazil
during the previous years, or being in contact with any infected
individuals.The amniotic fluid from each patient was then tested
for any non-human genomic sequences, and ZIKV genome was
identified in both samples. (Calvet, et. al 2016; Schuler-Faccini,
et. al. 2016) The samples were also tested with RT-PCR for dengue and chikungunya, and the results were negative. ELISA test
identified the presence of anti-ZIKV IgM in both samples as
well. (Calvet, et. al. 2016) This study proves that ZIKV infection
can cross the placental barrier. And since the ultrasounds at
earlier gestation stages (during the first trimester) appeared to
be normal but during the second trimester the fetuses started
to develop signs of microcephaly and other brain anomalies
(after the mothers being infected in the first trimester), the link
between ZIKV and microcephaly is evident.
Also, according to Shepard, a pioneer in the field of teratology,
in order to consider something a teratogen, there has to be an
association of a rare environmental exposure with a rare defect.
(Rasmussen, et. al. 2016) Considering the stats for microcephaly obtained in Brazil would not qualify because exposure to
ZIKV wasn’t rare. Yet, ZIKV is a rare exposure for the people
that spent only a short time in the ZIKV affected areas and
gave birth to infants with such brain anomalies. Considering
microcephaly statistics in the United States of America, it can
be assumed to be a rare defect, with only 6 cases in 10000
live-born infants. One of the recent reports in the U.S. illustrates this connection: a pregnant woman traveled to Mexico,
Belize, and Guatemala during her 11th gestation week. She was
tested positive for ZIKV IgM after her return. Ultrasonography
and MRI of the fetus was performed during gestation weeks 19
and 20 and severe brain anomalies were diagnosed; the head
circumference had dropped from the 47th percentile during the
16th week of gestation to the 24th percentile at gestation week
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20. The pregnancy was terminated in the 21st gestation week,
but considering the trend of the head circumference decrease,
microcephaly would have developed if the pregnancy continued.
(Rasmussen, et. al. 2016).

List of Acronyms
Arbovirus

Arthropod-borne virus

CDC

Centers for Disease Control and Prevention

ELISA

Enzyme-Linked Immunosorbent Assays

Mechanisms of infection of the fetal brain by Zika virus

HIV

Human Immunodeficiency Virus

The most recent research suggests that ZIKV is able to infect
human neural progenitor cells, dysregulate transcription and
stunt their growth. Human induced pluripotent stem cells (hiPSCs) were used as an in vitro model to investigate the mechanism of ZIKV infection and impact on neural cells. This study
was able to determine that cells of different cell lines have variation in their susceptibility to the virus; hiPSCs showed one of
the highest permissiveness levels. Further investigation of hiPSCs established that human neural progenitor cells (which can
further be differentiated into cortical neurons, astrocytes, and
oligodendrocytes) are a direct target of a ZIKV.Within 72 hours
after being infected with ZIKV, total number of viable cells was
observed to be reduce by 29.9 +/- 6.6%. Levels of caspase-3, involved in apoptotic pathway regulation, in infected hNPCs were
found to be significantly higher than those in control group.
(Tang, et. al. 2016) However, it is hard to conclude if all strains
of ZIKV affect human embryotic brain cells in the same manner,
for only one strain of virus was used in this research. In addition,
assessing the level of neurotropism expressed by ZIKV is intricate because Zika infects other types of cells as well.

hiPSC

Human Induced Pluripotent Stem Cell

hNPC

Human Neural Progenitor cell

HTLV

Human T-Cell Lymphotropic Virus

IgG

Immunoglobulin G

IgM

Immunoglobulin M

NAT

Nucleic Acid Amplification Test

RT-PCR

Reverse Transcriptase-Polymerase Chain 		
Reaction

TORCHES

Toxoplasmosis, rubella, cytomegalovirus, 		
herpesvirus, and syphilis

ZIKV

Zika Virus

Conclusion
Evidence linking frequent occurrence of microcephaly in regions
with ongoing ZIKV is deficient and scarce, for the pandemic is
very recent and emerging. There are still many questions that
remain unanswered, such as whether there’s a range of associated birth defects, how this range is affected by the timing of fetal
exposure to the virus and severity of maternal infection, if such
range exists, and whether severe anomalies are only limited to
the CNS.
However, based on the data available for analysis, it may be concluded that ZIKV can cross the placental barrier and exhibit
higher tropism to a specific range of tissues. The accumulation
of geographical and temporal and rare exposure-rate defect associations between maternal ZIKV infection and microcephaly
in fetuses and neonates, and multiple case-study findings support a causal relationship present between the two events. Yet,
more research must be conducted to have a better understanding of the effects and mechanisms of infection and to be able to
propose possible treatment solutions.
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Abstract
US survey trends show that since the 1970’s there has been a decline in energy intake, (consumption of food) and a rise
in the prevalence of obesity. This suggests that there must have been a dramatic decrease in total energy expenditure.
Energy expenditure is the sum of energy (or calories) the body needs to carry out physical functions such as breathing
and digestion, as well as the energy used in physical activity. As the rate of obesity in the US increases, it is becoming
more and more important to find ways to increase energy expenditure, specifically through physical activity. Physical
activity is often thought of as the key to fat loss because it is the component of energy expenditure that is most variable
and can lead to the greatest total energy expenditure.The issue that follows is that many overweight individuals lack the
motivation to invest time and energy into a substantial amount of exercise.To overcome this problem and to help make
exercise more manageable, high interval intensity exercise (HIIE) can be a practical solution. HIIE is an exercise strategy
that prescribes short periods of intense exercise alternating with less intense recovery periods. HIIE can potentially,
with little time investment, result in energy expenditure equivalent to that of lower intensity continuous exercise done
for a longer period of time. The purpose of this review is to examine the effects of HIIE on body composition and fat
loss according to the current literature. If HIIE proves to be an effective way to burn fat without the time investment
exercise routines typically require, it may make fat loss goals more attainable and lead to better results if implemented
into weight loss programs.
Introduction
Fuel Source During Exercise
While the human body is at rest, skeletal muscle is responsible
for 30% of oxygen consumed. During strenuous exercise, skeletal
muscle can account for more than 90% of the total metabolism.
ATP is required in order for skeletal muscles to contract and
relax during exercise. As such, the purpose of muscle metabolism
is to generate ATP via oxidative phosphorylation. Skeletal muscle can use free fatty acids, glucose, or ketone bodies as fuel for
ATP production (Garrett et al., 2012). Since cellular respiration
involves several complex metabolic pathways, the relative utilization of fat and carbohydrate during exercise can vary enormously
and depends strongly on exercise intensity (Loon et al., 2001).
Generally, as intensity of exercise is increased, the amount of oxygen available decreases and the muscle carries out anaerobic
respiration. This refers to glycolysis, a metabolic pathway that
primarily uses carbohydrates as substrate. The increased carbohydrate metabolism (glycolytic flux) limits the transport of long
chain fatty acids into the mitochondria where fat oxidation generally occurs. Consequently, increased carbohydrate usage as fuel
will inhibit the use of fat as fuel (Christmass et al., 2000). In high
intensity intermittent exercise it’s often found that carbohydrate
breakdown decreases, and fat oxidation increases as the exercise
progresses (Talanian et al., 2006). This can be attributed to the
interval nature of HIIE and is known as the “substrate-shuttle”
effect. (EG Trapp et al., 2007).

The “Substrate-shuttle” Effect
Intramuscular triglycerides are an important supply of fuel for skeletal muscle. Each one is composed of three fatty acids esterified
to a glycerol backbone. When glycerol levels are elevated, it’s indicative of an increased reliance on fats for fuel. (Trapp et al., 2007).

Lactate is a waste product of glycolysis, generated from the anaerobic breakdown of glycogen. While exercising steadily, there
is normally a balance between lactate production and lactate removal. When the intensity of exercise reaches a point at which
there is an abrupt increase in lactate levels, lactate threshold has
been reached. If lactate levels are above threshold, the excess
blood lactate will inhibit carnitine- acyl CoA transferase, an essential enzyme which enables beta-oxidation to occur. (Trapp et
al., 2007) (explain beta oxidation).
Lactate and glycerol levels were analyzed in one particular study
of HIIE. 16 women, 8 trained and 8 untrained, participated in
two 20 minute short sprint sessions (8 second sprint/12 second
recovery) and two 20 minute long sprint sessions (24 second
sprint/36 second recovery). After exercising, they found that
plasma glycerol levels went up dramatically for both groups
(P<.0001). Lactate levels rose as well; they were higher during
long sprints for trained women than for short sprints (P<.01).
(Trapp et al., 2007).
The elevated glycerol levels indicate that there was an increased
fat oxidation for fuel. This enhanced fatty acid oxidation, seems
contradictory to the fact that lactate levels were elevated above
threshold (3.5mmol/L - 4.0mmol/L). The solution proposed
for this contradiction is the intermittent nature of HIIE. The
intervals in HIIE create a “substrate shuttle” with alternating
anaerobic and aerobic energy sources. During the high intensity periods, ATP and creatine phosphate are broken down to
produce energy. During the rest periods, they are resynthesized
aerobically. However, since the rest interval isn’t that long, it is
likely that the resynthesis is incomplete and anaerobic glycolysis provides the rest of the needed energy. This is verified by
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Bangsbo et al. 1991, who found that glycogen, the substrate for
anaerobic glycolysis, was shown to be progressively diminished
over the course of HIIE. Eventually, repeated exercise results in
an accumulation of cytosolic citrate which inhibits phosphofructokinase activity and impairs glycolysis. It is suggested that the
progressive depletion of glycogen and phosphocreatine along
with the increased levels of cytosolic citrate, act together to
inhibit glycolysis, and allow for repeated bouts of high intensity exercise, while reducing lactate accumulation. The aerobic
metabolism that accompanies lower lactate levels may enhance
fatty acid oxidation. (Trapp et al., 2007).

Methods
This comprehensive review is based on critical analysis of literature obtained using the Touro College Online library and
Google Scholar. References in these articles were retrieved and
served as additional points of reference for further research.
Review articles were useful in helping provide additional references to source material.

Discussion
Many studies have been performed in an effort to establish the
relationship of HIIE with increased fat loss. The studies examine
whether HIIE causes enhanced fat loss, and via which mechanisms this may occur. Since the mechanisms of carbohydrate
metabolism, fat oxidation, and fat loss in general are complex
and detailed, there are many different ways to determine if fat
loss occurred as a result of exercise. The study of energy expenditure, the analysis of skeletal muscle, the catecholamine response, and the respiratory exchange ratio can all provide useful
information regarding whether enhanced fat oxidation occurred
as a result of HIIE.

Energy Expenditure and Fat Loss
The volume of physical work done is often the factor that plays
the greatest role on energy expenditure (EE). This volume is
based on the duration and intensity of the exercise done. For
example, more energy is expended when walking 5 miles than
when walking 3. Generally, as long as the activity is done at the
same intensity, there is a linear relationship between EE and
work carried out. However, when exercise intensity is changed,
it affects how efficiently work can be performed. There is a
negative relationship between exercise intensity and efficiency
(Hunter et al., 1998). For example, for the same amount of cycling, EE was 22% greater when it was carried out at a high
intensity than at a low intensity (Treuth et al., 1996). The exact
reasons behind this inverse relationship between efficiency and
exercise intensity are unknown. In any case, it seems to be that
the best way to increase EE is to carry out a high volume of
work at high intensity. However, this kind of exercise can bring
about fatigue very quickly. Therefore, high intensity exercise

60

interspersed with rest intervals seems to be an ideal way to
increase EE by combining high intensities with multiple rest intervals (Hunter et al., 1998).
The question that follows is if two exercises have equal EE, yet
one was reached via HIIE and the other via low intensity continuous exercise, will HIIE generate more fat loss?
One study that compared results of high and moderate intensity exercise programs with equivalent EE found that this was indeed the case. This 15 week intervention study was performed
on 34 healthy women aged between 18 and 30 years old. They
were divided into an HIIE group, a continuous exercise group,
and a control group. The HIIE protocol consisted of 8 seconds
sprinting on an ergometer(?), alternating with 12 seconds of
turning the pedals slowly. As each subject was able to complete
20 minutes of HIIE at a resistance of .5kg, the resistance for
that subject was increased by increments of .5kg. The continuous exercise protocol consisted of a five minute warmup and
cooldown, and a 15-20 minute (later increasing to 40 minute)
work session pedaling at a continuous intensity of 60% VO₂
peak. VO₂ peak is the point when a subject’s oxygen consumption plateaus at ≤150 ml/min VO₂ as the test progressively gets
more difficult. When this happens, it’s indicative of the fact that
the subject is close to his actual VO₂max capacity, or maximal
oxygen intake. In the continuous exercise group as well, the resistance was raised by incremnets of .5kg as the fitness of each
subject improved. The control group was instructed to maintain
their usual diet and physical activty. Total EE for the continuous
exercise group and HIIE group was 36.3 ± 3.4 MJ and 41.5 ± .81
MJ, respectively. This is considered a non-significant difference.
Nevertheless, there was a substantial decrease in total body
mass for the HIIE group compared to the other groups. The
HIIE group also displayed a significant decrease in fat mass while
the other two groups had a fat mass gain. (Trapp et al., 2008).
Not only did the HIIE group expend the same amount of energy
in a shorter amount of time, that equivilent EE caused more fat
loss when reached via higher intensity exercise.
It should be noted that studies have indicated a direct correlation between initial adiposity and amount of fat lost. Research
has shown that subjects with higher fat levels to begin with,
tend to lose more fat (Trapp et al., 2007), (Trapp et al., 2008).
This would support the notion that HIIE would generate a more
significant loss of fat in overweight individuals than in thinner
subjects.That being said, there were four lean women in the
HIIE group of the aforementioned study who possesed significantly lower fat mass than the rest of the group.With these four
women removed, the HIIE group displayed a 4.3% decrease in
total body mass, a 14.7% decrease in total fat mass, and a 9.5%
decrease in central abdominal fat. Conversely, the continuous
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exercise group displayed a 10.5% increase in central abdominal
fat. (Trapp et al., 2008). These results futher demonstrate that
for a given expenditure of energy, fat loss is greater when intensity is high.
Another study was performed on 21 middle aged obese women
with the metabolic syndrome, displayed similar results. During
this 16-week exercise intervention program, the women were
divided into 3 groups – control, low intensity exercise training (LIET), and high intensity exercise training (HIET). The LIET
group trained five days a week at an intensity at or below their
lactate threshold. The duration of each session was adjusted so
that the participants expended a specific amount of energy per
week. The HIET group also exercised 5 days a week, with high
intensity sessions for three of the days and moderate intensity
exercise sessions for the remaining two. Participants exercised
at an intensity between their lactate threshold and VO₂peak on
the high intensity days and at an intensity at or below their lactate threshold on the lower intensity days.Again, the duration of
sessions was modified based on the progression of caloric expenditure as the training intervention proceeded. The findings
indicate that exercise of higher intensity generates greater fat
loss compared to exercise of lower intensity under isocaloric
training conditions. (Irving et al., 2008).
It should be noted that the HIET group in this study likely had
a total EE that was slightly greater than that of the LIET group.
This is because the total EE per session was a combination of
the kcal expended during training as well as resting metabolism.
Therefore, on HIET days when the duration of exercise was
slightly shorter, the resting metabolism would contribute to a
lower fraction of the total EE. This caused a 25 kcal difference
between the HIET and LIET groups per week, totaling a difference of 400 kcal over the course of the training intervention.
(Irving et al., 2008).
The previous studies examined the difference in fat loss when
EE was equal between groups. Overall, greater fat loss was
noted when exercise was done at higher intensites. Research
has also been done to compare HIIE and continuous exercise
when EE is not equivalent.
In one study, the mean estimated total energy cost was 120.4 MJ
for the continuous/endurance training (ET) exercise program,
and 57.9 MJ for the HIIE program. Nevertheless, the reduction
in the sum of six skin folds was greater after HIIE. Since there
is an association between exercise duration and fat loss, the
changes in subcutaneous fat were corrected based on the total
energy cost of training. As demonstrated when the decrease
in the sum of the skinfolds was divided by energy expenditure
and expressed as changes in subcutaneous skinfolds per MJ, the

participants in the HIIE program lost nine times more subcutaneous fat than those in the ET program (Tremblay et al., 1994).
However, not all studies show HIIE to be the superior to ET.
Very often, when the EE is not equivalent, HIIE will not bring
about more favorable results than ET. Nevertheless, if HIIE brings
about the same results with a smaller time investment, it is still
extremely worthwhile. In the present study is an example of
HIIE that brought about results copmarable to ET. Sprint interval
training is a form of HIIE where the high intensity intervals involve 30 second “all-out” sprints on an ergometer. 16 active men
were separated into a sprint interval training (SIT) group and a
high volume endurance training (ET) group. In this study, the SIT
protocol consisted of 6 sessions of 4-6 repeats of 30 seconds
“all-out” cycling at about 250% VO₂peak with 4 minute recovery
periods. The ET program consisted of 90-120 minutes of continuous cycling at 65% of VO₂peak. Total EE was 630 KJ for the SIT
group, and 6500 KJ for the ET group. Despite the fact that EE for
the ET group was 10 times more than the EE for the SIT group,
the results showed that SIT brought about similar improvements
in muscle oxidative capacity. (Gibala et al., 2006).
Another SIT study yielded similar results. 20 young men and
women were separated into SIT and ET groups for 6 weeks of
training. The SIT consisted of 4-6 30 second “all-out” cycling
tasks (at 500W) three times a week, and the ET group consisted of 40-60 min of continuous cycling at about 65% VO₂peak
five days a week. Total weekly exercise volume was 90% lower
in the SIT group. Moreover, since most of SIT exercise time is
actually spent in recovery from the 30 second bouts of cycling,
actual weekly exercise time was only about ten minutes in SIT,
compared to 4.5 hours in ET. Nevertheless, results between
the two groups were very similar: whole body fat oxidation
was increased and carbohydrate oxidation was decreased.
(Burgomaster, 2008).

Skeletal Muscle Analysis
As mentioned earlier, the “substrate-shuttle” effect supports
enhanced fat oxidation by activating aerobic metabolism and
enabling the mitochondria to produce ATP. In line with this, it’s
likely that HIIE will result in increased mitochondrial enzyme
activity. Therefore, when studying the effects of HIIE on skeletal
muscle, many researchers focus on changes in mitochondrial
enzymes. Based on increased activity of mitochondrial enzymes
and the fact that aerobic metabolism favors enhanced fatty acid
oxidation, it’s possible to surmise that an increase in mitochondrial enzyme activity during HIIE will correlate with fat loss.
Citrate synthase and β-HAD (Hydroxyacyl- Coenzyme A dehydrogenase) activity, are important indicators of enhanced fatty
acid metabolism, that were significantly increased in an HIIE
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intervention in just 2 weeks. In this study, skeletal muscle enzyme activity was measured to confirm an increase in the use of
fats as fuel. 8 healthy recreationally active women participated
in this study. Each of them performed a VO₂peak test before and
after 2 weeks (7 sessions) of HIIE. The VO₂peak tests involved
a 60 minute cycling trial at about 60%VO₂peak. The seven HIIE
sessions consisted of 10 cycles of 4 minutes of high intensity
cycling at 90%VO₂peak alternating with 2 minute resting periods. Whole body fat oxidation and total fat oxidation were
both significantly increased during the 60 minute cycling session
after HIIE. Accordingly, there was a significant decrease in whole
body carbohydrate oxidation and a 23% decrease in total carbohydrate oxidation. These results were then supported with a
skeletal muscle analysis. (See Table 2)
ANALYZED

IN 60 MINUTE SESSION
AFTER HIIE

β-HAD activity

increased by 32%

citrate synthase activity

Increased by 20%.

HSL protein content

Increased by 13%

FABPpm

increased 25%

FAT/CD36

remained unchanged

Resting muscle glycogen
content

Unchanged

Net muscle glycogen utilization Decreased by 12%
Intramuscular triglycerides

Decreased by 17%

(before HIIE, by 12%)
Table 2 Summary of skeletal muscle analysis conducted
after a 2 week HIIE intervention study (Talanian et al.,
2006).
Usually, exercise training results in increased fat oxidation from
fatty acids stored in adipose tissue and intramuscular triglyceride (IMTG) stores. In this study, however, HIIE did not cause a
significant increase in IMTG utilization. HSL (hormone sensitive
lipase) protein content was also not seen to be significantly increased. HSL is a key regulatory enzyme in lipolysis of IMTG
stores. It’s possible that the HIIE protocol in this study was too
short to bring about significant adaptations in skeletal muscle
(Talanian et al., 2006).
FABPpm (plasma membrane fatty acid-binding protein) and FAT/
CD36 (fatty acid translocase) are two proteins that transport
long chain fatty acids (LCFA) across the plasma and mitochondrial membranes. They are useful in determining if skeletal fat
oxidation was enhanced or limited during exercise. In this study,
FABPpm concentration was increased by 25% after HIIE,, and
FAT/CD36 concentration remained unchanged. It is true that an
inhibition of FABPpm will reduce the uptake of LCFA, but an unchanged FAT/CD36 doesn’t necessarily mean the same thing. It’s
possible that there was a shift in the fractional concentrations
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of FAT/CD36 on the mitochondrial and plasma membranes that
could have increased LCFA uptake without a notable increase in
FAT/CD36 concentration. (Talanian et al., 2006).
The elevated citrate synthase and β-HAD levels indicate increased use of fats for ATP. Citrate synthase is a critical enzyme
in the citric acid cycle, a cycle which favors aerobic metabolism,
and likely the use of free fatty acids as fuel. β-HAD, or 3-hydroxyacyl-CoA dehydrogenase, is an enzyme that catalyzes an
important step in fatty acid metabolism. (Talanian et al., 2006)
In another SIT program, citrate synthase and β-HAD were
analyzed as well. The results after 6 weeks of training showed
that both citrate synthase and β-HAD increased after SIT in a
similar manner to that of ET (See Figure 1), suggesting that fatty
acid oxidation was occurring. This was further proven by the
tremendous increase in whole body fat oxidation noted after
training (Burgomaster, 2008).
Malate dehydrogenase (MDH) is another enzyme that is needed
in the citric acid cycle. Increased MDH is indicative of aerobic
conditions, and likely increased fat oxidation. In one particular
study that compared HIIE to ET, increased MDH was found in
both groups. 27 men and women partook in this study. 8 men
and 9 women participated in a 20 week ET intervention, and 5
men and 5 women participated in the 15 week HIIE intervention.
The ET program included a 30 minute (increasing to 45 minutes)
cycling session, 4 times (increasing to 5) times) a week. Intensity
corresponded to 60% (and increasing to 85%) of the maximal
heart rate reserve.The HIIE intervention consisted of 25 sessions
with 30 minutes of continuous exercise at an intensity similar to
the endurance training program. Half of these were completed by
the fifth week of the program. It also included 16 short interval
sessions (10-15 bouts of 15-30 seconds of high intensity intervals,
alternating with recovery periods to allow heart rate to return
to 120-130 beats per minute), and 19 long interval sessions (4-5
bouts of 60-90 seconds of high intensity intervals alternating with
recovery periods to allow heart rate to return to 120-130 beats
per minute).The results showed that participants in the HIIE program lost nine times more subcutaneous fat than those in the ET
program. These results were supported by the increased MDH
activity. Furthermore, there was a substantial increase in β-HAD
in the HIIE group alone, another indication of the fact that HIIE
leads to better lipid utilization (Tremblay et al., 1994).

Catecholamine Response
Epinephrine is a catecholamine known for stimulating lipolysis.
As such, elevated epinephrine concentrations after exercise
would indicate an increased use of fat as fuel. Trapp et al., 2007
demonstrated this in their study when examining the different responses of trained and untrained women during HIIE.
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Figure 1 Activity
of citrate synthase
and β-HAD before
and after 6 weeks
of SIT training
(Burgomaster, 2008).

resting metabolic rate. The fact that no noteworthy weight loss
was noted in this study is explained by the fact that the intervention was short-term. Based on the increased fat oxidation, it
can be inferred that a longer-term intervention would likely yield
more substantial weight loss results (Whyte et al., 2010).

Can HIIE really help the overweight population?

It was found that epinephrine and norepinephrine levels both
increased after short sprint and long sprint exercise (see Figure
8). The elevated catecholamine levels serve as another explanation of why the glycerol levels in that previously mentioned
study were increased despite lactate levels above threshold.

Respiratory Exchange Ratio (RER)
RER is the ratio of carbon dioxide produced to oxygen consumed. Based on the RER, it is possible to estimate which particular fuel is being oxidized to produce energy. An RER close to .7
is indicative of fat as the energy source, and an RER close to 1.0
is indicative of carbohydrate as the energy source. An RER value
between the two indicates a mixture of fat and carbohydrate.
Therefore, by measuring RER after an exercise intervention, one
can deduce what fuel was oxidized in order to produce ATP.
In one study, 10 obese males participated in 6 sessions of sprint
interval training over a 2 week period. After the 2 week intervention, it was noted that the RER decreased from .78 +/- .01
to .73 +/- .01, suggesting that fat was the primary substrate used
for oxidation. This was further confirmed by the fact that resting
carbohydrate oxidation was significantly lower after training and
that resting fat oxidation was increased by 18.2%. Even though
significant weight loss wasn’t noted in this study, (body mass was
somewhat lower (P=.055), and waist and hip circumference were
reduced by ≈1 %,) the magnitude of increase in resting fat oxidation is used in order to predict the extent of exercise-induced
fat loss. This estimate is based on resting fat oxidation alone and
is independent of exercise energy expenditure and change in

The actual benefits of interval training can be seen when comparing it to another weight loss method. 62 overweight adolescents were divided into two groups- aerobic interval training
group (AIT) and multidisciplinary approach group (MTG). The
AIT group did HIIE on a treadmill twice a week for 3 months,
and were then encouraged to perform at least 2 interval sessions for the next 9 months. The HIIE sessions included 4, 4
minute bouts at 90% of maximal heart rate, alternating with 3
minute lower intensity sessions at 70% maximal heart rate. The
MTG were subjected to a 12 month regimen which included
meeting every 2 weeks with a doctor, a clinical nutritional physiologist, and a nutritional psychologist. After 3 and 12 months,
only the subjects in the AIT group had a decreased percentage
of body fat. It’s interesting to note that the subjects in the AIT
group followed a better diet than those in the MIT group even
though they were not given clear guidelines regarding caloric
intake. This is possibly because AIT brought about a motivational side effect of improving their aerobic capacity. Indeed, some
members commented that they became more conscious of
their eating habits after 3 months of the AIT program. (Tjonna
et al., 2009).

Limitations
When analyzing fat loss over an extended period of time, it is
difficult to isolate the cause of it. Even though subjects in the
HIIE studies were instructed to maintain their regular diets, it’s
not guaranteed that they did. As a result, it’s possible that some
of the fat loss displayed after an exercise intervention was partly
due to dietary modifications.
Another limitation the study of HIIE poses, is the varying intensities and duration of intervals. Most studies mentioned in this
paper prescribed a different HIIE “formula.” Since there hasn’t
yet been a study that tests every combination of intensity and
duration of exercise, it is difficult to determine the minimum
length and intensity needed in order to bring about the benefits
of HIIE. It’s possible that the results discussed in this review
would not be successfully replicated if done at a slightly lower
intensity, or for a shorter amount of time.

Conclusion
HIIE is an arduous method of exercising which requires subjects
to push themselves to their maximum capacity for short intervals of time. Most studies conducted regarding HIIE involve high
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intensity intervals that are extremely difficult and demanding.
Although HIIE has been shown to enhance fatty acid oxidation and increase fat loss, it may be dangerous for an obese,
non-physically active person to attempt.
That being said, for individuals who could handle the workload
of HIIE, the short duration of intense intervals might encourage
exercise because there’s only a small span of time where they
are required to push themselves. Moreover, more people might
be motivated to exercise daily since only a few short sessions of
HIIE are needed to improve whole body fat oxidation. As mentioned earlier, it took only 7 sessions of HIIE to increase total fat
oxidation by 36% in previously untrained women (Talanian et al.,
2006), and only 6 sessions of sprint training for overweight men
to increase resting fat oxidation by 18.5% (Whyte et al., 2010).

HSL – hormone sensitive lipase
IMTG – intramuscular triglycerides
LCFA – long chain fatty acids
LIET – low intensity exercise training
MDH – malate dehydrogenase
MTG – multidisciplinary approach group
RER – respiratory exchange ratio
SIT – sprint interval training
β-HAD – Hydroxyacyl- Coenzyme A dehydrogenase
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Abstract
The global shortage of donor organs is a cause for countless fatalities across the world. Although, diseases can be
treated through organ transplantation it can come along with many complications. Not only is there a high demand for
donor organs, there is also the risk of the body’s rejection of the newly implanted organ. Through the method of 3D
printing organs, many lives could be saved as well as reducing the need for donor organs. Finding materials to create a
suitable scaffold is the focus of many experiments. Materials that are used in organ printing are made from soft materials,
therefore, suspended hydrogel techniques are utilized for printing organs and for creating vascularization systems in the
printed organs. The vascularization level of 3D printed organs is the most complicated because of its vast and detailed
preciseness. Detailed magnetic resonance imaging is taken to generate the 3D image of the structure and consequently
print the image layer by layer as opposed to the older method of manually applying cells onto scaffolds. While many
research teams have made progress with 3D organ printing, complex organs such as the heart and kidney are currently
undergoing research to be implemented into clinical settings.
Introduction
Transplanting new organs is a way of trying to deal with life
threatening diseases. Instead of the chronic maintenance of diseased organs medical professionals would be able to replace
them, thus curing the condition. One leading major health crisis is the shortage of organs available for transplants. Although
medicine’s advancements help people live longer, organs tend
to fail more often as a result of longer lifespans. For instance,
in the United States, a name is added to the Transplant List
on an average of every ten minutes. Additionally, the number
of patients needing organs have doubled while the amount of
transplant procedures has barely increased (OPTN, 2016). 3D
organ printing technology is a promising step to help solve the
organ transplantation crisis.
The field of regenerative medicine deals with replacing, engineering, or regenerating human cells, tissues, or organs in order
to help achieve normal function. Regenerative medicine is not
a new field; Alexis Carrel, a Nobel Prize winner, writes in his
book, “The Culture of Organs” (Carrel, Lindbergh, 1938) about
technologies that are still used today for blood vessel grafting.
Thomas Boland, self-described as the “grandfather of bioprinting,” took an old Lexmark computer, emptied the ink cartridge
and filled it with collagen instead. He then glued a thin, black
silicon sheet onto blank paper and inserted it into the printer.
He opened a Word document on his PC, typed his initials, and
hit print.The paper came out with “TB” clearly presented in offwhite proteins. By 2000, Boland and his team had reconfigured
a Hewlett-Packard DeskJet 550C to print with E. coli bacteria.
Then they expanded to larger mammalian cells obtained from
Chinese hamsters and lab rats. Once printed, 90 percent of the
cells remained viable, which meant the product was useful, not
only art. Boland introduced 3D printing for cellular construct
when he patented the process for using the ink-jet printer for
printing cells. Boland’s process used a system where cells were
deposited into 3D matrices placed on a substrate. Instead of
using ink, 3D printers use cells in a cartridge where the cells are
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being layered in order to create a three-dimensional structure
that can lead to functional organs and tissues (Wilson, Boland,
2003). This paper will review the current progress in organ
printing technology with its promises and challenges and evaluate whether functional organs can be produced.

Methods
The information in this paper was obtained by the analysis of
scientific articles and research papers obtained from the Touro
College Online Library, specifically, the Health Science related databases such as Pubmed, Proquest Medical Library, and
EBSCO multisearch.Additionally, websites like NIH.gov,Webmd.
com, Mayoclinic.com and OPTN.com were used to gain general
knowledge and information about the subject. Keywords such
as “3D organ printing” and “regenerative medicine” were used
to search for scientific articles.

Discussion:The Bladder
At first, researchers were pipetting cells into petri dishes by
hand without the use of 3D printers. To do so, researchers
would seed the cells from the petri dishes onto artificial scaffolds; a suitable base for the organs. The scaffolds were made
from biodegradable polymers or collagen which provided a
temporary matrix for the cells to cling to until they were able
to stand on their own. Dr. Anthony Atala, the lead researcher
at Wake Forest Institute for Regenerative Medicine, implanted
the first lab grown bladder organs into seven patients at Boston
Children’s Hospital between 1999 and 2001 (Atala et. al., 2006).
There are a variety of injuries that can lead to damage or loss
of the bladder, requiring eventual replacement or repair of the
organ. Children with congenital anomalies such as: bladder exstrophy, myelomeningocele, or posterior urethral valves, can
develop high-pressure and hypertonic low compliant bladders.
Often times, these patients require cystoplasty when drug
treatment fails. Gastrointestinal segments are frequently used
as donor tissues for cystoplasty. However, when such tissues
are incorporated into the urinary tract, several complications
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can ensue; such as metabolic disturbances, urolithiasis, increased
mucous production, and malignant disease (Emedicine, 2016).
Atala, along with his research team, explored an alternative approach using autologous engineered bladder tissue for reconstruction. Seven patients with myelomeningocele, aged 4-19 years
old, with poorly compliant bladders were identified as candidates
for cystoplasty. Urethral and muscle cells from the patients
were grown in a culture, and seeded on a biodegradable bladder
shaped scaffold made of collagen, or a composite of collagen and
polyglycolic acid. About seven weeks after biopsy, the autologous
engineered bladder constructs were used for reconstruction and
implanted into patients. Tests such as serial urodynamics, cytograms, ultrasounds, bladder biopsies and serum analyses were
performed. The bowel function of the patients returned to normal promptly after surgery with no metabolic consequences and
renal function was preserved (Atala et. al., 2006).
Researchers soon adopted 3-D printers to make scaffolds
more precisely because manually placing the cells onto scaffold
remained a time-consuming and arduous process. Engineered
bladders were made possible because they can be made with
just two cell types however, an organ such as a kidney consists
of thirty cell types.When attempting to engineer more complex
tissues, there is no way to manually place different cell types into
different locations that can replicate the native tissue structures.
Manual placement is not the optimal method for delivering cells
(Murphy, Atala, 2014).

The Heart
The human heart is a complex biological machine. It pumps
blood to all parts of the body, begins to beat three weeks after
conception and does not stop until the day of death. It is remarkable how the heart can last that long and function with the
same redundancy and efficacy. The heart operates for billions of
cycles, it is chemically powered and electrically synchronized.
The heart is composed of over a hundred billion cells including
cardiomyocytes, conduction system, fibroblasts, endothelial cells,
smooth muscle cells and neurons. The main reason researchers
are trying to 3D print the heart is because the heart is unable to
regenerate itself and for this reason heart disease is the leading
cause of death in first world countries (Mayo Clinic, 2016).
A heart transplant is a lifesaving procedure which removes a
damaged or diseased heart and replaces it with a new one.
Heart failures come as a result of different conditions such as
coronary heart disease, damaged heart muscle or valves, congenital heart defects, or viral infections of the heart. Once the
human heart is damaged, there is only a limited amount of regeneration that can occur and may require a heart transplant.
A heart transplant comes with many risks and complications

such as infection or the recipient’s body attempting to reject
the newly placed heart. To prevent rejection, the patients must
immediately be given immunosuppressants as a lifelong treatment (Mayo clinic, 2016). There are currently 4,138 candidates
who are on the UNOS list for a heart transplant (OPTN, 2016).
The high number of candidates results in an agonizing wait for
a new heart which usually does not have a positive ending. This
long waiting list can be reduced through the possibility of 3D
printing of the human heart.
The hierarchical structure and function in the heart has levels
that scales from the nanometer level up to the macroscopic
level. Every heart beat is powered by molecular motors, the
actin and myosin, which are only a few nanometers in size and
generate pico newtons amount of force. The actin and myosin
are built into larger structures called the sarcomeres, the contractile unit of a muscle cell. Then, these are built into myofibrils
which form tissue and surrounds the ventricles of the heart. At
this present day, technology is unable to engineer something
this complex starting from the nanometer scale and up. Yet, scientists are able to figure out where they are able to interface
with the system, by providing information into the biology that
can guide the living system to do the work of producing the
components of the microstructures. Once the cells are formed,
they themselves manufacture the microstructures necessary
and the 3D bioprinting scaffolds, the suitable base, are used to
build larger structures up to the size of a whole organ.
The embryo is a perfect example of biological manufacturing, it
starts off with one cell and those cells divide and build an extracellular matrix around themselves until there is a full functioning organism. The extracellular matrix is a nanofiber network of
protein and other molecules. It mechanically integrates cells into
tissues, acts as an insoluble signaling network and functions as a
scaffold that fills the space between the cells and tissues.This matrix acts as information because it provides cells with instructive
cues on how to organize and form tissue. It signals between the
cells using physics, chemistry and mechanics and is integral to
tissue formation and function (Rozario, Desimone, 2010). A technique called Bottom Up Engineering of the Extracellular Matrix
(ECM) was an attempt to build the ECM in the same way cells do;
from single molecules into a complex 3D fiber with tissue specific
structure and function according to the organ that is being engineered. This technique thereby accelerates the system of tissue
formation (Szymanski et. al., 2014).
The idea of using the extracellular matrix is utilized in the following technique for 3D bioprinting organs and other structures. Soft materials such as collagen and fibrin are difficult for
scientists to work with because they collapse under their own
weight and do not have the mechanical strength to be printed
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in air. To overcome this problem, a gel in gel technique dubbed
Freeform reversible embedding of suspended hydrogels is used.
This approach involves soft materials such as fibrin, collagen
and the polysaccharide alginate. The materials are inside a thick
slurry of gelatin microparticles and water in a petri dish. The
semiliquid mixture of gelatin microparticles is able to flow
around the printing needle as it operates. At the same time, the
soft biomaterials being released are firmly implanted during the
layer by layer printing technique. Once the printing of the scaffolds is completed, the dish is warmed up to 37 degrees Celsius
thereby removing the gelatin and revealing the scaffold replica
of an organ or tissue (Hinton et. al., 2015, Figure 1).

Figure 2 (Hinton et. al., 2015)

Figure 1 (Hinton et. al., 2015)
Freeform reversible embedding of suspended hydrogels
technique
One application of this technique is using magnetic resonance imaging (MRI) to print patient specific scaffolds to engineer tissues.
Through magnetic imaging the right coronary arterial tree is 3D
printed. The right coronary artery along with the left coronary
artery supplies blood to the heart. The right coronary artery is
specifically responsible to supply blood to the right atrium, right
ventricle, bottom portion of the left ventricle and the back of
the septum. Additionally, the coronary arteries become blocked
during a heart attack. The 3D printed artery was made of ECM
materials such as fibrin, hyaluronic acid and alginate with solid
walls and an open lumen. On a makerbot 3D printer the artery
took about one hour to print which is the timeframe within the
viability of cells. The wall thickness, lumen diameter and density
can be tailored based on patient anatomy. To evaluate whether
the 3D printed arterial tree was manifold it was set up in a custom made 3D printed perfusion fixture. A solution of CaCl₂ and
0.1% black food coloring was injected into the root of the tree.
Perfusion was successful and captured on camera. The printed
coronary artery has not been used for transplants such as a coronary artery bypass, yet this technique is a step up from the current printing of just straight tubes. This technique creates more
complex architecture like the real coronary artery tree that can
hold a better potential graft (Hinton et. al., 2015, Figure 2).
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(D) A model of a section of a human right coronary arterial tree
from 3D MRI is processed at full scale into machine code for FRESH
printing. (E) An example of the arterial tree printed in alginate (black)
and embedded in the gelatin slurry support bath. (F) A section of
the arterial trees printed in fluorescent alginate (green) and imaged
in 3D to show the hollow lumen and multiple bifurcations. (G) A
zoomed-in view of the arterial tree shows the defined vessel wall that
is <1 mm thick and the well-formed lumen. (H) A dark-field image of
the arterial tree mounted in a perfusion fixture to position a syringe
in the root of the tree. (I) A time-lapse image of black dye perfused
through the arterial tree false-colored at time points of 0 to 6 s to
show flow through the lumen and not through the vessel wall. Scale
bars, 4 mm (B), 10 mm (E), 2.5 mm (F), 1 mm (G), and 2.5 mm (H
and I). (Hinton et. al., 2015).
Another application of the Freeform reversible embedding of
suspended hydrogels technique is used to build the embryonic
heart. The 3D model of the embryonic chick heart was generated from 3D optical imaging data of a fluorescently labeled
5-day-old heart.The embryonic stage is the time when the heart
muscle forms. It is the only time where the human body has the
potential to form new heart muscle. In order to accurately 3D
print an organ, there needs to be accurate data input to the
system. The first step is the 3D imaging of the embryonic heart
to identify the ECM macrostructure and microstructure associated with myogenesis and vascularization. 3D imaging goes
through the embryonic heart and images the entire heart, ventricles, and trabeculated tissue together with all the exquisite
details. A 3D computer model of the trabeculated embryonic
heart is generated based on confocal imaging of cells and the
extracellular matrix. Then, based on the computer model the
3D heart is printed and compared with the computer generated image (Hinton et. al., 2015, Figure 3).

3D Organ Printing

One step further in 3D cardiac printing is the ability to print
cardiac cells called organoids. This research called “Body on
a Chip” is currently ongoing at Wake Forest Baptist Medical
Center. The research converted human skin cells into a network of functioning heart cells, and also fused them with lab
grown liver cells using a 3D printer. The heart organoid is able
to beat because it contains specialized cardiac cells and the cells
receive correct environmental cues such as keeping them at

Figure 3
Printed embryonic heart scaffolds with complex internal
and external architectures based on 3D imaging data from
whole organs
the same temperature as the human body. The organoid heart
cells are made by genetically modifying adult human skin cells
into induced pluripotent stem cells. Then, these cells are reprogrammed to produce the organoids which have a diameter of
0.25 millimeters. The organoids grow and form balls which then
are 3D printed into different forms and sizes. These cells will
create tiny organ-like structures that mimic the function of the
real organ. The organ structures are then placed on a chip to
provide for an online monitoring. The ultimate goal is to create
mini organs to test them with different biological and chemical

agents and the effectiveness of various treatments against diseases (Wakehealth.edu 2016, Figure 4).

The Kidney
In addition to the great need of heart transplants there is even
a greater number of patients waiting for a kidney transplant.
Currently, there are over a hundred thousand people anxiously
waiting for a lifesaving kidney (OPTN, 2016). The kidneys are
responsible for removing excess fluid and waste from the blood.
When the kidneys lose their filtering ability, there is a dangerously high level of fluid and waste accumulating in the body. This
condition is known as kidney failure or end stage kidney disease.
A kidney transplant procedure is often the best way to treat
a kidney failure. Only one kidney is necessary to replace two
failed kidneys, thus making a living donor kidney transplantation
possible (Kidney.org, 2014).
A kidney transplant can pose risks to both the donor and the
recipient. There can be possible surgical complications such as
pain, infection, blood loss, blood clots, allergic reactions to anesthesia, pneumonia, injury to surrounding tissue and organs, or
even death. There are also long term risks for donating a kidney
such as hypertension, large amounts of protein in the urine, hernia, organ impairment or failure that can lead to the need for dialysis or transplantation and can even cause death. Additionally,
there is the problem of the recipient’s body rejecting the kidney
as a foreign invader. Just as in a heart transplant, the patient will
need to remain on immunosuppressants every day to prevent
rejection of the new kidney. These anti-rejection medications
have a large number of possible side effects because the body’s
immune system is suppressed (kidney.org, 2014).
Dr. Anthony Atala demonstrated an early stage experiment that
could solve the kidney organ donor problem. The experiment
uses a 3D printer that contains live cells and kidney shaped structure of collagen to output a transplantable kidney. A blueprint is
created through a CT scan that goes layer by layer using computerized morphometric imaging analysis and 3D reconstruction
which leads to actually imaging the kidneys. The image can even
do a full 360-degree rotation to analyze the kidney in its full volumetric characteristics.This information is then taken and scanned
into a printing computerized form. The printer is then guided by
the computer imaging and drips the cells layer by layer over the
scaffold causing the inert mold to come to life. Overtime, the
millions of cells begin to communicate and function as one organ.
It took the research team about seven hours to print the 3D
kidney structure (Murphy, Atala, 2014, Figure 5, Xu et al., 2013).

Vascularization
Figure 4 (Wakehealth.edu
3D printed beating, cardiac cells called “organoids)

The kidney represents a challenge more than other organs due
to the kidney’s detailed, tiny structures that allow the organ
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to perform its sophisticated filtration job by removing waste
chemicals from blood and turning the waste into urine. The
function of removing waste is processed by roughly one million
nephrons which are tiny vessels made up of even smaller urine
collecting structures called tubules.The kidneys are also responsible to measure chemicals such as sodium and potassium that
are then released back into the bloodstream in healthy dosag-

Figure 5 (Murphy, Atala, 2014) (TED.com 2011)
Dr. Atala holding his printed kidney during a TED talk
called “On Printing a Human Kidney,” in March 2011.
es. The kidney’s complex vascular structure especially poses a
challenge. The vascular tree of the kidney can come down to
the size of a capillary about eight microns in diameter. Due to
the kidney’s complexity, it has not been printed for transplant
in humans at this present time, however researchers are avidly
looking for ways to make it a reality and help people suffering
from dialysis treatments while being on a multiple year waiting
list for a kidney (Murphy, Atala, 2014).
For a transplant tissue to thrive, a complex level of vascularization must be achieved. To some extent, capillaries can branch
out from already existing blood vessels and into transplanted
tissue on their own. Researchers have seen signs of spontaneous vascularization in small areas of engineered tissue such as
in healed rat bone defects around three millimeters in diameter
(Fielding, Bose, 2013). Rather than letting blood vessels spontaneously branch off and expand to engineered tissue, researchers
are crafting templates for more orderly vascular growth. The
idea is to create hierarchical microvascular networks that will
guide the endothelial cells that line blood vessels to form tubes
along predetermined courses. However, capillaries are small,
measuring just a few microns in diameter. Therefore, even with
high resolution printers, such small vascular structures would
most likely collapse especially when printed into soft, biocompatible gel.
Jennifer Lewis researched the vascularization problem using
a customized, high resolution 3D printer that can form microchannels in biocompatible gels. Lewis’s research group is
able to print hydrogel materials down at the micron length
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scale. The smallest microvascular channel the group was able
to print was about ten microns in diameter. To solve the problem of collapsing channels, she prints them in fugitive ink which
is a substance designed to melt away forming the channels
pattern. The fugitive ink used is called Pluronic 4127, a gel that
is often used in eyeglass lense cleanser and cosmetics. Pluronic
4127 is made up of three parts, the two poles of the molecule
are hydrophilic while the middle segment is hydrophobic. The
ink also liquefies when it is cooled down as opposed to most
materials that solidify when they are cooled down (Wu et.
al.,2011).
Lewis also used Pluronic F127 as the matrix for the printed
channels, but the matrix molecules were modified so that they
polymerize, and thus solidify, in the presence of UV light. This
allows the matrix to become firm before cooling the gel so that
the fugitive ink melts away.Taking advantage of the printer’s finetipped nozzle, the research team printed a capillary network
of fluorescently labeled fugitive ink into the Jello-like matrix.
Through this technique, a way to pattern hydrogels with vascular channels was accomplished (Wu et. al., 2011). The next step
is to take advantage of the self-organizing quality of endothelial
cells in the 3-D–printed constructs, seeding the printed vascular
structures with these blood vessel–lining cells. The self organizing quality is the tendency of the finest capillaries to grow
spontaneously out of larger microvascular structures which is
the work of biology when the cells are given a reasonable environment (Perryn et. al., 2008).
Inspired by some of Lewis’s lab work with “fugitive inks,” Jordan
Miller, at Rice University, created a technique for 3D printing of
vasculature-mimicking channels. Using a simple open-source 3D
printer, Miller and his team constructed a carbohydrate lattice
made from a combination of simple and complex sugars. There is
a major difference between Miller’s experiments and those done
by Jennifer Lewis. Lewis uses machines that are very high-end
and have incredible precision, but they are not easily duplicated
by others. Miller saw potential in a cheaper printer called the
Frostruder, a printer originally used to extrude sugar frosting for
printing fancy designs onto edible treats. Miller adapted a printer
to incorporate elements of the Frostruder printer’s design and
was soon able to print dissolvable lattices of carbohydrate filaments (Miller et. al., 2012). The experiment used a process called
“3-D sacrificial molding” that is similar to the lost-wax method
used by sculptors. His printer deposits filaments of carbohydrate
on top of each other in sequence so they are self-supporting.
Then the entire lattice structure is covered in a protective layer
of a biodegradable polymer. After pouring and cross linking a cellfilled gel over the carbohydrate lattice, the lattice is dissolved with
an aqueous solution (Miller et. al., 2012).

3D Organ Printing

Miller’s channels are not as small as Lewis’ channels. His channels range from 150 microns to around a millimeter in diameter.
However, when he and colleagues seeded the channels with
endothelial cells, they lined the interiors of the channels and
even began to penetrate the surrounding cell-gel mixture. By
guiding blood cells into the larger channels, he can set the stage
for endothelial cells to spontaneously form their own capillary
networks. Miller has successfully pumped human blood through
his constructs in vitro, and the research team plans to cooperate with a surgeon to connect one of his printed tissues to the
vascular system of a rat to see how long he can get blood to
flow through his channels (Miller et. al., 2012).
Vascularization procedures done by Miller and team take a
short amount of time to complete which benefits the large
scale tissues, like liver cells. Large scale tissue cannot survive
the several hours it takes in the extruder nozzle long enough to
build something the size of the human liver. Additionally, quickly
pouring the cells and gels over the 3-D–printed lattice is easier
on fragile cells than the arduous process of printing. The one
disadvantage is that the researchers cannot control the exact
placement of the cells. Therefore, this may not be the optimal
method for experiments involving multiple cell types. In the
versions of the constructs printed with rat liver cells or with
human embryonic kidney cells, the cells near the channels survive longer than the cells deeper in the gel, suggesting that the
experiment is leading in the right direction (Miller et. al., 2012).

Conclusion
At this present time, a 3D printed organ is unable to be inserted
into a patient with the same efficacy as a normal organ. Many more
years of research need to be conducted. There are constantly
many advances being made by countless numbers of research
teams who are devoted to help suffering patients and increase
the availability of organs for transplant. However, even though 3D
printed organs cannot be inserted into patients, they can be used
to assist doctors and surgeons in surgery. Advanced models of
organs that are 3D printed are able to prepare surgeons on what
they might encounter in the operating room. Simply by looking
at models, doctors are able to avoid potential complications that
could have been unforeseeable without the physical model. 3D
printed organs can also help train medical students and professionals. Researchers and Doctors are able to replicate the part of
the patient with the complicated problem so students can learn
how to go about saving lives. It also allows healthcare professionals to better explain situations to the patient. The healthcare
provider can physically hold the model and explain what is wrong
and the different procedures available for the patient. Currently,
the main use of the 3D printed organs has been for screening
new medications and modeling various diseases.
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Abstract
Transhumanism, designer babies, gene therapy, and super-soldiers are founded upon the same concept—genetic engineering. Clustered Regularly-Interspersed Short Palindromic Repeats (CRISPR) is a natural bacterial immune response
method that takes advantage of gene manipulation to prevent an infection from mobile genetic elements. Since Mojica
et al. (2005) first suggested the relationship between the CRISPR/Cas system and prokaryotic immunity, significant
advancements have been made in understanding the mechanism and subsequent applications of CRISPR. CRISPR,
has three main subtypes based on unique proteins and interference pathways and serves as an accurate and effective
method for gene editing. Its mechanism consists of spacer acquisition, crRNA production, and interference. This highly
dynamic form of genetic modification generates significant CRISPR sequence differences in species that are almost
identical when comparing the rest of their genome. CRISPR/Cas9 demonstrates the simultaneous alteration of multiple
gene loci in individual cells with a high degree of specificity and precision. Duchenne muscular dystrophy (DMD) is a
genetic neuromuscular disorder characterized by progressive muscle loss and eventual death in the late teens to early
twenties. DMD affects calcium homeostasis, vasculature, genetic regulation, muscle movement, glycosylation, tissue
remodeling, and inflammatory response mechanisms. Current treatments include antifibrotic pharmaceuticals, calcium
maintenance, myostatin inhibitors, upregulation of uthrophin, nonsense suppression drugs, vector-mediated gene therapy, and cell transplantation. This review describes the mechanism of CRISPR/Cas9 and its application as a therapeutic
approach to treating Duchenne muscular dystrophy.
Keywords: CRISPR, genomic engineering, Duchenne Muscular Dystrophy, Cas protein, interference mechanism,
PAM recognition
Introduction
DNA sequencing assays are highly efficient and economical and
dramatically increase our understanding of genetic diseases.
Once we identify and comprehend the cause of the disease, the
quandary is to figure how to reverse the mutation and cure it.
The ability to modify genes in mice serves as a crucial function
to model human diseases (Yang et al., 2014). Conventional approaches to study and develop disease models utilize homologous recombination, such as retroviral insertion (Kuehn et al.,
1987), in embryonic stem cells, to knockout the gene of interest
(Thomas and Capecchi, 1987). Genetic variations among embryonic stem cells (Ledermann, 2000) coupled with relatively long
time requirements (Markel et al., 1997) cause significant limitations to this approach (Carbery et al, 2010). Other methods
used in gene editing include zinc-finger nucleases (ZFNs) (Kim
et al., 1996; Geurts et al., 2009) and transcription activator–like
effector nucleases (TALENs) (Nanjidsuren et al., 2016; Tesson
et al., 2011).
Plasmids, bacteriophages, and transposons promote adaptation
and survival by inducing the development of toxic compound
degradation, antibiotic resistance, and other evolutionary advantages (Frost el at., 2005). Among mechanisms used to resist
harmful infections and monitor the entry of genetic material,
bacterial species utilize clustered regularly interspersed short
palindromic repeats (CRISPR) (Labrie et al., 2010). CRISPR, a
defense mechanism ensuring resistance against viral invasion,
is exhibited by an estimated 40 percent of eubacterial and 90
percent archaeal species (Hatoum-Aslan et al., 2011). Kunin et

al. (2007) used PILAR-CR, an algorithm that identifies CRISPR
repeats, and found 561 arrays in 44 percent of the genomes
tested. A population of ~1031 viruses coupled with ~1025/s
rates of infection promoted the evolution of defense pathways
that effectively identify foreign genetic elements and mount a
response to degrade harmful foreign nucleic acids (Hendrix,
2003; Richter et al., 2012). These repeats are ubiquitous in archea and evident in some bacteria (Lillestøl et al., 2006).
While sequencing the Escherichia Coli iap gene in 1987, a researcher identified an “unusual structure” at the 3’ end flanking
the gene, noting five repetitive sequences of 29 nucleotides each
having unique 32 bp spacer segments (Ishino et al., 1987). In
2005, Francisco Mojica was first to suggest a relationship between the CRISPR-Cas system and bacterial immunity. This observation later turned out to be extremely significant, yielding
a dramatic benefit to genetic research. CRISPR, an adaptive
bacterial immunological response mechanism, consists of alternating sequences, one repetitive and the other a segment of a
viral genome or a plasmid sequence. CRISPR utilizes CRISPR
associated (Cas) proteins and small non-coding RNAs for its
function. Abutting each CRISPR loci, CRISPR-associated (CAS)
genes encoding for various enzymatic proteins couple with
CRISPR to form a multitude of different CRISPR/CAS pathways
(Horvath and Barrangou, 2010). Incorporation of phage DNA
into the spacer portion of a CRISPR array in Streptococcus
thermophilus yielded resistance towards viral infection of the
corresponding phage (Barrangou et al., 2007). CRISPR can be
involved in several processes such as; replicon partitioning in
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halo bacteria (Mojica et al., 1995), DNA rearrangements within
a replichore (Deboy et al., 2006), and thermal adaptation in E.
Coli (Riehle et al., 2001). There is a direct correlation between
an increased sensitivity to viral infection and a mutation to the
Cas genes or the spacer sequences of the corresponding virus
(Barrangou et al., 2007; Brouns et al., 2008; Oost et al., 2014).
CRISPR/Cas systems can be used to manipulate genes with substantial precision and accuracy, effectively giving researchers the
ability to develop causal linkages between known mutations and
observed phenotypes (Hsu et al., 2014). This review article will
assess the application of the CRISPR/Cas system as a therapeutic approach to Duchenne muscular dystrophy.

Various Cas genes are found adjacent to all CRISPR arrays with
the exception of Thermoplasma acidophilum (Marraffini and
Sontheimer, 2010a). More than 45 distinct CRISPR associated
protein families have been identified using Hidden Markov models (Haft, 2005). Each subtype of CRISPR is classified based on
associated Cas genes as well as its distinct repeat characteristics
(Gesner, 2011). Three main subtypes are classified based on the
presence of a unique Cas protein: type 1 has Cas3, type 2 has
Cas9, and type 3 has Cas10 (Gleditzsch et al.; 2016, Makarova
et al., 2011a; Richter et al., 2012). A fourth subtype, with its
mechanism and function still uncharacterized, is called CRISPR
type U (Koonin and Makarova, 2013).

Methods

Cas1 and Cas2, a metal-dependent nuclease (Wiedenheft et al.,
2012) and a pH-dependent nuclease (Ka et al., 2014), respectively, are necessary in initiating spacer acquisition by incorporating non-self DNA into the leading end of the CRISPR array
(Mojica et al., 2009). Strains of E. Coli lacking the endogenous
cas genes prevented spacer acquisition from occurring without
affecting further steps in the pathway, outlining their importance
in the first step. Both Cas1 and Cas2 are evident among almost
all CRISPR systems (Makarova et al., 2011b), possess a crucial
role in spacer acquisition (Yosef et al., 2012), and contain highly
conserved motifs. CRISPR type U is the only known form of
CRISPR that does not possess a CRISPR array or Cas1 (Koonin
and Makarova, 2013). These findings outline the importance of
Cas1 and Cas2 in spacer acquisition (Oost et al., 2014). Cas1
and Cas2 form a complex determined by a 2.3Å resolution
crystal structure (Nuñez et al., 2014).

An analysis of scholarly articles with a focus on papers published in peer-reviewed journals with high impact factors were
performed through access to databases of the Touro College
Online Library, Medline, Proquest, NCBI Pubmed, and Google
Scholar. In-print articles were obtained from the Touro College
library in the Avenue J campus. An analysis of both review and
experimental research articles were conducted to delineate
the mechanism and outline recent applications of CRISPR in
a clinical setting. In each database, the search word “CRISPR”
prompted recent publications on that topic. Articles that were
labeled as “similar” to papers published recently were also used.
Proteins associated with CRISPR discussed in this paper were
analyzed using the uniprot database. Original research papers
describing aspects pertaining to the discovery, mechanism, and
applications of CRISPR were found on the webpage of Dr. Lluís
Montoliu’s Lab at Centro Nacional de Biotecnología.

Results
Spacer Acquisition
The genetic interference pathway of the CRISPR/Cas system
is initiated with spacer acquisition upon entry of foreign genetic material (Swarts, 2012; Richter et al., 2012; Marraffini,
2010a). This step is highly dynamic and involves the recognition of foreign DNA by the host as well as its first integration
into the spacer portion of a CRISPR array. Identification of the
foreign genetic element is essential to the CRISPR mechanism.
Proto-spacer adjacent motifs (PAMs) or spacer precursors are
important components of the CRISPR systems. Each CRISPRCAS variant can correspond to a specific spacer precursor or
proto-spacer that will be evident on the foreign DNA particle.
The interference target is determined by a specific short motif
sequence that corresponds to each CRISPR variant. Using the
classification of CRISPR variants determined by Kunin et al.
(2007), a sequence of either two or three nucleotides abutting each proto-spacer was found to be conserved in six main
groups (Mojica et al., 2009). This finding suggests a correlation
between PAMs and each CRISPR-CAS system.
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Both DNA recognition and spacer acquisition will be prevented
if the Cas1-Cas2 complex formation is disrupted by a mutation
(Nuñez et al., 2014). In addition to its role in the CRISPR/Cas
system, Cas1 is believed to be involved DNA repair (Babu et
al., 2010). The recognition of a variant-specific adjacent short
sequence on the foreign DNA particle prompts the incorporation of a spacer precursor. This completes the first step in the
CRISPR defense mechanism (Mojica et al., 2009). Replication
of the inserted repeat begins with the repeat most proximal to
the leader portion of the array (Yosef et al., 2012). The CRISPR
response is amplified through the increase in spacer sequences
corresponding to a specific foreign DNA element (Swarts et
al., 2012).

crRNA Expression
The successful incorporation of a foreign DNA segment into
the spacer region of the CRISPR array and the production of
a multiunit precursor (Koonin, 2006) permits the subsequent
processing of the precursor CRISPR RNA (pre-crRNA) (Oost
et al., 2009; Wiedenheft et al., 2012). The crRNAs specific to
each CRISPR array are integral to the CRISPR pathway. Analysis
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of the CRISPR/Cas system in Escherichia Coli K12 determined
that both the repeats and the spacers within the CRISPR
are transcribed into a long precursor RNA (Marraffini and
Sontheimer, 2010a). The crRNA transcript transcribed from
the CRISPR array requires cleavage prior to activation.
Cas proteins catalyze the conversion of precursor RNAs
(pre-crRNA) into small crRNAs (Gleditzsch et al., 2016;
Marraffini and Sontheimer, 2010b). Eight Cas genes were
identified in this strain: cas123 and casABCDE (Brouns et al.,
2008). After knocking out each individual Cas gene using inframe single-gene deletions (Baba and Mori, 2008), the resulting
transcript determined the position of each gene on the CRISPR
array. Further, the RNA cleavage assays did not require ATP
or divalent metal ions to progress. CasE, an endoribonuclease resembling an RNA-binding protein, fused together with
the maltose binding protein (MalE) in Escherichia coli K12, did
not require any other Cas proteins to cleave the pre-crRNA.
Northern blot analysis determined His20 residue to be essential for catalysis of the pre-crRNA. A casE knockout prevents
the processing of pre-crRNA in Escherichia coli K12 outlining
its importance in the pathway (Brouns et al., 2008). Cascade
(CRISPR-associated complex for antiviral defense), a ribonucleoprotein, is a 405 kDa undecamer made of five different
Cas proteins. Cascade is coupled with a 61 nucleotide crRNA
structure spanning the length of the protein complex that
has a 5’-hydroxyl and 2’,3’-cyclic phosphate termini forming a
seahorse configuration prior to target DNA binding (Jackson et
al., 2014, Jore et al., 2011).
Cas3, essential to all type I CRISPR systems, functions both
as an ATP-dependent type A superfamily 2 helicase and a ssDNA nuclease (Brouns et al., 2008; Gesner, 2011; Huo et al.,
2014; Sinkunas et al., 2011). Cas3, together with the mature
crRNA as a guide and Cascade as a targeting complex, catalyze
the degradation of double stranded DNA elements (Huo et
al., 2014). Brouns et al. exposed Escherichia coli to virulent
Lambda phage in various scenarios to determine the role of
Cascade and Cas3 in resisting phage infection. Two Escherichia
coli strains each contain a CRISPR variant that targets four
important lambda genes: the coding strain produced crRNAs
complimentary to both the coding and non-coding strand of
the four genes, while the template strain produced crRNAs
complementary to the proto-spacer regions. With both
Cascade and Cas3 present, results showed a hundred-fold
and ten million-fold decrease in sensitivity to phage infection
with the coding strain and template strain, respectively. Based
on the aforementioned experiment, the presence of Cascade
and Cas3 is crucial to phage resistance in the CRISPR defense
mechanism (Brouns et al., 2008).

High resolution X-ray structure analyses of Cse3, a component
of Cascade, both before and after cleavage of pre-crRNA, suggests a molecular basis for the mechanism of crRNA recognition
by the Cascade. Three structures of Cse3 bound to different
RNA products all displayed a stem loop complex, suggesting the
involvement of Cse3 in RNA recognition (Gesner et al., 2011).
Processing of pre-crRNA into mature crRNA allows effective
interference by the CRISPR-Cas system.

Interference
The interference stage differs mechanistically among the three
main subdivisions of CRISPR: type I, II, and III. Each subtype accomplishes the same goal of foreign DNA degradation, differing
only in the route of interference. The goal of CRISPR interference is to degrade the foreign genetic elements that correspond
to the acquired spacer sequences in the CRISPR array.
CRISPR type I, evident in both bacteria and archaea, exploits
Cas3 for target degradation. Cascade is the multi-subunit crRNP
(CRISPR ribonucleoprotein) complex that is unique to CRISPR
type I. Different routes, depending on the subtype of CRISPR
type I, can induce a conformational change in the crRNP complex which may cause the recruitment of Cas3 for degradation
(Oost et al., 2014). The interference in CRISPR type I is initiated when the mature crRNA binds to a variant of Cas6, an
endoribonuclease. The variant will depend on the subtype of
CRISPR type 1 (Richter et al., 2012). The crRNA forms a stem
loop within each repeat and bind to the corresponding Cas6
protein. Cas5d, the Cas6 variant of type I-C/Dvulg, processes
the pre-crRNA. Further, Cas5d binds to the mature crRNA
(Nam et al., 2012) and recruits the Cascade which induces a
conformational change in the complex (Oost et al., 2014). In
type I-E, CasA or Cse1, functions to discriminate between self
and foreign DNA through the recognition of a proto-spacer
adjacent motif (PAMs) (Sashital et al., 2012; Westra et al., 2013)
as well as induce interactions between DNA and Cascade (Jore
et al., 2011). The initial interaction with the foreign DNA employed by a short loop on Cse1 recognizes a sequence of seven
nucleotides near the 5’ end in addition to the PAM (Richter et
al., 2012).
The CRISPR Type II system uses trans-activating crRNAs (tracrRNA) in crRNA processing. Strains lacking tracrRNA did not
yield mature crRNA, demonstrating the importance of tracrRNA in crRNA processing. The tracrRNA base pairs with 24
nucleotides (Deltcheva et al., 2011) of the crRNA and recruits
RNase III for cleavage. The fusion of tracrRNA and crRNA to
become a single-guide RNA (sgRNA) can be easily programmed
and is used in the modification of multiple DNA sequences simultaneously (Bolukbasi et al., 2016; Cho et al., 2013; Mali et
al., 2013). The process of cleaving tracrRNA and crRNA also
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requires a Cas protein called Csn1 determined by in-vivo inframe deletions of the gene. The subsequent appearance of
mature crRNA and cleaved tracrRNA after the induced expression of Csn1 further supports the hypothesis that Csn1
is vital to the processing of crRNA and tracrRNA (Deltcheva
et al., 2011). However, Csn1 only serves to stabilize the interaction between pre-crRNA and tracrRNA without a direct
contribution to the catalysis, further emphasizing catalytic role
of RNase III (Fonfara et al., 2013). CRISPR-associated endonuclease Cas9 or Csn1 is Mg2+-dependent and contains two
endonuclease domains. One is a RuvC-like nuclease domain
and the other is a HNH nuclease domain cleaving the target
DNA non-complimentary and complimentary to the crRNA,
respectively (Jinek et al., 2012; Anders et al., 2014; Nishimasu
et al., 2014). Csn1 undergoes a conformational change upon
binding to the tracrRNA and mature crRNA, effectively activating its nuclease activity (Jinek et al., 2014). Although both type I
and type II use PAM recognition to bind to DNA, there are two
technical differences. Firstly, the PAM motif is adjacent to the 5’
end of the crRNA in type I and the 3’ end in type II. Secondly,
the PAM motif of the target DNA in type I is the strand that
directly interacts with the crRNA whereas it is on the displaced
strand in the mechanism of type II. After the ribonucleoprotein
complex is in its active form, the subsequent activation of the
nuclease domains mediates site-specific double stranded breaks
of the foreign DNA via Cas9 (Oost et al., 2014). Sternberg et al.
classified the interaction between the RNA-Cas9 and the target
DNA to be through a three-dimensional collision outlining the
specificity of the CRISPR mechanism (2014).
The crRNP complexes in CRISPR type III are structurally alike
and have similar roles to type I. Type III-A and type III-B are
associated with csm and cmr complexes, respectively. The type
III-A system displays the ability to degrade double-stranded
DNA and single-stranded RNA (Niewoehner and Jinek, 2016),
whereas the type III-B system targets RNA (Hale et al., 2009).
Type III-A, present in staphylococcus epidermidis RP62a, contains nine csm genes (Hatoum-Aslan et al., 2014) and does
not rely on PAM recognition for target degradation (Marraffini
and Sontheimer, 2010b). Instead, the csm complex uses the
csm3 and cas10 subunits to target and degrade single-stranded RNA and double-stranded DNA, respectively. Csm6, a
single-stranded RNA-specific endoribonuclease noted for
its higher eukaryotes and prokaryotes nucleotide-binding
(HEPN) domain, is integral to the function of the csm complex.
Ribonuclease activity was determined to be a common feature
among orthologs of csm6, outlining its importance in the type
III pathway. Although the mechanism of csm6 interference is
currently inconclusive, a notable theory posits that when the
csm complex is unsuccessful in resisting foreign invasion, csm6
somehow activates and targets its own nucleic acids inducing
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apoptosis. Such regulatory methods serve as an important
defense in preventing further infection. Structural analysis of
csm6 in Thermus thermophilus describes multiple binding domains which could indicate that there are ligand-dependent
levels of catalytic activity (Niewoehner and Jinek, 2016). Type
III-B in Thermus thermophilus uses the cmr complex, an 11
subunit protein complex comprised of six distinct proteins
aptly labeled cmr1-6, for RNA degradation. The cmr complex is a Mg2+-dependent endoribonuclease that targets the
RNA strand at multiple sites complementary to the crRNA.
Degradation begins at the 3’ end of the target RNA strand
and cleaves toward the 5’ end with each cleavage separated
by six nucleotides. The distance between two cmr4 subunits
is consistent with the six nucleotide intervals present in the
cleavage mechanism which suggests characterizing cmr4 as a
ribonuclease within the cmr complex (Staals et al., 2013). A
significant distinction in the molecular mechanism of CRISPR
type III is that it relies on Cas10/Csm or Cas10/Cmr complex
for target interference whereas type I and type II require a
recognition sequence (Samai et al., 2015).
It is important to note the ability of the CRISPR/Cas system
to differentiate its own genetic material from foreign nucleic
acids. Without the basic capacity to distinguish self versus nonself, all CRISPR mechanisms would act on their own DNA and
subsequently induce autoimmunity and cell death. The basic
mechanism behind preventing self-degradation relies on a genetic distinction between target and self. Since the sequences
incorporated in the spacers are meant to assist in the recognition of foreign genetic elements, they are the same and should
cause self-interference. However, analysis of the CRISPR array
in Staphylococcus epidermidis yielded dissimilarities between
sequences of target DNA and the CRISPR DNA that are not
in the spacer region. The higher degree of base complementarity between CRISPR DNA and crRNA in regions flanking
the spacer sequences prompts evasion of interference. Adding
fifteen base pairs matching both sides of the spacer’s flanking
sequences onto a target strand showed that interference was
unsuccessful in the plasmid that had the 5’ flanking sequence.
The exact “protective region” was determined to be eight base
pairs flanking the spacer sequence. It is the variable complementarity within sequences abutting the spacer region that
prevents autoimmunity in all CRISPR systems (Marraffini and
Sontheimer, 2010b).

CRISPR/Cas9 Genome Engineering
Jinek et al. (2012) was the first to propose the application of
CRISPR/Cas9 for genomic manipulation. CRISPR/Cas9 is a
form a CRISPR type II and is well understood (Ran et al., 2013).
The purpose of CRISPR/Cas9 is to induce double-stranded
breaks at specific locations within a chromosome. Cong et al.
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(2013) investigated the application of CRISPR/Cas9 in genomic engineering by reconstructing the CRISPR type II locus of
Streptococcus pyogenes SF370 in mammalian cells. A spacer
sequence that resembles a specific portion of the EMX1 gene
adjacent to the proper PAM sequence was designed and then
transfected into 293FT cells along with RNase III, Cas9, tracrRNA, and pre-crRNA. Notably, cleavage activity was prevented
when a base mismatch between the protospacer and the guide
RNA sequence was within eleven nucleotides of the PAM sequence, demonstrating the specificity and accuracy of CRISPR/
Cas9. Results yielded effective cleavage even without the addition of RNase III. This finding outlines three essential components required for this method of genetic engineering; Cas9,
mature crRNA, and trans-activating crRNA.
Cas9 is an endonuclease that requires a Mg cofactor in order to
bind to target DNA (Jinek et al., 2012) and is inhibited by EDTA
(Jiang et al., 2016). The target sequence needs to abut the 5’ end
of a protospacer adjacent motif. Each ortholog of Cas9 requires
a specific PAM sequence. The crRNA contains the twenty nucleotide sequence used to target the gene of interest that leads
to the PAM. Furthermore, the crRNA requires tracrRNA for its
activation into discrete units. When used in genome editing, the
crRNA and tracrRNA are fused together to become a complex commonly called single-guide RNA (sgRNA) or guide RNA
(gRNA) (Ran et al., 2013).
Mali et al. (2013) described how the CRISPR/Cas9 system can
be used to both stimulate homologous recombination and modify a locus. They developed human embryonic kidney HEK 293T
cells that contain a green fluorescent protein (GFP) sequence
with an interruption that prevented functionally fluorescing
GFPs. Two gRNAs were designed to target the region that disrupted florescence. After transfection of a donor to repair the
sequence, Cas9, and a gRNA, flow-activated cell sorting (FACS)
began detecting fluorescing cells at ~20 hours, elucidating the
efficiency of CRISPR/Cas9 in inducing homologous recombination with a repair donor. To demonstrate how CRISPR/Cas9 can
modify genomic loci, Mali et al. (2013) introduced two gRNAs
that would each target nineteen base pairs with one base pair
in-between them and then a double stranded donor sequence
to take its place at the AAVS1 locus. PCR and Sanger sequencing assays confirmed the integration of a foreign sequence in a
genome. These findings demonstrate important applications of
CRISPR in genomic engineering.
Another important application of CRISPR/Cas9 is the single-step induction of mutations in multiple genes. Developing
disease models through targeted deletions and engineering
in multiple chromosomes gives extensive insight into the
formation of various illnesses. Maresch et al. (2016) exploited

electroporation to introduce CRISPR/Cas9 vectors in pancreatic cells and demonstrated optimal results when targeting a “few
hundred cells” in each organ. To investigate pancreatic tumorigenesis, sgRNAs for thirteen tumor-suppressor genes and two
neutral genes were transfected into a mixture of C57BL/6J and
129S mice strains. Magnetic resonance imaging determined the
average time for tumor development to be 10.7 weeks and a
54% tumor incidence at 24 weeks. Next generation sequencing
analysis confirmed a significant number of mutations in the target sites of tumor tissue samples. Furthermore, it did not find
any significant mutation rates in the target sites of the tissue
surrounding the tumors which is explained by the electroporation protocols that target only a few hundred cells in relatively
small area (Maresch et al., 2016). All the aforementioned capabilities of CRISPR/Cas9 amalgamate to produce a highly efficient
and effective method of genomic engineering with a short time
period required to develop disease models. Prospective applications of CRISPR/Cas9 can involve the introduction of targeted
mutations that can prevent the acquisition of diseases such as
Human Immunodeficiency Virus (Lombardo et al, 2007). The future applications of CRISPR engineering are limitless and serve
as an extremely viable option for use as a therapy for Duchenne
Muscular Dystrophy.

Duchenne Muscular Dystrophy
In 1836, Gaetano Conte was the first to describe a case of
Duchenne muscular dystrophy (DMD) (Nigro, 2010), an X
chromosome linked recessive disorder that is classified as
a severe progressive muscle wasting disorder. This neuromuscular disease is caused by a mutation in the DMD gene
that codes for dystrophin (Hoffman et al., 1987), a 427 kDa
rod-shaped cytoskeletal multi-domain protein made of 3,685
amino acids (Koenig et al., 1988) that is expressed in all human
muscle cell types. Dystrophin interacts with dystrobrevin
alpha (Sadoulet-Puccio et al., 1997), alpha-1-syntrophin (Ahn
et al., 1996), and beta-1-syntrophin (Ahn and Kunzel, 1995).
The primary function of dystrophin is to connect a cytoskeleton component, actin, with the extracellular matrix (Norwood
et al., 2000). DMD occurs when mutations affecting the open
reading frame cause premature termination of dystrophin
during translation, resulting in a protein with complete loss of
function (Yiu, 2015). The end result of a deficiency in dystrophin is muscle fiber degeneration and is believed to be secondary to factors such as sarcolemma impairment, structural damage to the cytoskeleton, and an aberrant calcium homeostasis.
Patients with DMD require respiratory, cardiac, orthopaedic,
and nutritional management throughout their lives (Yiu, 2015).
Life expectancy for DMD patients is usually 25 years with the
cause of death commonly being cardiomyopathy or lung issues
(Long et al., 2014).
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Pathophysiology
DMD, being a neuromuscular disorder, detrimentally affects
the body’s mechanical abilities, calcium homeostasis, vasculature, genetic regulation, glycosylation, tissue remodeling, and
inflammatory response mechanisms. The absence of dystrophin or other proteins within the dystrophin associated
complex could significantly decrease normal contractions that
increase tension as the muscle lengthens, or eccentric contractions, thereby damaging the membrane of the muscle fibers. A muscle biopsy will show muscle fiber degeneration or
necrosis. Eventually, the continual attempts to regenerate the
muscle fibers leads to a burnout and begin substituting muscle
for connective and adipose tissues (Deconinck and Dan, 2007).
DMD induces a leak within the calcium channels of the cell.
The lack of dystrophin affects the structure of the membrane
causing compensatory mechanisms that maintain calcium
levels to eventually become ineffective. When there is a prolonged influx of extracellular calcium, proteases are activated,
causing further degradation of the membrane, which leads to
a further increase in intracellular calcium. This glut of calcium
can presumably lead to cellular death.
Neuronal-type NO synthase (nNOS) is normally localized
to the membrane of white muscle fibers and produces nitric
oxide, which is a short-lived highly reactive signaling molecule with important biological functions (Nelson and Cox,
2013). The absence or deficiency of dystrophin causes a
reduction in nNOS activity as well as its delocalization from
the sarcolemma (Brenman et al, 1995; Crosbie et al., 2002).
Dabiré et al. (2012) demonstrated a link between vascular
endothelial dysfunction and the expression of endothelial
and neuronal nitric oxide synthases in DMD patients.
The conversion of mechanical stimuli into electrical or chemical signals is known as mechanotransduction and is involved in
genetic expression and other important physiological processes (Katsumi et al., 2004). Goldspink (1998) demonstrates the
effects of muscle activity on mechanotransduction. The progressive loss of muscle tissue occurs secondary to the lack of
autocrine insulin-like growth factor-1 production, which is used
to repair muscle tissue.

CRISPR/Cas9 Therapy
The human dystrophin gene contains seventy-nine exons and
seventy-eight introns (Kole and Krieg, 2015) with at least seven
promoters. Alternative splicing yields different variants of dystrophin depending on the stage of development and type of
tissue (Im et al., 1996). A spontaneous mdx gene mutation in
a colony of C57BL/10ScSnJ mice resulted in increased serum
levels of specific proteins as well as histological similarities
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compared to that of human muscular dystrophy (Bulfield et al.,
1984). This spontaneous point mutation yielded a stop codon
affecting exon 23 in the dystrophin gene (Sicinski et al., 1989).
Biochemical similarities coupled with cross-breeding analysis
of mutant and normal mice set the precedent to use the mdx
mouse as a model for muscular dystrophy (Bulfield et al., 1984).
Although not entirely equivalent to the human disease, researchers utilize the mdx mouse as the predominant model to
investigate pathogenic mechanisms of DMD (Partridge, 2013).
The primary goal is to cure DMD by correcting any harmful
mutations. Treatments either alleviate the symptoms or aim to
cure the disease itself. Pharmacological approaches improve
muscle function with corticosteroids (Mendell et al., 1989),
maintain calcium homeostasis (Zhao et al., 2012), inhibit the
IKK/NF-κB signaling pathway (Acharyya et al., 2007), reduce inflammation and induce the upregulation of uthrophin as a surrogate to dystrophin (Gordon et al., 2013). Glucocorticoids,
such as prednisone or deflazacort, are beneficial to muscle
function and are the only accepted drug therapy of DMD
(Matthews et al., 2016). Van Deutekom et al. (2001) describes
a form of gene therapy that attempts to correct the reading
frame through the induction of skipping an additional exon.
An exon 45 deletion exhibited in DMD patients causes a stop
codon in exon 46. The open reading frame is restored when
exon 46 is deleted. The resulting protein is still dysfunctional
yet displays a milder form DMD, outlining a method of treating
the disease. Other attempted strategies of treatment include
antifibrotic pharmaceuticals, myostatin inhibitors, nonsense
suppression drugs, vector-mediated gene therapy, and cell
transplantation (Shimizu-Motohashi, 2016).
The aforementioned therapeutic approaches to treat DMD
focus on either reestablishing the expression of or compensating for a deficiency in dystrophin. The efforts to treat DMD are,
in many instances, relatively transient and compensatory without any curative effects. CRISPR/Cas9 is revolutionary for its
attempt to treat the underlying cause of the disease— mutation
or mutations in the dystrophin gene. Long et al. (2014) demonstrated the application of CRISPR/Cas9 to repair the genetic defect in an animal model of DMD. The zygotes of the mdx mouse,
containing a nonsense mutation in exon 23 of the dystrophin
gene (Sicinski et al., 1989), were injected with a 20 nucleotide
single-guide RNA containing a PAM sequence, Cas9, and 90 base
pair single stranded template. This template strand incorporates
four silent mutations as well as a TseI restriction site for data
analysis. After a double-stranded break was induced by Cas9,
the strands were repaired by either homology directed repair
(HDR) or nonhomologous end-joining (NHEJ). The optimized
condition involved injecting the Cas9, sgRNA, and template into
the zygote and then performing re-implantation into a female
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mouse. The offspring of that mouse determined the results of
the experiment. Analysis of eleven repaired mdx progeny revealed adult development of all mice without signs of abnormal
phenotypes. Control groups were used to test for off-target
effects and yielded data consistent with previous genome-wide
studies outlining the specificity of Cas9. Using histological analysis of different muscles, the results of this experiment demonstrated the capability of CRISPR/Cas9 to repair the primary
mutation that causes DMD, thereby preventing the symptoms
associated with the disease. The determined threshold for sufficient repair was 17% which effectively displayed a dystrophin
level comparable to the wild-type mouse.This finding suggests a
mechanism of selective advantage for the repaired skeletal myocytes. Soles and heart tissue immunostaining of a three-week
old mdx repaired mouse of 40% displayed myofibers without
dystrophin while the nine-week old mdx repaired mouse of 41%
did not reveal any myofibers without dystrophin. The dystrophin expression levels between the three and nine week old
mice were insignificant, suggesting a compensatory mechanism
of rescue by the repaired nuclei in a myofiber. Immunostaining
revealed myofibers containing dystrophin secondary to a fusion
between a repaired cell and dystrophic muscle, providing further evidence of a rescue mechanism. Additionally, the serum
creatine kinase levels were inversely related to the percentage
of genomic repair, which is consistent with previous data in this
paper. A higher level of serum creatine kinase signifies muscle
breakdown. The repair of only a percentage of cells can induce
a total rescue, suggesting an unknown mechanism that induces
muscle regeneration in mice treated with CRISPR/Cas9. The
results of this experiment yield a breakthrough in our approach
to cure previously incurable diseases by effectively correcting
the underlying cause of the disease.

Discussion & Conclusion
Analysis of the CRISPR/Cas system, both in terms of its mechanism and bioengineering applications, yields a plethora of data
on various diseases. The short time requirements (Markel et
al., 1997) coupled with the simultaneous manipulation of multiple genes (Bolukbasi et al., 2016) characterizes CRISPR as an
advanced and highly efficient approach to modeling and thus
understanding maladies. Applying a form of CRISPR type II to
induce double stranded breaks provides researchers the ability
to target a portion of DNA with high specificity and then stimulate homologous recombination to modify a specific locus (Mali
et al., 2013). Duchenne muscular dystrophy is a debilitating
neuromuscular disease commonly affecting males and generally
leads to death before the age of 25 (Long et al., 2014). DMD is
a prime example to be used in the application of CRISPR/Cas9
for its well defined mutations that cause the disease. The data
presented in experiments using CRISPR/Cas9 to modify a gene
seem to be consistent and display accuracy and efficiency (Cong

et al., 2013; Mali et al., 2013; Maresch et al., 2016). Based on
current data, CRISPR/Cas9 genomic engineering is a promising
and hopeful route to effectively reverse disease-causing genetic
mutations such as Duchenne muscular dystrophy.
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